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ABSTRACT
Enterococcus faecalis is an opportunistic pathogen. In the host, it is exposed to fatty acids
which impact cellular physiology and induce tolerance to the antibiotic daptomycin. To
determine the requirements for induction of daptomycin tolerance, I examined the impacts
of blocking de novo fatty acid synthesis or protein synthesis and removing cell wall. I
observed that removal of the cell wall induced daptomycin tolerance, indicating that
peptidoglycan is necessary for daptomycin to function. As specific exogenous fatty acids
induce protection against daptomycin in E. faecalis, I also opted to examine whether
incorporation of these free fatty acids was necessary to induce drug tolerance. To do this,
I deleted the genes predicted to encode fatty acid binding proteins (FakBs). I found that
combined deletion of specific fakB genes caused altered physiology, including distorted
morphology, increased levels of free fatty acids, and altered growth kinetics in the
presence of exogenous fatty acids. This led me to investigate whether a thioesterase,
TesS, which cleaves fatty acids from acyl-ACP, was causing a buildup of free fatty acids
within the fakB deletion strains. Deletion of tesS in the fakB deletion strains reverted free
fatty acid levels to wild-type levels. Additionally upon deletion of tesS, I was able to delete
all four fakB homologs, generating a quintuple deletion strain. I followed up on the
physiology of this strain and found that the growth kinetics and free fatty acid levels
associated with deletion of the fakB genes were reverted to the wild-type phenotype.
Further, I observed that the quintuple deletion strain could not grow in the presence of a
de novo fatty acid biosynthesis inhibitor, even when supplemented with oleic acid. These
data indicated that the quintuple deletion strain had a reduced ability to incorporate
exogenous fatty acids. Additionally, deletion of fakB genes led to increased basal
daptomycin tolerance, yet exogenous fatty acids were still able to induce daptomycin
protection. These data indicated that the fakB genes play a role in normal cellular
physiology, and that incorporation of fatty acids into membrane phospholipids is likely not
the driver for fatty acid-mediated daptomycin tolerance.
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CHAPTER 1: INTRODUCTION
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This article was written by Rachel D. Johnston with editorial commentary from Elizabeth
M. Fozo. It has not been published anywhere, nor will it be before the final version is
submitted at the estimated time of defense, so a publication statement was not included.

Enterococci
Enterococcus is a genus of Gram-positive, facultatively anaerobic bacterium. These
organisms were first described as “entérocoque” due to their ovoid shape and their
isolation source: an intestinal smear [1]. The organism was first named Micrococcus
zymogenes by Hastings and Maccullum [2], who described their isolate (from a patient
with acute, fatal endocarditis) as a very small Gram-positive microorganism which grows
in pairs or short chains. They thus placed it in the genus Micrococcus, although they noted
that their isolate was much smaller than the already-characterized Streptococcus
pneumoniae (described in the literature of the time as Micrococcus lanceolatus) [2, 3]. As
they found that the isolate was able to ferment lactose and gelatin, and because it was
so different from Streptococcus pneumoniae and Streptococcus pyogenes, they gave it
the genus of zymogenes [2]. A few years later, in 1906, Andrewes and Horder, in an
attempt to classify 300 isolates of putative Streptococci strains, termed the organism
Streptococcus faecalis, as the microorganism was typically found in the human intestinal
tract [4]. This nomenclature, with multiple variates and classification strategies, was then
used in the literature to describe small, Gram-positive diplococci or short chains, typically
originating from the mammalian gastrointestinal tract. However, it was noted that there
were several physiological differences among members of the Streptococcus genus: the
enterococci of the group had marked tolerance for diverse environmental conditions,
being able to grow at both high and low temperatures (45°C and 10°C), high salt (6.5%),
high pH (9.6), and in media containing methylene blue (0.1%), as well as being able to
survive at 60°C for 30 minutes, while other members of the Streptococcus genus were
not so universally tolerant in these conditions [5]. Furthermore, the enterococci members
of the Streptococcus genus were consistently noted to grow in the shape of a diplococcus
[1, 2], forming chains only under stressful growth conditions (notably on supplementation
2

of the media with bile or in old cultures [6, 7]. Immunological evidence also surfaced,
indicating different groupings within the Streptococcus genus: antisera generated for
different species of the Streptococcus genus and subsequently used for precipitin tests
against Streptococcus species revealed four distinct groups [7], of which the enterococci
were group D [5]. Eventually, with the development of tools for elucidating genetic
differences, further evidence arose separating enterococci from the other members of the
Streptococcus genus. In 1984, Schleifer and Balz found, via DNA hybridization studies,
that Streptococcus faecalis and Streptococcus faecium were separate species (they
shared only 18% DNA homology), yet these two species had <9% DNA homology when
compared to other streptococci [8]. While this was not direct sequencing data but
hybridization data, it led to the proposal that S. faecalis and S. faecium be transferred to
the genus Enterococcus [8]. The 1984 version of Bergey’s manual supported these
transfers into the newly minted genus Enterococcus.
While they normally colonize the gastrointestinal tract of mammals, enterococci are
able cross the divide between commensal interactions and pathogenic interactions with
their hosts, as demonstrated by their varying isolation sources (often from fecal matter,
but also from blood or tissue in infected individuals). Enterococcal isolates are often
described as “hardy” as they able to survive for months in culture with no nutrients added
[2, 4], and can also survive from weeks to months on hospital fabrics and plastic [9]. As
they are able to persist under such nutrient-limited conditions, it is little wonder that
enterococci commonly cause healthcare-acquired infections.

Treatment options for enterococcal infections
A major problem when trying to treat an infection caused by E. faecalis (or E. faecium) is
their resistance or high tolerance to a variety of antibiotics. As a whole, this genus has
reduced susceptibility to β-lactams including ampicillin and penicillin, and is resistant to
aminoglycosides and clindamycin [10, 11]. When other treatment options fail, severe E.
faecalis infections are often treated with vancomycin, a cell-wall targeting antibiotic.
However, in response to utilization of vancomycin as a treatment of enterococcal
3

infections, vancomycin resistance has increased in enterococcal populations. As
enterococci have the ability to pass and receive genes through bacterial conjugation [1216], the upsurge of vancomycin resistance is alarming. Of note, vancomycin resistance
loci, predominantly mediated by the vanA gene cluster [17], have been found on plasmids
and conjugative transposons which can integrate into both bacterial chromosomes and
plasmids which are shared between bacterial cells [18-20]. The potential for horizontal
spread of vancomycin resistance among enterococcal populations or to other bacterial
species is of pressing concern, as these infections are difficult to treat, and result in an
estimated cost of more than $342 million annually [21, 22].
Vancomycin resistant enterococcal (VRE) infections have been treated in the clinic
using daptomycin. However, with increases in daptomycin usage for the treatment of VRE
infections, resistance to daptomycin has also increased [10, 23]. This rise of antibiotic
resistance in enterococcal populations hampers treatment of infections, increases the risk
of horizontal transfer of genes encoding resistance factors to other species, and increases
national healthcare-associated costs. With limited treatment options for VRE infections,
and with the difficulty with bringing new antimicrobials to market, it is critical to elucidate
how microbes such as Enterococcus evade death by daptomycin treatment. Thus, the
mechanism of this antibiotic must be examined.

Proposed mechanisms of daptomycin function
Daptomycin (originally A21978C), which was originally isolated from Streptomyces
roseosporus found in the soil on the slopes of Mount Ararat, is a cyclic lipopeptide
consisting of 13 amino acids with a fatty acid tail (usually of 10 carbons) [24]. Three
primary modes of action for this drug have been proposed since its discovery: inhibition
of peptidoglycan (PG) biosynthesis; inhibition of lipoteichoic acid (LTA) biosynthesis; and
disruption of membrane potential. While an abundance of data points towards each of
these three mechanisms, the specific details remain unclear.
The target of daptomycin was originally thought to be peptidoglycan (PG), as
daptomycin inhibited the incorporation of alanine into PG, (93% inhibition at 100 µg/mL),
4

but incorporation of labelled DNA, RNA, lipid, and protein precursors was impacted to a
lesser extent (<25% at 100 µg/mL) [25]. Adding daptomycin to Bacillus megaterium
cultures also resulted in inhibition of biosynthesis of PG precursors, including lipid I (UDPNAM-pentapeptide) and uridine diphosphate n-acetylglucosamine (UDP-NAG), lending
support towards PG as daptomycin’s target [26]. An investigation on the importance of
presence of cell wall to daptomycin efficacy revealed that removal of the cell wall of E.
faecium did not protect the cells against the drug [27].
Further study of daptomycin suggested that lipoteichoic acid (LTA) was a target, as
LTA synthesis, which occurs in and near the membrane and cell wall, was inhibited by
daptomycin [27, 28]. Some evidence supported this hypothesis: LTA precursors
accumulated in cells following daptomycin exposure [29]. However, daptomycin did not
appear to inhibit LTA synthesis more strongly than it inhibited other cellular processes,
including lipid synthesis and RNA synthesis; thus, LTA synthesis was likely not the
primary target [30].
Several lines of reasoning later pointed towards the membrane as the true target of
daptomycin. First, daptomycin has an acyl tail, which, upon changing the length, alters
toxicity [31]. As the acyl tail of daptomycin is hydrophobic, it was proposed that the tail
mediated insertion of daptomycin into the bacterial membrane. Indeed, removal of the
acyl tail resulted in abolishment of antimicrobial activity, while increasing the length of the
fatty acid was found to increase toxicity against Staphylococcus aureus and
Streptococcus pyogenes [31]. These data suggested that the acyl group plays a major
role in the mechanism of action. Further, the structure of calcium-bound daptomycin
revealed that daptomycin is similar to cationic antimicrobial peptides (CAMPs), many of
which work by disrupting bacterial membranes resulting in depolarization [32]. This
similarity, along with the fact that daptomycin requires calcium as a cofactor to function,
led investigators to hypothesize that daptomycin had a CAMP-like activity. Experiments
showed that indeed, daptomycin treatment dissipated membrane potential [33-37].
Furthermore, in vitro evidence showed that daptomycin was shown to interact with the
membrane phospholipid phosphatidylglycerol and form oligomers in the membrane,
5

much like traditional CAMPs [38]. Thus, the leading hypothesis for years was that
daptomycin inserts into the membrane in a calcium-dependent manner, oligomerizes, and
forms a pore-like structure allowing ion leakage, membrane depolarization, and cell
death.
Evidence tying the hypotheses for the above proposed targets together was found
by studying daptomycin localization, physiological effects on cell shape, and binding
activity. It was observed that exposure of cells to daptomycin caused the ordinarily rodshaped Bacillus subtilis to bend and sometimes become swollen at one end [39]. In cells
treated with sublethal doses of daptomycin for short (<1 h) time spans, the cell division
protein DivIVA, which orchestrates localization of PG synthesis proteins in the membrane,
was mislocalized, likely explaining the altered shape of cells treated with daptomycin [39].
These data indicated that treatment with daptomycin caused misplaced cell wall
synthesis. Further data demonstrated that daptomycin binds the membrane at regions of
increased fluidity (RIFs), causing misplacement of proteins critical for phospholipid
synthesis and PG synthesis – thus targeting, in a potentially indirect manner, multiple vital
cellular processes [40]. Daptomycin was also found to bind to the PG precursor lipid II,
indicating PG biosynthesis as a primary target [41]. Importantly, lipid II also plays a role
in the localization of proteins critical for cell division [42]. Taken together, these data
suggest that while PG synthesis may be a primary target, the pleiotropic effects of
daptomycin treatment described above may be explained by mislocalization of membrane
proteins.

Cell wall synthesis and cell membrane organization
As the literature has consistently pointed towards daptomycin targeting different
components of the cell envelope, primarily the cell membrane and cell wall, it is crucial to
link these pathways together. Naturally, as components located outside the membrane,
lipoteichoic acid and PG synthesis and anchoring are closely linked to the membrane.
Lipoteichoic acid is a modification of the membrane lipid monoglucosyl-diacylglycerol
(MGDAG; Figure 1.1). Type I LTA, which is the classically studied LTA and is the type
6

Figure 1.1. LTA biosynthesis.
In E. faecalis, the glycosyltransferase BgsA synthesizes diglycosyldiacylglycerols
(DGDAGs) by adding a glucose to monoglycosyldiacylglycerol (MGDAG). In B. subtilis,
glycerophospho-diglycodiacylglycerol (GP-DGDAG) is synthesized by addition of a
glycerol-phosphate (GroP) group to DGDAG by an LTA primase, and lipoteichoic acid
(LTA) is synthesized by successive addition of GroP groups to GP-DGDAG by an LTA
synthase. LTA is then D-alanylated by enzymes encoded in the dlt operon.

7

observed in E. faecalis, is built upon a glycolipid backbone. Specifically, to build type I
LTA, the enzyme BgsA adds a glucose to MGDAG, forming diglucosyl-diacylglycerol
(DGDAG) [43, 44]. LTA primase then adds a glycerol-phosphate (GroP) group to the
DGDAG, and the LTA molecule is extended by successive additions of GroP by LTA
synthase [45]. The amino acid D-alanine is then added to the LTA molecule by genes
encoded within the dlt operon [46]. Of note, many of these enzymes are located within
the lipid membrane, and indeed, LTA itself is built upon DGDAG (Figure 1.1).
Lipoteichoic acid also has a role in membrane lipid turnover. In S. aureus,
phosphatidylglycerol was confirmed as a GroP donor for LTA synthesis [47]. Loss of the
GroP moiety from phosphatidylglycerol resulted in formation of diacylglycerol (DAG),
which was used for phospholipid synthesis [47]. Thus, membrane makeup and LTA
synthesis are closely linked. Furthermore, LTA synthesis has been linked with cell division
through localization studies. It was observed that the proteins involved in LTA synthesis,
including LTA synthase and the enzyme responsible for formation of the DGDAG
glycolipid (named UgtP in B. subtilis), localized to the septum in B. subtilis cells [48].
Additionally, UgtP in B. subtilis was found to interact with FtsZ, a protein important for
orchestrating the divisome in bacteria [49]. These data suggest that LTA synthesis,
phospholipid synthesis and turnover, and coordination of cellular division are closely
linked.
Peptidoglycan, like LTA, is partially synthesized in the bacterial membrane (Figure
1.2). In particular, once the peptide stem has been built, it is added to the lipid
undecaprenol, and further steps, up until transpeptidation, are performed in the
membrane. Of note, the lipid bound PG precursor, lipid II, has been implicated in
localization of the cell division protein MreB in B. subtilis, which positions PG synthesis
machinery [42]. Furthermore, MurG, the enzyme responsible for synthesizing lipid II, was
found to specifically localize to the septum of Mycobacterium smegmatis, in correlation
with sites of active cell wall synthesis [50]. In B. subtilis, these findings were corroborated
with the discovery that MurG localizes to negatively curved regions of the membrane [51,
52]. Similarly, DivIVA, a protein involved in organizing cell division proteins, was found to
8

Figure 1.2. Peptidoglycan biosynthesis.
Shown is the pathway for Lys-type peptidoglycan synthesis. Note that this type of
peptidoglycan is synthesized in E. faecalis, but other peptidoglycan forms are synthesized
by other bacterial species. In this type of peptidoglycan synthesis, the stem peptide is
built upon UDP-MurNAc by enzymes MurC, MurD, MurE, and MurF. This molecule is then
attached to undecaprenol by MraY, forming the peptidoglycan (PG) precursor lipid I. Lipid
II is then synthesized by addition of GlcNAc to the MurNAc moiety of lipid I by MurG.
Following this reaction, in E. faecalis, other modifications are made to the peptide stem –
namely two L-alanine groups are added to L-lysine by MurM and MurN, successively. The
PG precursor is then flipped to the outer leaflet of the membrane by MurJ, and is
subsequently crosslinked by glycosyltransferases (GTases). Crosslinking of the peptide
chains is performed by DD-transpeptidases (DD-TPases), and trimming of the peptide
stem is performed by DD-carboxypeptidases (CPases).
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localize to negatively curved regions of the membrane [50, 53, 54]. Taken together, these
data suggest that membrane organization and PG synthesis are intricately intertwined.
Thus, while the target of daptomycin is unclear, it is logical that multiple effects of
daptomycin treatment on bacterial physiology have been observed.
As direct studies on daptomycin mechanism of action have proven unsuccessful in
affirming the specific target, studies have been performed to elucidate how bacterial cells
resist treatment with daptomycin.

Daptomycin resistance
Over the course of treatment of bacterial infections with daptomycin, resistance (ability of
the bacterium to grow in the presence of the drug) arises [23, 55-57]. In E. faecalis,
several mechanisms contributing to daptomycin resistance have been discovered. The
most prevalent contributor to daptomycin resistance is increased activation of the threecomponent regulatory system LiaFSR (lipid II-interacting antibiotic response regulator
and sensor) [58-65], which is responsible for maintaining cell envelope homeostasis.
Common mutations result in a loss-of-function in LiaF [58, 60-62, 65], which inhibits the
activation of the regulatory component, LiaR. The downstream consequences of
increased activation of LiaR are not fully understood; however, one known result is
increased transcription of liaX [59, 66]. Interestingly, genetic evidence suggested that the
presence of a functional LiaX protein is important for cell membrane organization –
notably, a C-terminus truncation or full deletion of liaX caused altered anionic
phospholipid arrangements [66]. Furthermore, a nonsense mutation resulting in a Cterminal truncation of liaX resulted in daptomycin nonsusceptibility in a clinical isolate [67],
confirming the contribution of this protein to daptomycin efficacy. Notably, the role of LiaX
in altering the response of cells to daptomycin is likely two-fold: this protein has two
domains; the C-terminal domain negatively regulates LiaSR, while the N-terminal domain
can be released from the cell and can bind to extracellular daptomycin [66]. Thus, a Cterminal truncation of liaX would likely result in increased activation of LiaR, while the Nterminus could potentially sequester daptomycin.
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While the LiaFSR system is thought to mediate phospholipid distribution in response
to membrane stress via LiaX [66], specific mutations (often paired with the daptomycin
resistance driving mutations in the LiaFSR locus) in phospholipid metabolism genes can
also contribute to daptomycin resistance in E. faecalis. These include mutations in
cardiolipin

(CL)

synthase

(cls),

which

catalyzes

the

condensation

of

two

phosphatidylglycerol (PtdGro) molecules to form CL, and glycerophosphoryl diester
phosphodiesterase (gdpD), which is likely involved in hydrolyzing phospholipids [68-70].
Introduction of the altered cls alleles into the daptomycin-susceptible laboratory strain E.
faecalis OG1RF conferred daptomycin resistance to this bacterium [68]. Further, a
directed evolution experiment in E. faecalis lacking a functional LiaFSR system revealed
that mutations in another two-component system, YxdJK, which is associated with
sensing and responding to antimicrobial compounds, arose in response to increasing
concentrations of daptomycin [71]. Additionally, mutations in the E. faecalis homolog of
FakA (efFakA; a protein involved in phosphorylation of free fatty acids originally described
in S. aureus) [72], also arose in response to increasing concentrations of daptomycin [71].
The variants containing mutations in efFakA had decreased colony size and altered cell
morphology [71].
Of note, other daptomycin resistant strains implicated altered envelope physiology,
potentially mediated by increased net surface positivity, increased cell wall thickness, or
membrane fluidity [58, 73, 74]. Cell charge can be modulated by altered production of
lysyl-phosphatidylglycerol (lysyl-PtdGro). To generate lysyl-PtdGro, MprF (multiple
peptide resistance factor) adds lysyl groups to phosphatidylglycerol (PtdGro) and flips
the newly formed lysyl-PtdGro to the outer leaflet of the membrane [75]. In S. aureus,
gain-of-function mutations in mprF are associated with daptomycin resistance [74, 76].
Cell surface charge can also be altered through alanylation of LTA. Increased
transcription of the dlt operon, which encodes genes responsible for alanylation of LTA
has been linked to daptomycin resistance in S. aureus [77, 78]. Interestingly, gain-offunction mutations in mprF and modified regulation of the dlt operon cause daptomycin
resistance [74, 76]. However, while increased lysyl-PtdGro production and d-alanylation
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of lipoteichoic acid alter the charge of cells, in E. faecalis, daptomycin protection was not
correlated with gross changes in global surface charge or membrane fluidity [79]. Thus,
while physiological changes in cells resistant or tolerant to daptomycin have been
demonstrated in the literature, a unifying trend has not been observed.
Altered lipid content is also correlated to both daptomycin resistance. Namely,
diglycosyldiacylgycerols (DGDAGs) are increased in resistant strains of enterococcus,
while PtdGro is decreased in the same strains [80, 81]. The phospholipid composition of
daptomycin-resistant S. aureus, like E. faecalis, significantly differs from its susceptible
parental isolate; PtdGro is substantially decreased in the membrane, while glycolipid
abundance is increased, possibly indicating a common means of tolerating daptomycin
in both species [80, 81]. However, it is unknown whether these specific changes drive
daptomycin tolerance or are a downstream effect of mutations conferring daptomycin
resistance.

Daptomycin tolerance and persistence
Interestingly, many studies on the killing mechanism of daptomycin using high drug
concentrations resulted in biphasic killing of cells [27, 35, 82-87], a known sign of
persistence. In the 1940s, it was demonstrated by Hobby and Bigger that treatment of
bacterial cells with high concentrations of the bactericidal antibiotic penicillin revealed two
subpopulations of cells: one population of cells that is rapidly killed and a second
population of cells (persister cells) which is able to survive [88, 89]. The persister cell
population is genetically identical to the population which is rapidly killed and is unable to
grow in the presence of the drug [55], yet when the drug is removed from the media,
growth is again possible [90-92]. Persister cells are thought to arise from induction of
stress responses [93-99] or by varying expression of the toxin portion of toxin/antitoxin
systems [100-105]. It has been observed that the toxin portion of toxin-antitoxin systems
can lead to metabolic dormancy, which is hypothesized to cause bacterial persistence
[105]. Addition of nutrients to the growth media can resuscitate dormant cells [106],
potentially leading again to the ability of an antibiotic to kill the cells. Indeed, this has been
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demonstrated with daptomycin: the biphasic killing associated with treatment of S. aureus
cells was eliminated by addition of glucose to the media following daptomycin treatment
[86]. Interestingly, supplementation with specific fatty acids can lead to the opposite
effect.

Fatty acids trigger daptomycin tolerance
Daptomycin tolerance (i.e., ability to survive high dosages of the drug without an increase
in the MIC [55]) can be induced by addition of fatty acids to the growth media [35, 79, 82,
87, 107]. Note that in the host environment, E. faecalis is exposed to bile in the
gastrointestinal tract (commensal state) and sera in tissues (pathogenic state). Studies
have established that exposure to these host fluids, which are rich in fatty acids, changes
membrane composition and confers tolerance to daptomycin [35, 82]. Furthermore,
exposure to the specific fatty acids, oleic acid (C18:1 cis9) or linoleic acid (C18:2 cis9,12), both
of which are found in bile and serum, alters membrane composition and induces tolerance
to daptomycin [35, 79, 82, 87, 107]. Notably, this induction of protection is not dependent
on induction of the LiaFSR response, as oleic acid was protective in a strain deleted for
liaR [82]. Addition of oleic acid was also protective in a daptomycin resistant clinical isolate
of E. faecalis [82], as well as in strains lacking the genes necessary for synthesis of
cardiolipin and lysyl-PtdGro [107]. However, protection against daptomycin by oleic acid
was not due to direct interactions between the fatty acid and daptomycin [82]. Taken
together, these data indicated that addition of fatty acids was protecting through an
induction of altered regulation or activity of key players involved in daptomycin resistance
or by sequestering daptomycin. Thus, the mechanism for fatty acid-induced daptomycin
tolerance remains unclear. One area that has not been fully explored in E. faecalis is how
fatty acids are used.

The use of free fatty acids by bacteria
In the context of living in a human host, bacteria are exposed to a multitude of nutrients,
including fatty acids, which are present in bile and serum. Of note, bacteria have multiple
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uses for free fatty acids. Free fatty acids may be used as a carbon source for bacterial
growth (reviewed in [108]), or can be used in phospholipid synthesis. To be used as a
carbon source, the fatty acid (acyl) must first be “activated“ by the addition of coenzyme
A (CoA). Two carbons are removed from the carboxylic end of the acyl chain, forming
acetyl-CoA and a shortened (by two carbons) acyl-CoA. The resulting acyl-CoA can be
consecutively shortened to produce more acetyl-CoA, which can be used in the citrate
cycle for energy. This process, called β-oxidation, does not occur in all organisms
however. Specifically, Enterococcus faecalis does not have the genes required for βoxidation and fatty acids cannot be used as sole carbon sources [109, 110]. Therefore,
the induction of daptomycin tolerance by exposure to free fatty acids in this organism is
not due to the breakdown of fatty acid supplements.
While free fatty acids are not involved in generating energy via β-oxidation for E.
faecalis, they can be used in phospholipid synthesis, as supplementation of E. faecalis
cultures with fatty acids alters the lipid profile [107] and specific exogenous fatty acids
can support growth of E. faecalis when de novo fatty acid biosynthesis is inhibited [87].
This is likely accomplished by uptake of free fatty acids through a fatty acid kinase (Fak)
system (Figure 1.3).
The Fak system was first described in Staphylococcus aureus [72]. Free fatty acids
(which are thought to passively associate with the cell membrane [111]) are bound by a
fatty acid binding protein (FakB), and then phosphorylated (“activated”) by the enzyme
FakA using ATP as the phosphate donor [72]. The resulting acyl-phosphates are then
used in the phospholipid biosynthetic cycle via conversion to acyl-ACP by PlsX, or
incorporation into the SN-1 position of glycerol-3-phosphate (G3P) by PlsY, generating
lysophosphatidic acid [72]. If converted into acyl-ACP, the fatty acid can then enter into
the fatty acid biosynthetic cycle (FasII), or can be incorporated onto the SN-2 position of
lysophosphatidic acid by PlsC to generate phosphatidic acid, the precursor to membrane
lipids [72]. Importantly, individual FakB homologs do not bind all fatty acids equally: the
two individual FakB proteins of S. aureus were demonstrated to have specific binding
affinities for different fatty acids [72]. FakB1 of S. aureus (saFakB1) bound with higher
14

Figure 1.3. The proposed use of free fatty acids by E. faecalis based on homology
to S. aureus and S. pneumoniae.
Free fatty acids, whether exogenous or produced by cleavage of a fatty acid (acyl) from
acyl-ACP by TesS, are bound by a FakB protein. The FakA enzyme phosphorylates the
acyl, forming acyl-phosphate (Acyl-PO4). Acyl-phosphates are incorporated onto the SN1 position of glycerol-3-phosphate by PlsY to form lysophosphatidic acid (LPA). Acylphosphates can also be bound to the acyl carrier protein (ACP) through the action of PlsX
– this process is reversible. Acyl-ACP, generated through the de novo fatty acid synthesis
cycle (FasII), is used as the acyl donor to form phosphatidic acid, the precursor to
membrane phospholipids. The acyl group can be cleaved from acyl-ACP to form a free
fatty acid.
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affinity to saturated fatty acids, while saFakB2 bound with higher affinity to unsaturated
fatty acids [72]. The same specificities were observed in two FakB homologs of
Streptococcus pneumoniae (spFakB1 was specific for saturated fatty acids and spFakB2
was specific for monounsaturated fatty acids), but a third FakB (spFakB3) had specificity
for polyunsaturated fatty acids [112]. Note that acyl-ACP, generated by FasII or by PlsX
activity on acyl-phosphates, can be cleaved by TesS to release ACP and a free fatty acid;
these free fatty acids could then be used as described above [113]. However, this was
proposed to be a minor pathway, as PlsX had the ability to interconvert acyl-phosphates
and acyl-ACP [113].
Interestingly, studies demonstrated that only specific fatty acids could induce
protection against daptomycin in E. faecalis: oleic acid (C18:1 cis9) and linoleic acid (C18:2
cis9,12)

[35, 87]. Additionally, individual fatty acids caused different physiological responses

in the cells. Namely, supplementation with free fatty acids caused different effects on
morphology (indicative of altered cell wall placement) depending on the fatty acid
supplement, as well as differences in generation time [87]. This indicates that individual
fatty acids play differing roles in the cellular physiology of E. faecalis.

Summary
Here I have investigated the contribution of cell wall and the fakB genes of E. faecalis on
cellular physiology and daptomycin tolerance. This work began by examining how
bacterial physiology impacts daptomycin tolerance. Given the variety of data suggesting
that daptomycin targets the bacterial envelope and that daptomycin treatment reveals two
subpopulations of cells (one of those subpopulations likely being persister cells), in
Chapter 2 I investigated the role of cell wall, ATP levels, fatty acid biosynthesis, and
protein synthesis on daptomycin efficacy. Upon finding that removal of PG greatly
increases daptomycin tolerance, yet treatment with protein synthesis and fatty acid
biosynthesis inhibitors also induces tolerance, I then investigated the role of exogenous
fatty acid incorporation into phospholipids on daptomycin tolerance. Thus, in Chapter 3, I
generated several fakB deletion strains. Unexpectedly, I noted that the specific deletion
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strain ΔfakB1,2,5 had hyperseptation compared to wild-type E. faecalis. Additionally, this
strain grew slowly in liquid media containing fatty acid supplements or ethanol. These
data, combined with the fact that I was initially unable to delete all four fakB homologs,
led me to investigate whether the tesS homolog of E. faecalis played a role in the
essentiality of the Fak system. I found that deletion of tesS enabled deletion of all of the
fakB genes and the ΔfakB1,2,4,5/ΔtesS deletion strain was able to grow in free fatty acids
without the negative growth phenotypes associated with lower order deletion strains.
Having characterized the Fak system of E. faecalis, in Chapter 4 I investigated the
distribution of the E. faecalis FakB homologs within a network of fatty acid-binding
domains (DegV). Within this network analysis, I observed that among the strains within
the network, the majority were Gram-positive bacterial organisms. Furthermore, I found
evidence that DegV domains cluster according to the isolation source(s) of the strains
from which they originated. Within this chapter, I also investigated the role of incorporation
of the fak genes on daptomycin tolerance. I observed that strains deleted for the fak genes
had an increased basal tolerance to daptomycin. Further, addition of free fatty acids within
these deletion strains still induced daptomycin protection, indicating that incorporation of
free fatty acids may not be the key to inducing daptomycin tolerance. Finally, in chapter
5, I discuss my findings in the context of how global changes to cell wall placement,
membrane makeup, and membrane organization alter daptomycin tolerance.
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TOLERANCE IN ENTEROCOCCUS FAECALIS

34

Publication Note
A version of this chapter was originally published by Rachel D. Johnston, Brittni M.
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Johnston RD, Woodall BM, Harrison J, Campagna SR, Fozo EM. Removal of
peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in
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Abstract
Daptomycin is a cyclic lipopeptide antibiotic used in the clinic for treatment of severe
enterococcal infections. Recent reports indicate that daptomycin targets active cellular
processes, specifically, peptidoglycan biosynthesis. Within, we examined the efficacy of
daptomycin against Enterococcus faecalis under a range of environmental growth
conditions including inhibitors that target active cellular processes. Daptomycin was far
less effective against cells in late stationary phase compared to cells in exponential
phase, and this was independent of cellular ATP levels. Further, the addition of either the
de novo protein synthesis inhibitor chloramphenicol or the fatty acid biosynthesis inhibitor
cerulenin induced survival against daptomycin far better than controls. Alterations in
metabolites associated with peptidoglycan synthesis correlated with protection against
daptomycin. This was further supported as removal of peptidoglycan induced
physiological daptomycin tolerance. Additionally, a synergistic relation between
daptomycin and fosfomycin, an inhibitor of the fist committed step peptidoglycan
synthesis, was observed, as well as an additive effect when daptomycin was combined
with ampicillin, which targets crosslinking of peptidoglycan strands. Removal of the
peptidoglycan of Enterococcus faecium, Staphylococcus aureus, and Bacillus subtilis
also resulted in significant protection against daptomycin in comparison to whole cells
with intact cell walls. Based on these observations, we conclude that bacterial growth
phase and metabolic activity, as well as the presence/absence of peptidoglycan are major
contributors to the efficacy of daptomycin.
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Introduction
As therapeutic strategies have been developed for treating bacterial infections over the
past century, there has been a subsequent rise in antibiotic resistant bacteria. Among the
CDC’s Resistance Threats in the United States are Gram-positive, vancomycin-resistant
enterococci (VRE) [1]. VRE are of particular concern because of the lack of successful
treatment strategies available for these pathogens. In the clinic, the Gram-positive
targeting lipopeptide daptomycin has been used to treat VRE when other strategies fail.
However, due to an abundance of contradictory data, an air of mystery has surrounded
the mechanism of action of daptomycin since its discovery in the 1980s. Over the course
of its characterization, three main modes of action have been proposed: inhibition of
peptidoglycan synthesis, inhibition of lipoteichoic acid (LTA) biosynthesis, and disruption
of membrane potential.
Peptidoglycan was proposed as the target of daptomycin, as treatment of both
Staphylococcus aureus and Bacillus megaterium with the antibiotic resulted in a failure to
incorporate L-alanine and L-lysine into peptidoglycan in either species [2], and cellular
levels of lipid II precursors, needed components for peptidoglycan formation, were
increased [3]. Gross cell wall changes were also correlated in some studies with
daptomycin resistance and daptomycin treatment in S. aureus [4, 5], Enterococcus
faecalis [5-8], and Enterococcus faecium [8], though this was not true in all cases [9].
However, peptidoglycan was dismissed as a target for daptomycin as removal of the cell
wall (generating protoplasts) of E. faecium did not afford the cells protection against the
drug [10]. Recent evidence in S. aureus, though, supports a model for daptomycin
targeting peptidoglycan biosynthesis, as daptomycin was shown to bind to lipid II in the
presence of the membrane lipid phosphatidylglycerol, and other lipid II binding molecules
blocked daptomycin from interacting with lipid II [11].
Older data initially pointed towards LTA as a potential target, as daptomycin was
found to inhibit LTA biosynthesis in S. aureus and E. faecium [10, 12], and LTA precursors
within the cell were found to decrease over time following exposure to daptomycin [13].
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However, LTA biosynthesis as the target was later abandoned, as daptomycin inhibited
not only the production of LTA, but also that of lipids and RNA [14].
Given that daptomycin contains an acyl tail, many speculated that the cell membrane
was the true target of the drug. In vitro studies using giant unilamellar vesicles
demonstrated that daptomycin formed oligomers [15], caused protrusions within vesicles
[16], and led to aggregation of lipid bound to daptomycin on the outer surface of the
vesicle [16].

Several in vivo studies further found that daptomycin interacted with

phosphatidylglycerol [17, 18], localized to the cell membrane [18], formed pores in the
membrane [19], and dissipated membrane potential [19-23]. Importantly, many of the
supportive in vivo studies for a membrane target of daptomycin were conducted using
drug concentrations well above (~7–10x) the minimal inhibitory concentration (MIC) of the
bacterium being tested or at late time points [17, 20, 22, 23].
Combining these lines of evidence together, a study in B. subtilis found that
daptomycin associated with fluid regions of the membrane (regions of increased fluidity;
RIFs) and rigidified these regions [24]. This rigidification, potentially occurring after
binding of daptomycin to lipid II and its precursors [11], occluded peripheral membrane
proteins involved in cell wall and phospholipid biosynthesis [24]. The binding of
daptomycin to lipid II and its precursors, along with subsequent delocalization of cell wall
and lipid synthesis proteins at the membrane would negatively impact these cellular
processes, likely contributing to lethality.
Regardless of the specific target of daptomycin, the evidence from the studies
summarized above supports that daptomycin targets active cellular processes. Many of
the studies of daptomycin demonstrated that treatment with this drug causes biphasic
killing of cells [10, 22, 25-29], a hallmark of persistence [30, 31]. As demonstrated by
Hobby and Bigger, when bactericidal antibiotics are given at doses above the MIC, they
lead to rapid killing of actively growing cells while a genetically identical subset of cells,
called persister cells, survive [30, 31]. Persister cells can arise through varying
mechanisms – including induction of metabolic dormancy through varying expression of
the toxin component of toxin/antitoxin systems [32-37] and induction of stress responses
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[38-44]. In each of these cases, the persister cells in question are not genetically resistant,
as they do not grow during treatment with the drug [45]: rather, they are able to survive
antibiotic pressure through differential expression of genes which can be stochastic [32,
46] or triggered by environmental changes [38-44]. On removal of the antibiotic from the
media, these persister cells are then able to grow [47-49].
While some cells may be able to survive treatment with high dosages of drug, survival
alone does not indicate true genetic resistance, which results in a higher MIC compared
to susceptible cells, along with active growth in the presence of antibiotic [45]. Cells that
can survive antibiotic treatment without an increase in the MIC compared to susceptible
cells are deemed tolerant [45]. Given that there are subpopulations of cells that survive
high daptomycin concentrations [10, 22, 25-29, 50], we examined the role of active
cellular processes in daptomycin tolerance through comparison of survival of cells in
exponential phase, which are metabolically active and capable of stochastic switching to
persister cells [32, 46, 47] to cells in stationary phase, which have reduced metabolic
activity as well as a large population of persisters [51, 52]. Comparison of exponential to
stationary phase cells is of particular interest, as cells in stationary phase have increased
peptidoglycan turnover [53] and thicker peptidoglycan (for E. coli [54]), a phenomenon
also associated with daptomycin resistance and treatment [4-8]. We observed
significantly increased daptomycin tolerance as monitored by the number of survivors
following transient exposure to high dosage of the drug (7.5-10x MIC) within stationary
phase cells. We also tested whether protein and fatty acid biosynthesis were necessary
for survival under high concentrations of daptomycin and found that inhibition of these
processes significantly increased survival on treatment with daptomycin. Additionally, we
observed metabolic changes within stationary phase cells and cells in which protein or
fatty acid biosynthesis were inhibited pointed towards altered peptidoglycan metabolism.
We removed peptidoglycan from cells and found that these cells were significantly more
tolerant to daptomycin treatment. Combined, we demonstrate that inhibition of active
growth of E. faecalis serves to increase its ability to survive high doses of daptomycin,
supporting a model for daptomycin targeting peptidoglycan biosynthesis.
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Materials and Methods
Bacterial growth conditions
Bacterial strains used in the study are listed in Supplemental Table 2.1. E. faecalis, E.
faecium, and S. aureus strains were grown statically in brain heart infusion (BHI) medium
at 37°C unless indicated otherwise. B. subtilis cultures were grown in LB with shaking
(250rpm) at 37°C. Overnight growth cultures were diluted to a final optical density at 600
nm (OD600) of 0.01 from overnight cultures and harvested at either exponential phase
(OD600 ~ 0.3) or late stationary phase (24 h after dilution). For examining the effects of de
novo protein biosynthesis or fatty acid biosynthesis, chloramphenicol (15 µg/mL) or
cerulenin (10 µg/mL), respectively, were added to cultures upon reaching OD600 ~ 0.225–
0.250 (chloramphenicol) or OD600 ~ 0.100–0.125 (cerulenin). Cultures were exposed to
chloramphenicol for 30 min or cerulenin for 90 min to ensure cellular stasis, with stasis
confirmed by determining colony forming units pre- and post-treatment (Supplemental
Figures 2.1 and 2.2).

Minimal inhibitory concentration (MIC) determination
To perform MIC assays, cells were diluted to a final OD600 of 0.01 from overnight cultures
into 2 mL of media containing 1.5 mM CaCl2 and daptomycin (0, 0.25, 0.5, 1, 2, 4, and 8
µg/mL), and grown for 24 hours prior to determine the minimal inhibitory concentration
(Supplemental Table 2.2). Minimum of n = 3 for all experiments.

Cell survival assays
For all daptomycin and SDS challenge assays, cellular survival was determined via
enumeration of colony forming units. Daptomycin challenge concentrations were chosen
to reflect ~7.5–10X the MIC of the respective organisms (Supplemental Table 2.2). Cells
were harvested via centrifugation at 2739xg for 10 min. Where indicated, the cells were
washed with either isotonic buffer (20% sucrose, 0.145M NaCl, 50mM Tris-HCl) [55] or
1x phosphate buffered saline solution (PBS) [25] before resuspension in challenge
medium. Daptomycin challenge cultures were set up as follows: for E. faecalis and E.
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faecium, daptomycin was added at 30 µg/mL to cells suspended in BHI with 1.5mM
calcium chloride or isotonic buffer containing 1.5mM calcium chloride [50]. For S. aureus
and B. subtilis cultures, daptomycin was added at 5 µg/mL. Serial dilutions were plated
onto BHI agar (E. faecalis, E. faecium, and S. aureus) or LB agar (B. subtilis) at time zero
(immediately prior to daptomycin or SDS addition) and at the indicated time points posttreatment. Colony forming units were enumerated after 18–24h of incubation at 37°C.
Sodium dodecyl sulfate challenge medium consisted of BHI containing 20% sucrose as
an osmoprotective agent and 0.05% SDS. Colony forming units at all time points were
normalized to the colony forming units at time zero (before addition of daptomycin or SDS
to the culture). Minimum of n = 3 for all experiments. Raw CFU data are in Supplemental
Table 2.3.

ATP depletion and tracking
ATP levels were determined as indicated in the text using the BacTiterGlo kit (Promega).
For ATP depletion assays, E. faecalis cells were grown to an OD600 of ~0.25. Sodium
arsenate dibasic heptahydrate (arsenate; Sigma-Aldrich) was added as indicated in the
text to a final concentration of 10 mM, or an equivalent volume of water (solvent control)
was added to the cells [56, 57]. The cells were incubated for 30 min at 37°C, harvested
by centrifugation at 2739xg, washed twice with 1x PBS, then resuspended in BHI prior to
use for ATP determination. Colony forming units were determined via plating to conclude
arsenate treatment did not result in cell death (Supplemental Figure 2.3). Relative light
unit values (RLUs) yielded by the BacTiterGlo kit (Promega) were normalized to colony
forming units taken at the time the ATP assay was performed. Minimum of n = 3 for all
experiments.

Daptomycin synergy
To determine synergy between daptomycin and other antibiotics, a microtiter plate
checkerboard assay was performed [58-60]. Overnight cultures were diluted back as
above into BHI containing 1.5 mM CaCl2 and aliquoted to microplates. Daptomycin (0,
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0.25, 0.5, 1, 2, 4, and 8 µg/mL) was added with the concentration increasing along the
vertical axis, while the secondary drug was increased along the horizontal axis. The
secondary drugs examined were fosfomycin (0, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512
µg/mL), D-cycloserine (0, 2, 4, 8, 16, 32, 64, 128, 256, 512,1024 µg/mL) or ampicillin (0,
0.015625, 0.03125, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8 µg/mL). One row and one column
of each plate contained media alone (BHI + 1.5 mM CaCl2) to provide a no-growth control.
For all experiments, n = 3. The fractional inhibitory concentration (FIC) of each drug (drug
A and B, respectively) was calculated as follows [60]:

Equation 1: FICA =
Equation 2: FICB =

MICcombined drug A/B
MICdrug A
MICcombined drug B/A
MICdrug B

The fractional inhibitory concentration index (FICI) was calculated as follows [60]:
Equation 3: FICI = FICA + FICB
Synergy, additivity, and no interaction are defined as follows: FICI of ≤ 0.5 is defined as
synergistic, FICI between 0.5 and 1 is additive, and FICI between 1 and 4 is defined as
no interaction [60, 61].

Cell wall removal/protoplast generation
E. faecalis and E. faecium were grown in 50 mL BHI to the appropriate growth phase. A
whole cell control (4 mL) aliquot and a protoplast (40 mL) aliquot were harvested from the
original culture by centrifugation at 2739xg for 10 min, washed once with isotonic buffer
(20% sucrose, 0.145 M NaCl, 50 mM Tris-HCl), then resuspended in 5 mL isotonic buffer
[55]. Lysozyme (final concentration of 1 mg/mL) [62] or an equivalent volume of water
was added to the appropriate cell mixture. These mixtures were incubated at 37°C for 60
min. Following mock or lysozyme treatment, cells were harvested by centrifugation as
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above, washed with isotonic buffer, and resuspended in 4 mL isotonic buffer prior to ATP
determination (Supplemental Figure 2.5) or were resuspended in 4 mL isotonic buffer
containing 1.5 mM CaCl2 prior to use for cell survival assays (note that protoplasts were
concentrated 10x while mock-treated cells were not). For S. aureus, cells were treated as
above except that lysostaphin was added at 5 µg/mL and DNase was added at 16 µg/mL
[55]. B. subtilis was grown in 100 mL LB to the appropriate growth phase. A whole cell
control (4 mL) aliquot and protoplast (80 mL) aliquot were harvested from the original
culture by centrifugation as above and resuspended in 4 mL osmoprotective LB (LB
supplemented with 20% sucrose, 50 mM Tris-HCl and 0.145 M NaCl). Lysozyme (final
concentration of 100 µg/mL) was added to the cells and incubated at 37°C with shaking
(250 RPM) for 30 min. Cells were harvested as above, washed with osmoprotective LB
and resuspended in an equivalent volume osmoprotective LB containing 1.5 mM CaCl2
prior to treatment with daptomycin. Protoplasts and whole cells for each strain were
confirmed by Gram-stain.

Metabolomics
Cell harvest and extraction (stationary-phase cells, chloramphenicol- and cerulenintreated cultures and their respective controls)
Cells were grown as stated above and cell harvest and extraction was adapted from
previous literature [63]. Cell culture volumes of 1 mL were harvested by filtration using
0.4 µM membrane filters (Fisher 09-300-71). Dilution plating of the original cell culture
was performed at the time of harvest for colony forming unit enumeration. After harvest,
the filters were washed with 8 mL of 1x PBS. To begin extraction, filters were immediately
placed into respectively labeled petri dishes containing 1.3 mL of prechilled (4°C)
extraction solvent (40:40:20 HPLC grade methanol, acetonitrile, water with 0.1% formic
acid). Filters were then placed at -20°C for 20 min. Following incubation at -20°C, the
filters were washed with 400 µL of extraction solvent, and the solvent was then transferred
to respectively labeled 2 mL centrifuge tubes and subjected to centrifugation at 16xg.
After centrifugation, the supernatant was transferred to a labeled centrifuge tube and the
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remaining pellet was resuspended in 200 µL of extraction solvent, placed at 4°C for an
additional 20 min, subjected to centrifugation as above, and supernatant was added to
the above. The samples were then subjected to drying under N2. Dried samples were
resuspended in 300 µL HPLC water and stored in an autosampler vial at 4°C until
analysis.

Cell harvest and extraction (whole cells and protoplasts):
As a very low number of protoplasts survived the process of filtration, we elected to
harvest cell pellets for whole cell and protoplast cultures (generated as above) prior to
extraction. Colony forming units were enumerated at the time of harvest and cell culture
volumes of 2 mL for protoplasts (double the volume for whole cells to increase the number
of viable cells used for analysis) and 1 mL for whole cells were harvested via
centrifugation (15 min 16xg) and the supernatant was removed. After harvest, pellets
were flash frozen and stored at -80°C prior to extraction. To begin extraction, samples
were thawed at 4°C for 30 min. Thawed samples were subjected to the addition of
prechilled extraction solvent (0.65 mL) and were shaken at 60 RPM. Afterwards, an
additional 0.65 mL of prechilled extraction solvent was added to the samples and the
samples were vortexed. Samples containing extraction solvent and cell pellets were
chilled for 20 min at -20°C. Samples were then centrifuged for 5 min (16xg) and the
supernatant was then transferred to new centrifuge tube. An additional 200 µL of
extraction solvent was added to cell pellet in the first tube and vortexed. After vortexing
the samples were placed at -20°C for an additional 20 min. Samples were centrifuged for
an additional 5 min (16xg) and the resulting supernatant was removed and placed in the
respective tube for drying under N2. After drying, samples were resuspended in 300 µL
HPLC water and placed into the autosampler at 4°C until analysis.

Liquid chromatography mass spectrometry analysis:
For liquid chromatography mass spectrometry analysis, 10 µL of sample was injected
onto a Synergi 2.5 uM Hydro-RP, 100 Å, 200 x 2.00 mm liquid chromatography column
44

(Phenomenex, Torrance CA) held at 25°C. The data acquisition parameters adapted from
Rabinowitz [64] included the operation of the mass spectrometer in full scan mode. The
eluent was ionized via electron spray ionization (ESI) in negative mode coupled to a
Thermo Scientific Exactive Plus Orbitrap mass spectrometer with the following
parameters: spray voltage 3 kV, nitrogen sheath gas 10 (arbitrary units), capillary
temperature 320°C, automatic gain control (AGC) target set to 3x10 6 ions. The mass
spectrometer was operated at 140,000 resolution with a scan window from 85-800 m/z
from 0-9 min and 110-1000 m/z from 9-25 min. Mobile phase A consisted of 97:3 water
methanol 10mM tributylamine, and 15mM acetic acid while solvent B consisted of 100%
methanol. Solvent gradient was 0 to 5 min: 0% B, 5-13: min 20% B, 13-15.5 min: 55% B
15.5-19 min 95% B and 19 to 25 min 0% B with a flow rate of 200 µL/min.

Data processing:
Raw data files generated by Xcalibur were converted to .mzML format using the MS
convert from ProteoWizard. El MAVEN was utilized to integrate areas under the curve for
known metabolite masses (selected based on our validated standard library of 1080
metabolites) matched with retention time with a mass error of less than 5 ppm. Base
background signal was removed, and integrated peak areas were normalized by the ratio
of colony forming units of experimental versus control group for each paired control and
treatment replicate. Heatmaps were constructed by determining the ratio of normalized,
log transformed intensities of experimental values over control values. A paired Student’s
T-test was utilized to determine significance. PLSDA plots were constructed utilizing
Metaboanalyst (metaboanalyst.ca) software. n = 5 replicates were performed for all
metabolomics experiments with the exception of removal of one replicate from the
chloramphenicol vs. ethanol experiment due to technical error, resulting in n = 4 replicates
in that experiment.
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Statistical analysis
All statistical analyses presented within the text, except where noted, were performed
using two-tailed Welch’s T-tests, using α = 0.05. For cell survival assays, data were only
compared within (not between) individual time points. For each described assay, a
minimum of n = 3 biological replicates were used. P-values for cell survival assays and
ATP assays are reported in Supplemental Table 2.4. In figures, P-values are represented
in ranges as follows: ns P > 0.05; * P = 0.05–0.01; ** P = 0.01–0.001; *** P ≤ 0.001.

Results
The sensitivity of E. faecalis to daptomycin is dependent upon its growth phase
During exponential phase, cells are in a state of active growth and division. However,
upon reaching stationary phase, metabolic activity is altered, resulting in physiological
changes including thickening of the cell wall [54], reduced protein production [65, 66], and
often, an increase in tolerance to antibiotics which target active cellular processes [26,
33]. To determine whether E. faecalis OG1RF stationary phase cells have increased
tolerance, i.e., increased survival, to daptomycin when compared to exponential phase
cells, we examined sensitivity to daptomycin using cell survival assays (via enumeration
of colony forming units over time; see Materials and methods). For these experiments,
daptomycin concentration was ~7.5–10x MIC (Supplemental Table 2.2).
Stationary phase cultures survived far better when exposed to the drug compared to
cells in exponential phase (Figure 2.1A; P < 0.001 after 15 minutes of daptomycin
treatment). We noted rapid killing of exponential phase cells within
the first 15 min of daptomycin exposure, with a reduction in killing rate over the first hour
of treatment. At four hours post-exposure, cells in exponential phase were below the
limits of detection, while 3.74% of the cells in stationary phase were still present even
after 24 hours of daptomycin exposure (Figure 2.1A and Supplemental Table 2.3).
Cells in exponential phase generally have higher ATP levels than do their stationaryphase counterparts, likely in order to support the active processes involved in cell division
[67]. Further, as reduced ATP levels have been implied in the formation of antibiotic
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Figure 2.1. Cells in stationary phase show increased daptomycin tolerance and
an altered metabolic profile.
(A) Cells were treated with 30 µg/mL daptomycin as described in Materials and Methods.
Shown are the average log ratios of colony forming units ± standard deviations for n = 3
replicates. *** P < 0.001. Note, cell survival for exponential phase cultures was below the
limits of detection at 4 hours and beyond. (B) ATP levels of cells were measured using
the Promega BacTiterGlo kit. Shown are the average relative light units (RLUs)
normalized to colony forming units ± standard deviations for n = 3 replicates. * P 0.05–
0.01; exact P-values are found in Supplemental Table 2.4. (C) Metabolites of cells were
extracted and detected via mass spectrometry as outlined in Materials and methods.
Represented are the log-transformed fold changes of normalized stationary phase cell
metabolites to normalized exponential phase cell metabolites. Normalization was
performed by dividing raw metabolite data by the ratio of colony forming units of stationary
versus exponential phase cells. n = 5 replicates.
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tolerant cells [46, 56, 68], we measured ATP in both exponential and stationary phase
OG1RF cultures.

As shown in Figure 2.1B, stationary phase OG1RF cells had

approximately 22-fold less ATP than their exponential phase counterparts when
normalized to colony forming units (P = 0.024; Supplemental Table 2.4).
As noted, metabolic state is altered when cells are in stationary versus exponential
phase [69-72]. To confirm an altered metabolic profile, we performed an untargeted
metabolomic approach (Figure 2.1C). Cells were grown as described above and used for
metabolic analyses: note that metabolic peak values were normalized to colony forming
units (see Materials and Methods) to ensure appropriate comparisons. Of interest, we
noted compounds with mass/charge ratios corresponding to peptidoglycan precursors,
UDP-NAG (UDP-N-acetylglucosamine) and UDP-NAM-Ala (UDP-N-acetylglucosaminealanine) were reduced, suggesting that peptidoglycan synthesis was reduced. We also
observed alterations in many mass/charge ratios corresponding to amino acids, indicative
of altered rates of protein degradation and synthesis [73], unsurprising for cells in
stationary phase.
To determine whether the increased survival of cells in late stationary phase was due
to reduced ATP content, ATP depletion [56, 57] was performed using sodium arsenate.
Importantly, treatment with sodium arsenate did not affect cell survival (Supplemental
Figure 2.3 and Supplemental Table 2.3), but did reduce ATP levels in exponential phase
cells (Figure 2.2B; P = 0.001). Cells treated with arsenate, however, survived daptomycin
treatment in a similar fashion to the solvent control (Figure 2.2A and Supplemental Table
2.3; P = 0.769 after 15 minutes of daptomycin exposure). Thus, reduced ATP levels did
not correlate with an increase in daptomycin tolerance.

Inhibition of active cellular processes protects OG1RF from daptomycin
Survival of a tolerant population has been attributed to a variety of mechanisms, including
a reduction in cellular growth [47]. As stationary phase OG1RF cells survived daptomycin
treatment far better than exponential cells, we hypothesized that reduced cellular growth
could induce daptomycin tolerance. We artificially induced growth stasis through inhibition
49

Figure 2.2. ATP depletion does not induce daptomycin tolerance.
(A) Cells grown to exponential phase were treated with 10mM sodium arsenate or mocktreated for 30 min, then subjected to 30 µg/mL daptomycin. Shown are the average log
ratios of colony forming units ± standard deviations for n = 3 replicates; exact P-values
are found in Supplemental Table 2.4. (B) ATP levels of pre-treated, mock-treated or
arsenate-treated cells (30 min) were measured using the Promega BacTiterGlo kit.
Shown are the average relative light units (RLUs) normalized to colony forming units ±
standard deviations for n = 3 replicates. * P ≤ 0.05; exact P-values are found in
Supplemental Table 2.4.
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of either de novo protein biosynthesis via addition of chloramphenicol or de novo fatty
acid biosynthesis via addition of cerulenin. Inhibition of cellular growth was used as a
proxy for inhibition of either process (Supplemental Figures 2.1 and 2.2). Upon addition
of chloramphenicol, cellular growth, as observed by colony forming units, was halted
(Supplemental Figure 2.1) but ATP levels were comparable to solvent control-treated
cultures (Figure 2.3B; P = 0.59). Yet, chloramphenicol treatment induced protection from
daptomycin, particularly during the first 15 min of treatment (Figure 2.3A and
Supplemental Table 2.3; 1.8 log fold change; P = 0.002 after 15 minutes of daptomycin
exposure). This protective effect of pre-treatment with chloramphenicol was not as great
as the protection observed in cells treated with daptomycin during late stationary phase,
which, when compared with their exponential phase counterparts, had a 4.1 log fold
increase in survivors during the first 15 min of treatment (Figure 2.1A).
We hypothesized that protection induced by chloramphenicol may be due to
alteration in the metabolic profile upon the inhibition of cellular growth. Using
metabolomics, we detected numerous species with altered ratios when examining
chloramphenicol versus mock-treated cultures (normalized to colony forming units,
please see Materials and Methods, Figure 2.3C). In the chloramphenicol-treated cultures,
we did note statistically significant decreases in mass/charge ratios corresponding to
UDP-NAG and UDP-NAM-Ala, a cytoplasmic precursor to the membrane-bound
peptidoglycan precursors lipid I and lipid II, relative to solvent control-treated cultures
(Figure 2.3C), along with statistically significant alterations of levels of mass/charge ratios
corresponding to different amino acids, including glutamine, unsurprising given that
chloramphenicol inhibits protein synthesis.
We also examined the effects of cellular growth stasis on daptomycin sensitivity by
inhibiting membrane fatty acid biosynthesis via cerulenin treatment. Upon treatment of
cells with cerulenin, cell growth was halted as observed via colony forming units
(Supplemental Figure 2.2) and there was a 1.1 log fold protection induced relative to the
solvent control (Figure 2.4A and Supplemental Table 2.3; P = 0.022 after 15 minutes of
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Figure 2.3. Chloramphenicol-treated cell have increased tolerance to daptomycin
and an altered metabolic profile.
(A) Cells were grown to an OD600 of ~0.250 and treated for 30 min with chloramphenicol
or solvent control, washed with 1xPBS, and then exposed to 30 µg/mL daptomycin.
Shown are the average log ratios of colony forming units ± standard deviations for n = 3
replicates. * P = 0.05–0.01; ** P = 0.01–0.001; *** P ≤ 0.001; exact P-values are found
in Supplemental Table 2.4. (B) ATP levels of pre-treated, solvent-treated or
chloramphenicol-treated cells were measured using the Promega BacTiterGlo kit. Shown
are the average relative light units (RLUs) normalized to colony forming units ± standard
deviations for n = 3 replicates.

ns

= P > 0.05; exact P-values are found in Supplemental

Table 2.4 (C) Metabolites of cells were extracted and detected via mass spectrometry as
outlined in Materials and Methods. Represented are the log-transformed fold changes of
normalized chloramphenicol-treated cell metabolites to normalized solvent controltreated cell metabolites. Normalization was performed by dividing raw metabolite data by
the ratio of colony forming units of chloramphenicol-treated versus solvent control-treated
cells. n = 4 replicates.
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Figure 2.4. Cerulenin-treated cells have increased tolerance to daptomycin and an
altered metabolic profile.
(A) Cells were grown to early exponential phase, treated with cerulenin or solvent control,
washed with 1x PBS, and then subjected to treatment with 30 µg/mL daptomycin. Shown
are the average log ratios of survivors ± standard deviations for n = 3 replicates. * P =
0.05–0.01; ** P = 0.01–0.001; exact P-values are found in Supplemental Table 2.4. (B)
ATP levels of pre-treated, solvent-treated and cerulenin-treated cells were measured
using the Promega BacTiterGlo kit. Shown are the average relative luminescence units
(RLUs) normalized to colony forming units ± standard deviations for n = 3 replicates. ***
P ≤ 0.001; exact P-values are found in Supplemental Table 2.4. (C) Metabolites of cells
were extracted and detected via mass spectrometry as outlined in Materials and Methods.
Represented are the log-transformed fold changes of normalized cerulenin-treated cell
metabolites to normalized solvent control-treated cell metabolites. Normalization was
performed by dividing raw metabolite data by the ratio of colony forming units of cerulenintreated versus solvent control-treated cells. n = 5 replicates.
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daptomycin treatment). However, unlike treatment with chloramphenicol, treatment with
cerulenin resulted in increased ATP levels (Figure 2.4B; P < 0.001).
Given these findings, we examined the metabolic profile of cerulenin-treated cells
versus their solvent controls, in order to identify potential metabolic signatures conserved
between chloramphenicol and cerulenin treatment (Figure 2.4C). We again observed a
decrease in the mass/charge ratio corresponding to UDP-NAM-Ala, but in this case, an
insignificant decrease in detected UDP-NAG. Unique to cerulenin-treated cultures, we
also observed a buildup of the mass/charge ratio corresponding to sn-Glycerol-3phosphate (G3P), the precursor to membrane phospholipids – this is likely because the
cerulenin-treated cultures were unable to synthesize fatty acids which are placed on G3P
to form lysophosphatidic acid [74].
Interestingly,

for

all

of

our

experimental

treatments

(stationary

phase,

chloramphenicol-treated, and cerulenin-treated cells), we noted decreases in the
mass/charge ratio corresponding to UDP-NAM-Ala and alpha-ketoglutarate, a key player
in the citrate cycle and a source of glutamine and glutamate, along with an increase in
the amino acid glutamine. Importantly, glutamine is not only used in protein synthesis but
is also converted to D-glutamate for building peptidoglycan. These changes in metabolite
levels indicate a dysregulation of cell wall synthesis which we investigated further below.

Removal of peptidoglycan protects OG1RF from daptomycin
Despite evidence from multiple studies implicating the cell wall, specifically peptidoglycan,
as the major target of daptomycin [2, 3], additional data supported that membrane
targeting and subsequent pore formation were critical for activity of the drug [17-20, 22,
23]. Given these discrepancies and our own above findings, in particular the significant
decrease in the mass/charge ratio corresponding to UDP-NAM-Ala in stationary phase
and chloramphenicol- and cerulenin-treated cells, we examined the role of peptidoglycan
in the daptomycin sensitivity of OG1RF. We divided exponential cultures such that a
portion was mock-treated (remained as whole cells) and the rest were treated to remove
peptidoglycan (protoplasts; see Materials and Methods).
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Upon treatment with daptomycin, when compared with whole-cell counterparts, we
note that the protoplasts had at least 1.8 log-fold more colony forming units at every time
point (Figure 2.5A and Supplemental Table 2.3; P < 0.001 after 15 minutes of exposure
to daptomycin). As removal of peptidoglycan could stimulate a variety of responses,
including possible stress-response regulons, we examined survival when cells were
treated with SDS, an anionic detergent that disrupts membranes and acts as a nonspecific stressor which activates efflux pumps and rpoS stress responses [75]. However,
removal of peptidoglycan did not induce any protection from SDS (Supplemental Figure
2.4; P = 0.222 after 15 minutes of daptomycin treatment) or significant differences in ATP
levels (Supplemental Figure 2.5). We also performed metabolomics analyses on
protoplast cells compared to whole cells (Supplemental Figure 2.6), and observed
increases in many metabolites, including UDP-NAG, however, the variation between
biological replicates was very high, resulting in insignificant results for most detected
metabolites.

Daptomycin activity is enhanced with specific peptidoglycan synthesis targeting
antibiotics
Our above data suggests that the presence of peptidoglycan renders OG1RF sensitive
to daptomycin. As there are a variety of different antibiotics that target unique, specific
enzymatic processes in the synthesis of peptidoglycan, we performed a checkerboard
assay to better conclude what daptomycin may specifically target. A checkerboard assay
measures the effectiveness of two separate antibiotics when combined versus when
given independently to an organism to quantitatively conclude whether the drugs are
additive or synergistic [58-60]. We examined D-cycloserine, which blocks the
interconversion of L-alanine and D-alanine, as D-alanine is found within the peptide
chains of peptidoglycan; fosfomycin, which targets the first committed step of synthesis,
namely condensation of enolpyruvate with UDP-N-acetylglucosamine by the enzyme
MurA; and ampicillin, which inhibits the transpeptidation reaction that crosslinks two
peptidoglycan molecules.
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Figure 2.5. Removal of peptidoglycan increases tolerance to daptomycin in E.
faecalis.
(A) Cells were grown to mid-logarithmic phase, split, and treated with either lysozyme to
generate protoplasts or solvent control (whole cells) and then treated with 30 µg/mL
daptomycin. Shown are the average log ratios of colony forming units ± standard
deviations for n = 3 replicates. *** P ≤ 0.001; exact P-values are found in Supplemental
Table 2.4. (B) Cells were grown to mid-logarithmic phase (Exp) or to late stationary phase
(24 hour cultures; Stat) and treated with either lysozyme to generate protoplasts or
solvent control (whole cells) and then treated with 30 µg/mL daptomycin. Shown are the
average log ratios of colony forming units ± standard deviations for n = 3 replicates.
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We noted that there was no interaction between D-cycloserine and daptomycin,
potentially due to the cellular growth conditions (Table 2.1, see discussion). Fosfomycin,
in agreement with previous studies in E. faecium and S. aureus [76-79], was synergistic
with daptomycin, suggesting that daptomycin impacts early peptidoglycan synthesis
steps in E. faecalis (see discussion). Additionally, we observed that ampicillin was
additive when combined with daptomycin (Table 2.1).

Peptidoglycan removal enhances stationary phase cell survival against
daptomycin
Combining our above data, we found that stationary phase cells were far more tolerant to
daptomycin when compared to their exponential-phase cell counterparts (Figures 2.1A
and 2.5B), and that removal of peptidoglycan also results in high tolerance (Figure 2.5
and Supplemental Table 2.3). Given that peptidoglycan turnover is increased in stationary
phase relative to exponential phase in E. faecalis [53], and that in stationary phase E.
coli, peptidoglycan is thicker and comprises a higher percentage of the total dry weight
compared to exponential phase cells [54], we decided to probe whether removal of the
cell wall of stationary phase cells altered their daptomycin tolerance. We found that there
was a small, but significant difference between survival of stationary phase whole cells
versus stationary phase protoplasts (Figure 2.5B and Supplemental Table 2.3; P = 0.023
at all time points).

Removal of peptidoglycan protects multiple Gram-positive bacteria from killing
by daptomycin
As removal of peptidoglycan in E. faecalis altered daptomycin tolerance, we examined
whether its removal in other Gram-positive species results in increased daptomycin
survival. Thus, we compared survival of whole cells and protoplasts of E. faecium, S.
aureus, and B. subtilis upon treatment with 7.5–10x MIC (Supplemental Table 2.2). We
found that protoplasts of E. faecium had a 2.1 log-fold survival (or more) over whole cell
counterparts (Figure 2.6A; P < 0.001 at all time points). Similarly, removal of the
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Table 2.1. Combination of peptidoglycan synthesis-targeting antibiotics with
daptomycin on E. faecalis.
Combination

Antibiotic

Antibiotic

(antibiotic A –

A MIC

B MIC

antibiotic B)

(µg/mL)

(µg/mL)

Antibiotic B
MIC (µg/mL)
at Dap MIC

FICI

Effect

of 0.5 µg/mL

Dap – FOF

4

32–128

8–32

0.25–0.375 Synergistic

Dap – DCS

2

128

128

1.25

Dap – AMP

4

0.5

0.25

.625

No
interaction
Additive

Represented are the ranges of individual antibiotic MICs along with the range of the MICs
of antibiotic B combined with daptomycin at 0.5 µg/mL. n = 3 for each experiment. FICI ≤
0.5: synergistic, FICI = 0.5–1: additive; FICI = 1–4: no interaction. DAP; daptomycin, FOF;
Fosfomycin, DCS; D-cycloserine, AMP; ampicillin.
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Figure 2.6. Removal of peptidoglycan increases tolerance to daptomycin in E.
faecium, S. aureus, and B. subtilis.
(A) Treatment of either E. faecium whole cells or protoplasts (see Materials and Methods)
with 30 µg/mL daptomycin. Shown are the average log ratios of survivors ± standard
deviations for n = 3 replicates. *** P ≤ 0.001; exact P-values are found in Supplemental
Table 2.4. (B) S. aureus whole cells or protoplasts (see Materials and Methods) treated
with 5 µ/mL daptomycin. Shown are the average log ratios of survivors ± standard
deviations for n = 3 replicates. *** P ≤ 0.001; exact P-values are found in Supplemental
Table 2.4. (C) B. subtilis whole cells or protoplasts (see Materials or Methods) treated
with 5 µ/mL daptomycin. Shown are the average log ratios of survivors ± standard
deviations for n = 3 replicates. *** P ≤ 0.001; exact P-values are found in Supplemental
Table 2.4.
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peptidoglycan of S. aureus protoplasts had a minimum 3.4 log-fold increase in survivors
(Figure 2.6B; P < 0.001 at all time points) while B. subtilis protoplasts had a 2.5 log fold
increase (or more) in survivors compared to whole cell controls (Figure 2.6C; P < 0.001
at all time points). This demonstrates that across these bacterial species, removal of
peptidoglycan negates most killing by daptomycin.

Discussion
While in the literature there have been multiple proposed targets for daptomycin, several
lines of evidence support peptidoglycan biosynthesis being its major target [2-8, 11]. Here
we demonstrate that daptomycin tolerance, i.e., increased survival following treatment
above the MIC, is dependent on several factors: growth phase, the ability of cells to
synthesize proteins and fatty acids, and the presence/absence of peptidoglycan.
Combined, these data support that peptidoglycan, which is intricately linked to membrane
biosynthesis and requires protein biosynthesis, is necessary for full daptomycin efficacy.
E. faecalis stationary-phase cells were protected to a high degree against daptomycin
relative to their exponential-phase counterparts (Figure 2.1A). However, similar levels of
protection were induced by peptidoglycan removal in exponential phase compared to
stationary phase whole cells (Figures 2.1B and 2.5B, Supplemental Table 2.3). This is
possibly due to cell wall changes which occur in bacteria during stationary phase,
including increases in wall thickness [54] and increases in peptidoglycan recycling [80] as
well as decreased peptidoglycan synthesis [81]. Additionally, this could be due to a
reduction in wall turnover in stationary phase cells compared to exponential phase cells
[82] or due to increased degradation of MurA, which catalyzes the first committed step of
peptidoglycan synthesis by transferring enolpyruvate from phosphoenolpyruvate to UDPNAG [83], in stationary phase cells [84]. In our data, we noted that in stationary phase
cells, phosphoenolpyruvate was decreased relative to exponential phase cells (Figure
2.1C), potentially indicating altered MurA activity.
Given these data and previous studies, why would addition of chloramphenicol, a de
novo protein synthesis inhibitor, or cerulenin, an inhibitor of fatty acid biosynthesis, induce
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daptomycin protection? The production of peptidoglycan is needed for cellular replication
and expansion of the population size. Inhibiting protein biosynthesis, as shown via a halt
in colony forming units (Supplemental Figure 2.1), prevents cellular division. However, in
E. faecalis (formerly Streptococcus faecalis), previous work indicated that upon treatment
with chloramphenicol, cellular division stopped while peptidoglycan synthesis still
occurred, though at a lower rate, resulting in thickening of the cell wall [85]. Thus, perhaps
the effectiveness of daptomycin may be altered because of a reduction in peptidoglycan
synthesis. Similarly, previous studies have shown that addition of the fatty acid
biosynthesis inhibitor cerulenin to exponentially growing E. faecalis reduces but does not
abrogate peptidoglycan synthesis [86], and can lead to cell expansion and
altered/misplaced cell wall biosynthesis [87]. The protective effect we observe on treating
exponentially growing cultures with chloramphenicol or cerulenin could possibly also be
explained by a dilution of targets caused by increased and misplaced wall synthesis [8587].
Our metabolomics data also suggests that decreased peptidoglycan biosynthesis
could be the cause of the protective effects we see, as the mass/charge ratio
corresponding to UDP-NAM-Ala is decreased in stationary phase cells, cells treated with
cerulenin, and cells treated with chloramphenicol (Figures 2.1C, 2.3C, and 2.4C). As
noted, we also observed a significant decrease in the mass/charge ratio corresponding
to alpha-ketoglutarate in stationary phase cells and upon treatment with chloramphenicol
and cerulenin, as well as a significant increase in the mass/charge ratio corresponding to
glutamine under these conditions. Fascinatingly, both of these metabolites can be linked
back to peptidoglycan synthesis, as alpha-ketoglutarate and glutamine are suppliers of
glutamate, which is an amino acid incorporated into the amino acid side-chains of
peptidoglycan. It should be noted here that in order to confirm these significant
metabolites among the experimental groups, a significant analysis microarray (SAM) was
performed to calculate potential rates of false discovery and identify those metabolites
that are statistically significant based on two different analyses (heatmap and SAM). The
results of these experiments also provide some insights as to why treatment with high
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levels of daptomycin result in “biphasic” killing of multiple bacterial species [10, 22, 2529]. Those cells that survive high daptomycin do so likely because they are not actively
synthesizing and turning over peptidoglycan [11, 24]. For both chloramphenicol-treated
and cerulenin-treated cultures, we also noted a significant decrease in the mass/charge
ratio corresponding to methionine sulfoxide, a precursor to methionine. However, due to
the lack of corresponding increases of mass/charge ratios of methionine sulfoxide in
stationary phase cells, we cannot confirm that this decrease is directly responsible for the
increases in daptomycin tolerance we observe under these conditions.
Further evidence to support peptidoglycan as a target for daptomycin comes from the
observed positive effects of combining daptomycin with other cell-wall targeting drugs
(Table 2.1). The synergistic effects between fosfomycin and daptomycin could potentially
be explained by an upregulation of MurA caused by exposure to daptomycin [88, 89]. In
turn, fosfomycin tightly binds to MurA, thus blocking the first committed step of
peptidoglycan biosynthesis [83]. Similarly, daptomycin was found in S. aureus to increase
the expression of PBP1 [90], the target of ampicillin, thus potentially explaining the
observed additive effect between daptomycin and ampicillin which is in line with synergy
observed during time-kill experiments combining β-lactam antibiotics with daptomycin
[91]. We did not observe an interaction between daptomycin and D-cycloserine: this could
be because D-cycloserine simply “freezes” the pools of L-ala and D-ala by binding to
alanine racemase. Note that its effect on peptidoglycan synthesis depends on the current
state of the pools of L-ala and D-ala [92] and given that our experiments were carried out
in rich media, it is possible that the pool of D-ala was great enough to prevent either a
synergistic or additive effect between daptomycin and D-cycloserine.
Interestingly, a recent study gave evidence that pre-incubation of B. subtilis with
teixobactin, a lipid II and lipid III targeting antibiotic [78], protected cells against
daptomycin, rather than acting synergistically with it [11]. As teixobactin shares a target
with daptomycin, a pre-treatment with (and subsequent washing away of, as performed
by Grein et al., 2020) teixobactin could reduce the number of targets for daptomycin to
effectively bind to, leading to protection against daptomycin [11].
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While the data presented above support peptidoglycan is a target for daptomycin, it
was originally dismissed, as daptomycin still killed E. faecium cells which had their cell
walls removed [10]. Though our observations agree with published literature that
protoplasted cells can be subject to killing by daptomycin [10], our inclusion of a whole
cell control provides a fuller picture. We found that some killing of protoplasted cells
occurred, however, when protoplasts were compared to the whole cell control, there was
a minimum of a 1.8 log-fold increase in survival against daptomycin, independent of the
bacterial species being tested (Figures 2.5 and 2.6).
While we have demonstrated here that bacterial growth state and that the presence
or absence of peptidoglycan are of major importance for daptomycin efficacy regardless
of bacterial species, it is possible and indeed probable that treatment of cells with
lysozyme and with different antibiotics may alter the cellular membrane, in particular
phosphatidylglycerol amounts and localization, reducing daptomycin binding. This is
critical as daptomycin has been shown to interact with lipid II and phosphatidylglycerol
[11, 17, 18].

Further investigation is needed to determine the bacterial membrane

composition under these conditions in order to assess whether specific changes to the
bacterial membrane are responsible for altered daptomycin efficacy.
Within this work, we have demonstrated that intact peptidoglycan is required for full
daptomycin efficacy, and that dysregulation of cellular metabolism can result in significant
increases in daptomycin tolerance. Our results aid in informing of possible effective
treatment combinations in the clinic and new therapeutic approaches.
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Appendix
Supplemental Table 2.1. List of bacterial strains used in this study.
Bacterial strain

Reference

Enterococcus faecalis OG1RF

Lab stock.

Enterococcus faecium DO (TX0016)

Generous gift of Barbara Murray.

Staphylococcus aureus USA300

From ATCC.

Bacillus subtilis sub. subtilis 168

Lab stock.
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Supplemental Table 2.2. Minimal inhibitory concentrations of daptomycin for the
bacterium used in this study.
Bacterial strain

MIC range (µg/mL)

Enterococcus faecalis OG1RF7

2-4

Enterococcus faecium DO (TX0016)

4

Staphylococcus aureus USA300

0.5-1

Bacillus subtilis sub. subtilis 168

0.5

Minimal inhibitory concentrations (MICs) were performed using broth dilution technique.
The ranges observed are reported above. Brain heart infusion + 1.5 mM CaCl2 was used
for Enterococcus and Staphylococcus strains grown statically. LB + 1.5 mM CaCl2 was
used for B. subtilis grown shaking (250 RPM). n = 3 for all experiments.
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Supplemental Table 2.3. Colony forming units per milliliter (CFU/mL) taken during
cell survival assays within this study.

Exponential

Variable

Corresponding
figure in text

Figure 2.1A

0 minutes
15 minutes
30 minutes
60 minutes
240 minutes
24 hours
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

CFU/mL
(replicate 1)
2.54 X 108
6.50 X 104
1.81 X 104
4.80 X 103
1.00 X 102
Below limit of
detection
1.27 X 109
8.70 X 108
8.70 X 108
6.20 X 108
4.70 X 108
6.40 X 107
3.50 X 108
3.20 X 104
1.07 X 104
5.90 X 103
1.78 X 108

CFU/mL
(replicate 2)
2.71 X 108
1.40 X 105
1.71 X 104
4.10 X 103
2.30 X 102
Below limit of
detection
1.49 X 109
7.00 X 108
7.80 X 108
5.50 X 108
3.00 X 108
5.00 X 107
5.00 X 108
5.20 X 104
7.80 X 103
2.90 X 103
1.81 X 108

CFU/mL
(replicate 3)
2.92 X 108
3.00 X 104
8.40 X 103
4.60 X 103
2.30 X 102
Below limit of
detection
1.42 X 109
7.20 X 108
5.70 X 108
7.30 X 108
3.00 X 108
4.00 X 107
3.80 X 108
9.20 X 103
1.78 X 103
9.60 X 102
2.08 X 108

15 minutes

9.90 X 103

1.13 X 104

3.60 X 103

30 minutes

2.21 X 103

1.83 X 103

7.20 X 102

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes

102

8.30 X
2.12 X 108
1.61 X 103
8.90 X 102
4.00 X 102

102

9.40 X
2.97 X 108
2.70 X 103
8.80 X 102
3.10 X 102

2.70 X 102
2.40 X 108
2.01 X 103
6.50 X 102
2.40 X 102

0 minutes

1.54 X 108

8.90 X 107

8.90 X 107

15 minutes

6.90 X 104

1.05 X 105

2.80 X 105

30 minutes

4.80 X 103

5.50 X 103

4.20 X 103

60 minutes

6.60 X 102

1.21 X 103

1.96 X 103

0 minutes
15 minutes
30 minutes
60 minutes
0 minutes
15 minutes

1.15 X 108
7.30 X 103
4.70 X 102
9.00 X 101
8.50 X 107

1.26 X 108
5.90 X 103
5.20 X 102
1.10 X 102
7.90 X 107

1.52 X 108
1.09 X 103
3.30 X 102
1.90 X 102
1.02 X 108

6.30 X 104

4.60 X 104

5.10 X 104

30 minutes

5.20 X 103

2.80 X 103

4.70 X 103

60 minutes

102

102

1.61 X 103

Time
0 minutes
15 minutes
30 minutes
60 minutes
240 minutes

Stationary

Figure 2.2A

Figure 2.3A

Solvent
control

Figure 2.3A

Figure 2.4A

Cerulenin

Chloramphenicol

Arsenate

Figure 2.2A

Solvent
control

Figure 2.1A

Water

24 hours

Figure 2.4A

6.10 X

1.80 X
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Supplemental Table 2.3 Continued
Corresponding
figure in text

Protoplasts
Whole
Cells
(Exp)
Protoplasts
(Exp)

Figure 2.5B

Figure 2.5B

Whole
Cells
[E.
faecium]

Figure 2.5B

Figure 2.6A

Protoplasts
[E.
faecium]

Figure 2.5B

Figure 2.6A

Whole
Cells
[B.
subtilis]

Figure 2.5A

Whole
Cells
(Stat)

Figure 2.5A

Protoplasts
(Stat)

Whole
cells

Variable

Figure 2.6B

0 minutes

CFU/mL
(replicate 1)
3.15 X 108

CFU/mL
(replicate 2)
3.25 X 108

CFU/mL
(replicate 3)
2.53 X 108

15 minutes

4.10 X 103

2.60 X 103

1.72 X 104

30 minutes

1.00 X

103

102

2.65 X 103

60 minutes

1.20 X 102

1.20 X 102

1.50 X 102

0 minutes

3.20 X 106

9.30 X 105

4.40 X 106

15 minutes

9.00 X 105

9.10 X 104

7.00 X 105

30 minutes

6.90 X 105

4.20 X 104

3.70 X 105

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

3.40 X 105
4.50 X 108
4.40 X 102
3.20 X 102
3.30 X 102
9.60 X 105

3.09 X 104
4.70 X 108
2.90 X 102
3.20 X 102
3.10 X 102
3.40 X 106

2.09 X 105
3.90 X 108
3.40 X 102
3.50 X 102
3.10 X 102
9.00 X 105

15 minutes

3.20 X 105

1.12 X 106

2.60 X 105

30 minutes

3.90 X 105

7.10 X 105

2.70 X 105

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

2.45 X 105
9.20 X 108
2.56 X 108
1.81 X 108
3.20 X 107
2.80 X 108

4.30 X 105
1.25 X 109
3.60 X 108
1.79 X 108
1.63 X 108
5.40 X 108

1.82 X 105
1.25 X 109
4.20 X 108
2.53 X 108
2.01 X 108
2.50 X 108

15 minutes

3.00 X 108

3.15 X 108

3.00 X 108

30 minutes

3.50 X 108

3.14 X 108

2.75 X 108

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

2.11 X 108
1.21 X 108
6.30 X 103
2.81 X 103
2.00 X 102
4.80 X 106

2.40 X 108
2.40 X 108
5.40 X 103
2.25 X 103
6.40 X 102
9.70 X 105

2.15 X 108
3.10 X 107
6.40 X 103
2.71 X 103
7.20 X 102
6.90 X 105

15 minutes

2.08 X 106

6.00 X 105

4.50 X 105

30 minutes

5.30 X

105

105

3.70 X 105

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes

1.70 X 105
1.82 X 107
2.10 X 102
2.20 X 102
2.30 X 102

5.40 X 105
1.76 X 107
1.50 X 102
1.90 X 102
1.20 X 102

3.70 X 105
3.20 X 107
1.30 X 102
1.30 X 102
1.40 X 102

Time

2.40 X

5.30 X
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Supplemental Table 2.3 Continued
Corresponding
figure in text

Figure 2.6C

Figure 2.6C

Sodium
Arsenate

Supplemental
Figure 2.3

Whole
Cells

Supplemental
Figure 2.3

Supplemental
Figure 2.4

Protoplasts

Mock
Treatment

Whole
Cells
[S.
aureus]

Figure 2.6B

Protoplasts
[S. aureus]

Protoplasts
[B. subtilis]

Variable

Supplemental
Figure 2.4

0 minutes

CFU/mL
(replicate 1)
2.90 X 105

CFU/mL
(replicate 2)
7.00 X 105

CFU/mL
(replicate 3)
5.40 X 105

15 minutes

6.50 X 104

9.30 X 104

1.64 X 105

30 minutes

3.10 X 104

4.90 X 104

1.32 X 105

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

4.60 X 104
4.70 X 106
2.74 X 103
1.17 X 103
2.30 X 102
1.39 X 107

9.40 X 104
2.81 X 107
1.64 X 104
2.36 X 103
5.10 X 102
2.28 X 107

2.30 X 105
8.10 X 106
2.52 X 103
1.70 X 103
1.90 X 102
1.50 X 107

15 minutes

1.22 X 107

1.45 X 107

1.36 X 107

30 minutes

1.52 X 107

1.04 X 107

1.12 X 107

60 minutes

1.17 X 106

9.10 X 105

9.80 X 105

108

108

3.06 X 108

Time

0 minutes

3.08 X

3.40 X

15 minutes

2.90 X 108

3.70 X 108

3.00 X 108

30 minutes

5.30 X 108

3.90 X 108

5.50 X 108

60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes
15 minutes
30 minutes
60 minutes
0 minutes

6.20 X 108
2.06 X 108
2.17 X 108
3.00 X 108
2.98 X 108
3.13 X 108
3.61 X 105
3.26 X 105
2.72 X 105
7.30 X 106

5.80 X 108
2.20 X 108
2.07 X 108
3.00 X 108
2.90 X 108
2.76 X 108
3.70 X 105
3.13 X 105
2.32 X 105
1.01 X 106

6.40 X 108
1.95 X 108
2.17 X 108
2.97 X 108
3.20 X 108
3.30 X 108
1.07 X 105
1.09 X 105
8.50 X 104
1.31 X 106

15 minutes

2.07 X 103

2.80 X 102

3.60 X 102

30 minutes

1.75 X 103

4.70 X 102

3.30 X 102

60 minutes

1.35 X 103

3.70 X 102

4.00 X 102
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Supplemental Table 2.4. P-values determined within this study.
Cell survival assays
Variable 1
Exponential

Mock treatment

Variable 2

Corresponding figure
in text

Stationary

Figure 2.1A

Sodium arsenate

Figure 2.2A

Chloramphenicol

Figure 2.3A

Cerulenin

Figure 2.4A

Protoplasts

Figure 2.5A

Protoplasts (Stat)

Figure 2.5B

Whole Cells
[E. faecium]

Protoplasts
[E. faecium]

Figure 2.6A

Whole Cells
[B. subtilis]

Protoplasts
[B. subtilis]

Figure 2.6B

Whole Cells
[S. aureus]

Protoplasts
[S. aureus]

Figure 2.6C

Mock Treatment

Sodium Arsenate

Whole Cells

Protoplasts

Solvent control

Solvent control

Whole Cells

Whole Cells (Stat)

Supplemental Figure 2.3

Supplemental Figure 2.4

Time
(min)
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60
15
30
60

P-value
<0.001
<0.001
<0.001
0.769
0.769
0.769
0.002
0.001
0.015
0.022
0.002
0.030
<0.001
<0.001
<0.001
0.023
0.023
0.023
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.884
0.884
0.104
0.222
0.233
0.233

ATP Determination Assays
Variable 1

Variable 2

Exponential
Mock treatment
Solvent control
Solvent control
Whole Cells

Stationary
Arsenate
Chloramphenicol
Cerulenin
Protoplasts

Corresponding figure
in text
Figure 2.1B
Figure 2.2B
Figure 2.3B
Figure 2.4B
Supplemental Figure 2.5

P-value
0.0246
0.0011
0.5948
<0.001
0.2675

Two-tailed Welch’s t-tests were used to generate P-values. In the text, α = 0.05 was used
to determine significance.
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Supplemental Figure 2.1. Addition of chloramphenicol halts cellular division.
(A) Optical density of cells over time. Shown are the average optical densities at 600 nm
± standard deviations for n = 3 replicates. Black arrow indicates addition of
chloramphenicol or solvent control at mid-logarithmic phase (at 175 min into the growth
curve; OD600 ~ 0.250). Red arrow indicates when cells were harvested and processed
prior to a subsequent cell survival assay (30 min post-chloramphenicol/solvent control
treatment). (B) The number of colony-forming units as determined by dilution plating of
the cultures in S1A. T0 is just prior to the addition of chloramphenicol or solvent control
into the cultures, and T30 and T60 are 30 and 60 min after addition of chloramphenicol
or solvent control into the cultures, respectively. n = 3.
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Supplemental Figure 2.2. Addition of cerulenin halts cellular division.
(A) Optical density of cells over time. Shown are the average optical densities at 600 nm
± standard deviations for n = 3 replicates. Black arrow indicates addition of cerulenin or
solvent control at early-logarithmic phase (at 125 min into the growth curve; OD 600 ~
0.125). Red arrow indicates when cells were harvested and processed prior to a
subsequent cell survival assay (90 min post-cerulenin/solvent control treatment). (B) The
number of colony-forming units as determined by dilution plating of the cultures in S2A.
T0 is just prior to the addition of cerulenin or solvent control into the cultures. T30, T60,
T90, and T120 are 30, 60, 90, and 120 min after addition of cerulenin or solvent control
into the cultures, respectively. n = 3.

86

Supplemental Figure 2.3. Cells treated with sodium arsenate are still viable.
E. faecalis OG1RF cells were grown in BHI until OD600 reached ~0.250. The cultures were
split and treated with 10mM arsenate or mock-treated with water for 30 minutes. Following
treatment, the cells were washed twice to remove arsenate and resuspended in BHI prior
to enumerating colony forming units. Represented are the log ratio of colony forming units
±standard deviations over time. ns P > 0.05. n = 3.
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Supplemental Figure 2.4. Protoplasts are not protected against sodium dodecyl
sulfate.
E. faecalis OG1RF cells were grown to mid-logarithmic phase (OD600 ~ 0.3–0.4), split and
treated with either lysozyme to generate protoplasts or solvent control to leave cell whole.
Subsequently washed cells were subjected to killing by 0.05% SDS. Shown are the
average log ratios of survivors ± standard deviations for n = 3 replicates. No significant
differences were observed. Exact P-values are reported in Supplemental Table 2.4.

88

Supplemental Figure 2.5. ATP levels of E. faecalis OG1RF whole cells and
protoplasts normalized to colony forming units.
Cells were grown to mid-logarithmic phase (OD600 ~ 0.3–0.4) and treated with either
lysozyme to generate protoplasts or solvent control to leave cells whole. ATP levels of
pre-treatment cells and whole cells or protoplasts were measured using the Promega
BacTiterGlo kit and normalized to colony forming units. Shown are the average relative
light units (RLUs) normalized to colony forming units ± standard deviations for n = 3
replicates. ** P = 0.01–0.001; exact P-values are reported in Supplemental Table 2.4.
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Supplemental Figure 2.6. Removal of peptidoglycan results in a buildup of several
metabolites.
Exponentially growing (OD600 ~ 0.3) E. faecalis cells were grown to mid-logarithmic phase
(OD600 ~ 0.3–0.4), split and treated with either lysozyme to generate protoplasts or solvent
control to leave cell whole as described in Materials and Methods. Metabolites of the cells
were extracted and detected via mass spectrometry as outlined in Materials and Methods.
Represented are the log-transformed fold changes of normalized whole cell metabolites
to normalized protoplast metabolites. Normalization was performed dividing raw
metabolite data by the ratio of colony forming units of protoplast versus whole cells. n =
5 replicates.
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CHAPTER 3: AN EXPANDED ROLE OF THE FAK SYSTEM AND THE
THIOESTERASE TESS IN ENTEROCOCCUS FAECALIS
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Future Publication Note
A version of this chapter will eventually be submitted for publication.

Johnston RD, Woodall BM, King, A, Getty T, Campagna SR, and Fozo EM. An
expanded role for the Fak system and TesS in Enterococcus faecalis. 2022/2023.

Experiments were completed by Rachel Johnston, with the following exceptions:
Transmission electron microscopy was performed by Ainsley King. Troy Getty performed
the growth assay of wild-type E. faecalis and deletion strains in 2.5 µg/mL palmitic acid.
Mass spectrometry experiments were performed by Brittni Woodall. GC-FAME was
completed by Microbial ID.
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Abstract
Enterococcus faecalis is a Gram-positive organism which commensally resides in the
human gastrointestinal tract, yet can cause infections in other bodily tissues. Although
these environments are rich in fatty acids, E. faecalis cannot use exogenous fatty acids
as carbon sources. It does, however, possess homologs to the Fak (fatty acid kinase)
pathway which enables organisms to utilize exogenous fatty acids in phospholipid
synthesis. Herein, we examined the role of these homologs in lipid synthesis. Further, we
demonstrate that upon deletion of three of the four fakB homologs (ΔfakB1,2,5) of E.
faecalis, several phenotypes arise, including accumulation of free fatty acids in the
membrane, an altered lipid profile, and severe growth issues. Moreover, we were unable
to delete all four fakB homologs without first deleting tesS, a gene which encodes a
thioesterase that liberates fatty acids from the acyl carrier protein. Upon deletion of all of
the fakB homologs and tesS (generating a quintuple deletion strain), growth was restored.
Taken together, these data indicate that the Fak system and TesS work together to
generate acyl-phosphates necessary for generating phospholipids. Additionally, we found
that deletion of the fakB homologs along with tesS resulted in inability of a supplied fatty
acid, oleic acid, to rescue growth inhibition by the de novo fatty acid biosynthesis inhibitor
cerulenin. This indicated that incorporation of exogenous fatty acids was reduced in the
quintuple deletion strain. This strain, however, was able to grow uninhibited in fatty acids
toxic to wild-type E. faecalis, indicating that incorporation of these fatty acids may mediate
their toxicity. Taken together, these data indicate that the FakB and TesS proteins of E.
faecalis play a role in fatty acid homeostasis.
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Introduction
Many bacterial species have a range of interactions with their hosts. These bacteria can
adapt to different host environments and may, in the same host, occupy both a
commensal niche and a pathogenic niche. One such organism, Enterococcus faecalis,
commensally colonizes the human gastrointestinal tract, yet upon entering wounds or
other tissues, causes infection. These two different environments, where E. faecalis is
exposed to bile (gastrointestinal tract; commensal state) or serum (host tissues;
pathogenic state), impact the physiology of E. faecalis given the presence of different
nutrient constituents, including long-chain fatty acids, found within these host fluids [1].
Long-chain exogenous fatty acids can be used by bacteria to generate energy, as
signaling molecules, or for membrane modification or synthesis. Gram-negative
organisms such as Escherichia coli can transport fatty acids (acyls), attach them to
coenzyme A (CoA) and begin the process of energy generation [2]. The acyl-CoA can
then be used in β-oxidation, (i.e., fatty acid catabolism), eventually forming acetyl-CoA,
which can then enter the citric acid cycle for generating energy [2]. Acyl-CoA can also be
transferred to glycerol-3-phosphate (G3P) to form phospholipid precursors [3].
While exogenous fatty acids can be used as a carbon source in some bacteria, they
can also act as signaling molecules which alter fatty acid metabolism. This has been
demonstrated in one such species, Bacillus megaterium, which can convert toxic
unsaturated fatty acids to epoxides, rendering them non-toxic [4]. In this system,
unsaturated fatty acids act as signaling molecules by binding to the repressor protein
Bm3R1, enabling the transcription of cyP102 [4] which codes for an enzyme capable of
completing the epoxidation reaction [5]. One other organism which demonstrates the
ability use fatty acids as signaling molecules is E. coli. Although E. coli can use free fatty
acids as a carbon source, growth in media containing fatty acids with a carbon chain
length of 12 or greater induced expression of genes involved in fatty acid degradation [6].
For many other bacterial species, exogenous long-chain fatty acids block de novo fatty
acid biosynthesis [3, 7-9]. In E. faecalis, fatty acids repress de novo fatty acid biosynthesis
through binding an auxiliary acyl carrier protein, AcpB [10]. The resulting acyl-AcpB then
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interacts with FabT, repressing fatty acid gene expression [10]. Deletion of acpB resulted
in continued de novo fatty acid synthesis even in the presence of supplied fatty acids [10].
Thus, exogenous fatty acids are important for regulation of de novo fatty acid synthesis.
Exogenously supplied long-chain fatty acids can also be used for forming
phospholipids (Figure 3.1). In organisms such as Streptococcus pneumoniae and
Staphylococcus aureus, β-oxidation does not occur; however, in these organisms,
exogenous fatty acids are bound by a FakB protein and are activated via phosphorylation
by a FakA protein [11, 12]. The phosphorylated fatty acid can then be incorporated onto
glycerol-3-phosphate by the enzyme PlsY or can be converted to acyl-ACP by the
enzyme PlsX [12]. Acyl-ACP can enter the de novo fatty acid synthesis cycle or can be
used as an acyl donor to form phospholipid precursors [12]. In S. aureus, there are two
proteins which initially bind exogenous fatty acids prior to their activation: saFakB1 (for S.
aureus FakB1), which specifically binds to saturated fatty acids, and saFakB2, which
binds to unsaturated fatty acids [12]. Similarly, S. pneumoniae possesses spFakB1 (for
S. pneumoniae FakB1) and spFakB2, which follow the specificity of S. aureus, along with
an additional protein, spFakB3, which binds polyunsaturated fatty acids [11]. While their
specificities remain unclear, we and others have noted that there are four FakB homologs
in E. faecalis [13].
Regardless of whether formed from exogenous or internally produced fatty acids,
phosphorylated acyl chains (acyl-phosphates) are critical for phospholipid biosynthesis
(Figure 3.1). Specifically, PlsY uses acyl-phosphates, generated either from PlsX (using
acyl-ACP) or from the Fak system, along with G3P to generate lysophosphatidic acid
(Reviewed in [14]). Additionally, while the Fak system phosphorylates free fatty acids from
the external environment for lipid synthesis, free fatty acids can also be generated
internally by cleavage of an acyl from acyl-ACP by the thioesterase TesS in S.
pneumoniae [15]. The newly generated free fatty acid can then be used as a substrate
for the Fak system to generate acyl-phosphates [15]. However, given that deletion of the
fak genes in S. aureus and S. pneumoniae was not lethal and did not impact the growth
of the cells, this route is thought to be a minor pathway in this organism.
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Figure 3.1. Synthesis and use of free fatty acids in E. faecalis.
Free fatty acids, whether exogenously supplied or produced by cleavage of a fatty acid
(acyl) from acyl-ACP by TesS, are bound by a FakB protein. The FakA enzyme
phosphorylates the acyl, forming acyl-phosphate (Acyl-PO4). Acyl-phosphates are
incorporated onto the SN-1 position of glycerol-3-phosphate by PlsY to form
lysophosphatidic acid (LPA). Acyl-phosphates can also be bound to the acyl carrier
protein (ACP) through the action of PlsX. Acyl-ACP, generated through the de novo fatty
acid synthesis cycle (FasII), is used as the acyl donor to form phosphatidic acid, the
precursor to membrane phospholipids. The acyl group can be cleaved from acyl-ACP by
TesS to form a free fatty acid.
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Whether being metabolized, functioning as signaling molecules, or being funneled
into the fatty acid biosynthesis pathway and/or membrane phospholipids, exogenous
long-chain fatty acids have a variety of effects on bacterial physiology. In S. aureus,
exposure to specific free fatty acids impacts membrane composition [16]. Furthermore,
exposure of S. aureus to specific “toxic” fatty acids (i.e., toxic to growth for this species),
such as palmitoleic acid (C16:1cis9), resulted in membrane depolarization and the release
of proteins into the growth medium [17]. In E. faecalis, the addition of specific saturated
fatty acids impacts the gross morphology of the cells [18]. Additionally, some
exogenously-supplied fatty acids severely impacted the generation time of E. faecalis,
and in some cases caused premature growth stasis [1, 18]. Importantly, several fatty
acids examined had positive effects on enterococcal physiology: for example, the addition
of oleic acid (C18:1cis9), which is prevalent in host fluids, yet not synthesized by E. faecalis,
enabled cells to overcome inhibition of membrane biosynthesis by cerulenin [18].
Given the clear evidence that exogenous fatty acids alter the physiology of E.
faecalis, and that E. faecalis cannot use these fatty acids for energy via β-oxidation, we
examined the role of the FakA/FakB system in enterococcal physiology. Unexpectedly,
we discovered a requirement for the Fak system in media lacking exogenous fatty acids.
Specifically, we were unable to delete all four fakB genes in E. faecalis. Combined
deletion of specific fakB genes resulted in altered growth in specific fatty acids; in
particular, the fakB1,2,5 strain had a longer generation time when unsaturated
exogenous fatty acids were present in its growth media compared to a wild-type strain,
and in unsupplemented medium had hyperseptation and alterations to its fatty acid profile.
However, we were able to delete all four fakB genes when combined with deletion of
tesS. We confirmed that this quintuple deletion strain (fakB1,2,4,5/ΔtesS) was
dependent upon de novo fatty acid biosynthesis for membrane formation, as the addition
of exogenous fatty acids could not overcome inhibition by cerulenin. Furthermore, the
negative growth phenotypes observed in ΔfakB1,2,5 were rescued in the quintuple
deletion strain. Finally, while the addition of specific fatty acids inhibited growth of the
wild-type strain, these same fatty acids had no effect on growth of the quintuple deletion
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strain, suggesting that incorporation of these fatty acids into phospholipids is responsible
for their toxicity.

Materials and Methods
Identification of FakA and FakB homologs
FakA and FakB homologs were identified using NCBI Basic Local Alignment Search Tool
for proteins (BLASTP). Briefly, each individual S. aureus (SAUSA300_0733 and
SAUSA300_1318 [12]) and S. pneumoniae FakB protein (Sp1557, Sp1112, and Sp0742
[11]) was used as a query for BLASTP (protein-protein BLAST algorithm) against E.
faecalis OG1RF using the non-redundant protein sequences (nr) database. Percent
identity and percent similarity from each BLAST result were reported from the resulting
alignments.

FakB protein modelling and multiple sequence alignment
The identified FakB homologs of E. faecalis (OG1RF_RS00080, OG1RF_RS07200,
OG1RF_RS05020, and OG1RF_RS06660) along with saFakB1 were modelled using
Protein Homology/analogy Recognition Engine V 2.0 (Phyre2; [19]). Briefly, the amino
acid sequence for each E. faecalis FakB homolog was entered into the server and
modelled using intensive mode. A multiple sequence alignment of the FakB homologs of
E. faecalis along with the FakB proteins of S. aureus and S. pneumoniae were aligned
using Clustal Omega [20, 21]. The resulting alignment was annotated by highlighting
residues important for FakB function noted by [22].

Bacterial growth conditions
Enterococcus faecalis strains (listed in Supplemental Table 3.1) were grown statically in
brain heart infusion medium (BHI; BD Difco) at 37°C. Overnight cultures were diluted to
an optical density at 600 nm (OD600) of 0.01 prior to performing assays. For the
determination of generation times, fatty acids were supplemented at the following
concentrations: oleic acid (C18:1 cis9) at 20 µg/mL, linoleic acid (C18:2 cis9,12) at 10 µg/mL,
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stearic acid (C18:0) at 20 µg/mL, myristic acid (C14:0) at 5 µg/mL, and palmitic acid (C16:0)
at 5 µg/mL or 2.5 µg/mL as indicated in the text. For cerulenin outgrowth assays, cerulenin
was supplemented at 5 µg/mL and oleic acid (C18:1 cis9) was supplemented at 5 µg/mL as
previously described [18]. For all experiments utilizing fatty acids, a solvent control was
also included, whereby an equal volume of ethanol was added to the control culture. All
fatty acids and reagents were purchased from Millipore-Sigma unless otherwise noted.
Counterselection was performed on M9 minimal medium containing yeast extract and
glucose (M9MMYEG) agar plates (final concentrations 1X M9 salts, 0.25% yeast extract,
150 µg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 0.5% glucose, and
10 mM p-Cl-phenylalanine (p-Cl-Phe; Sigma-Aldrich or Alfa Aesar). Escherichia coli
cultures were grown in LB medium at 37°C with shaking. Antibiotics were used at the
following concentrations when needed: erythromycin, 10 µg/mL (E. faecalis) or 100 µg/mL
(E. coli); spectinomycin, 1,000 µg/mL; fusidic acid, 25 µg/mL; rifampicin, 250 µg/mL;
chloramphenicol, 25 µg/mL. All media components, unless otherwise noted, were
purchased from ThermoFisher.

Generation of deletion strains
The strains and plasmids used in this study are listed in Supplemental Table 3.1, and the
sequences for oligonucleotides used are given in Supplemental Table 3.2. Deletion
strains were generated following the protocol of Kristich et al., 2007 [23]. Briefly, to delete
the fakB genes and tesS, ~1 kb upstream (designated as piece 1) and ~1 kb downstream
(designated as piece 2) of the respective gene was amplified from E. faecalis OG1RF
genomic DNA using primers with complementary overlaps with the vector (pCJK47) and
the neighboring piece. The vector, pCJK47, was amplified with complementary overlaps
to both piece 1 and piece 2. The amplified inserts and vectors were assembled using NEB
Gibson Assembly Master Mix. The resulting assembly was transformed into E. coli
EC1000. The resulting plasmids, pRDJ1, pRDJ2, pRDJ3, pRDJ4, and pRDJ5, used to
generate ΔfakB1, ΔfakB2, ΔfakB4, ΔfakB5, and ΔtesS respectively, were transformed
into a conjugative donor strain of E. faecalis, CK111/pCF10-101. The resulting
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CK111/pCF10-101 derivatives were then mixed with an OG1RF recipient at a ratio of 1
part donor to 9 parts recipient. The mixture was plated on BHI and mating was allowed to
proceed for 5 h at 37°C. To select for transconjugant recipients, the resulting mixture was
plated on BHI agar containing rifampicin, fusidic acid, erythromycin, and X-gal. To select
for donors, the resulting mixture was plated on BHI agar containing spectinomycin and
erythromycin. Blue colonies from the recipient plates were then re-isolated on the same
medium. The isolates were grown in BHI for 18-24 h, passaged again into fresh BHI, and
plated on M9MMYEG. White colonies were isolated onto BHI, tested for erythromycin
sensitivity by patching isolates onto BHI containing erythromycin, and screened for
deletion of the respective gene.

Phospholipid extraction and thin layer chromatography (TLC)
Briefly, 5 mL cultures were grown to mid-logarithmic phase in BHI. Following growth, the
cells were harvested by centrifugation (2379xg for 10 min) and washed twice with 1X PBS
to remove the growth media. The cells were pelleted and resuspended in 200 µL 4:1
ethanol:water, then boiled at 99°C for 15 min, with vortexing midway through. The cells
were then pelleted at 16,200xg for 3 min and the supernatant was collected into an
autosampler vial. This process was repeated on the pellets an additional two times with
100 µL 4:1 ethanol:water. Following the final harvest, the supernatant collected in the
autosampler vials was allowed to air dry. After drying, the phospholipid extracts were
stored at -20°C until used for TLC. Just prior to performing TLC, the phospholipid extracts
were resuspended in a mixture of 1:1 chloroform:methanol.
To perform TLC, a chamber was washed three times with 1:1 chloroform:methanol.
The solvent system, 40:35:30:2 of chloroform:triethylamine:ethanol:water, was made
fresh, added to the TLC chamber, and allowed to equilibrate for a minimum of 45 min.
Meanwhile, samples were loaded onto a Silica gel 60 F254 plate (Millipore). The plate was
then placed in the TLC chamber and was allowed to run for ~45 min or until the solvent
front reached within 1.5-2 cm of the top of the plate. The TLC plate was removed from
the chamber and was allowed to dry. The dried plate was then rapidly dipped into
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primuline (Sigma-Aldrich) solution (50 mg/mL in 80:20 acetone:water) and allowed to dry
prior to visualization using a handheld UV lamp. Band intensities were quantified using
the gel analysis tool in ImageJ [24].

Ultra-High Performance Liquid Chromatography High Resolution Mass
Spectrometry (UHPLC-HRMS)
To analyze the lipidome of the wild type strain (OG1RF) and the ΔfakB1,2,5 mutant, cells
were grown as indicated above to an OD600 of ~0.3 for harvest. At harvest, OD600
measurements were documented and 5 mL of cell culture was centrifuged (2739xg for 10
min) forming a cell pellet. Following centrifugation, cell pellets were resuspended and
washed with 15 mL 1X phosphate buffered saline (1XPBS) and stored at -80°C prior to
lipid extraction. Lipids were extracted according to the protocol listed in Woodall et al.,
2021 [25, 26].
Lipidome analysis was performed in the manner of Woodall et al., 2021 [26]. In brief,
an UltiMate 3000 ultra-high performance liquid chromatography system (UHPLC, Dionex,
Sunnyvale, CA) was used to inject 10 µl of sample onto a CORTECS C18 column (90 Å,
2.7µm, 2.1mm x 150mm; Waters,) controlled at 40°C. Mobile phase A was 60:40
acetonitrile:water with 10 mM ammonium formate as a buffer and 0.1% formic acid while
mobile phase B consisted of 90:10 2-propanol:acetonitrile with 10 mM ammonium formate
as a buffer and 0.1% formic acid. Eluent was introduced to the mass spectrometer via an
electrospray ionization (ESI) source, and mass analysis was performed using an Exactive
Plus (Thermo Scientific, Waltham, MA) mass spectrometer operated in dual polarity
mode. Ions of respective DAG and MGDG species were detected in positive mode while
free fat, PG, L-PG, and CL were detected in negative mode. Masses were detected in full
scan mode within a scan range of 100-1500 m/z, operated at a resolution of 140,000, with
an automatic gain control target of (AGC) of 3x106 ions, and a maximum IT time of 100
ms. Full scan data was complemented with all ion fragmentation data at a resolution of
35,000 utilizing 35 eV collisional energy. The mass spectrometer was calibrated every 24
hours.
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Statistical analysis and data processing also followed same procedure as stated in
Woodall et al., 2021 [26]. Raw files from Xcalibur were converted to .mzMLformat via MS
convert (ProteoWizard) and then imported into El MAVEN where area under the curve for
mass to charge (m/z) values matching retention time of an in-house curated lipid library
were integrated with a mass error of less than 5 ppm. Ion intensities from integration and
retention time data was analyzed in Excel and data visualizations were performed in R
studio.

Gas chromatography-fatty acid methyl ester (GC-FAME) analysis
GC-FAME analysis was performed as previously described [1]. Briefly, E. faecalis OG1RF
wild-type, ΔtesS, ΔfakB1,2,5 and ΔfakB1,2,4,5/ΔtesS were grown as indicated until midlog phase (OD600 = 0.3–0.4). Aliquots (10 mL) were harvested. Cell pellets were washed
with 1XPBS twice to remove the media. The cell pellets were then stored at -80°C prior
to gas chromatography fatty acid methyl ester analysis (GC-FAME), which was performed
by Microbial ID, Inc (Newark, DE).

Transmission electron microscopy
Transmission electron microscopy sample preparation and analysis was performed as
follows. Briefly, OG1RF wild-type (100 mL) and ΔfakB1,2,5 (150 mL) cultures were grown
in BHI as described above until mid-logarithmic phase (OD600 = 0.35-0.4) and harvested
by centrifugation (2379xg for 10 min). Cell pellets were washed twice with 1X PBS to
remove the growth media, pelleted (2379xg for 10 min) and resuspended in 1.5 mL 1X
PBS containing 3% glutaraldehyde (Electron Microscopy Sciences). Primary fixation was
allowed to occur at room temperature for two h. Following primary fixation, the cells were
washed with 1XPBS three times, then pelleted (2379xg for 10 min) and resuspended in
1.5 mL 1XPBS and stored overnight at 4°C. The following day, the cells were washed
once with 1XPBS and resuspended in 600 µL 1XPBS containing 2% osmium tetroxide.
Secondary fixation was performed at room temperature for a minimum of 2 h. Following
secondary fixation, the cells were washed three times with water, pelleted (16,200xg for
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5 min) and dehydrated with a graded series of ethanol (15 min incubations each with 1.5
mL ethanol at 25%, 50%, and 70% ethanol). The partially dehydrated cells were stored
overnight in 70% ethanol at 4°C. The following day, dehydration was completed as above,
using 1mL of 95%, 100%, and 100% ethanol. Cells were stored overnight at 4°C in 100%
ethanol. Following dehydration with ethanol, the cells were pelleted (16,200xg for 5 min)
and incubated for 15 min with 100% acetone (Electron Microscopy Sciences) twice. The
cells were then mixed with 3:1 acetone:resin (Embed 812, Electron Microscopy Sciences)
and incubated for a minimum of 2 h at room temperature. This step was repeated with
2:1 acetone:resin and 1:1 acetone:resin for 1 h each. The samples were incubated
overnight in a vacuum chamber to remove air bubbles and acetone. The following day,
cells were pelleted (16,200xg for 5 min) and transferred to 1 mL 100% resin and incubated
for 3 h at room temperature. This treatment was repeated with a 1 h incubation, followed
by centrifugation and resuspension in fresh 100% resin. The cells were then transferred
to Beem® capsules and pelleted (16,200xg for 5 min), then incubated at 68°C for a
minimum of 24 h.
Embedded samples were sectioned and placed onto a copper grid. Grids were
stained with UranyLess (Electron Microscopy Sciences) for 30 min, washed with water,
then stained with lead citrate for an additional 30 min and washed with water prior to
imaging on the JEOL JEM 1400-Flash at the Advanced Microscopy and Imaging Center
at the University of Tennessee Knoxville campus.

Results
Identification of Staphylococcus aureus FakA and FakB2 homologs
Previous work has demonstrated that growth in exogenous fatty acids altered the
membrane composition, affecting both fatty acid tails and polar head group composition
of E. faecalis OG1RF [1, 18, 26-29]. We wanted to test if E. faecalis OG1RF utilizes the
FakA/B system as described in Staphylococcus aureus [12] and Streptococcus
pneumoniae [11] for incorporation of fatty acids into membrane phospholipids. In both S.
aureus and S. pneumoniae, FakB1 specifically binds saturated fatty acids and FakB2
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binds monounsaturated fatty acids [11, 12]. However, in S. pneumoniae, a third FakB
protein (FakB3) binds to polyunsaturated fatty acids [11]. Following fatty acid binding, a
FakA enzyme phosphorylates the fatty acid, which can then be utilized in the fatty acid
biosynthetic pathway or to form phospholipids (Figure 3.1; [12]). Cuypers et al., 2019
noted four possible FakB homologs in E. faecalis V583 [13]. Herein, we used BLAST to
identify homologs of the Fak proteins in E. faecalis OG1RF. We identified a single
homolog of FakA (OG1RF_RS12165) and four homologs of the FakB proteins of S.
aureus and S. pneumoniae (OG1RF_RS00080, OG1RF_RS07200, OG1RF_RS05020,
and OG1RF_RS06660).
Given the specificity of the FakB proteins for different fatty acid types, we compared
each predicted OG1RF homolog to those of S. aureus and S. pneumoniae in an attempt
to predict the specificity of the enterococcal homologs (Table 3.1). However, the protein
identities and positive substitutions did not lead to any clear conclusions as to potential
specificity. For example, OG1RF_RS05020 has 28% and 51% identity and similarity to
saFakB1, but also has 29% and 51% identity and similarity to saFakB2. Predicted protein
structures (Phyre2; [19]) also did not lead to specificity hypotheses for the E. faecalis FakB
proteins (Supplemental Figure 3.1), and known residues important for fatty acid binding
are conserved in each of the E. faecalis FakB homologs (Supplemental Figure 3.2).
However, given that OG1RF_RS06660 shared the highest percent identity and positive
substitutions with saFakB1 and spFakB1, we named it efFakB1 (for E. faecalis FakB1).
Similarly, we named OG1RF_RS07200 as efFakB2, as it shared the highest percent
identity and positive substitutions with saFakB2 and spFakB2. The remaining two
proteins, OG1RF_RS00080 and OG1RF_RS05020, neither of which shared significant
homology with spFakB3, we named as efFakB4 and efFakB5, respectively.

Combined deletion of fakB genes impacts growth in specific fatty acids
In previous studies, it was noted that the addition of fatty acids present in bile and serum
impact the growth of E. faecalis. Specifically, the polyunsaturated fatty acid linoleic acid
(C18:2 cis9,12), the monounsaturated fatty acid palmitoleic acid (C16:1 cis9), and saturated fatty
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Table 3.1. Percent identity and positive substitutions of Enterococcus faecalis
FakB proteins to Staphylococcus aureus and Streptococcus pneumoniae FakB
proteins as determined by NCBI BLAST.
E. faecalis FakB loci and proteins

Percent
identity

S. aureus FakB1 (saturated specificity)
OG1RF_ RS06660 (FakB1)
40%
OG1RF_ RS05020 (FakB5)
28%
OG1RF_ RS07200 (FakB2)
26%
OG1RF_ RS00080 (FakB4)
26%
S. aureus FakB2 (unsaturated specificity)
OG1RF_ RS07200 (FakB2)
37%
OG1RF_ RS06660 (FakB1)
33%
OG1RF_ RS00080 (FakB4)
31%
OG1RF_ RS05020 (FakB5)
29%
S. pneumoniae FakB1 (saturated specificity)
OG1RF_ RS06660 (FakB1)
41%
OG1RF_ RS05020 (FakB5)
27%
OG1RF_ RS00080 (FakB4)
27%
S. pneumoniae FakB2 (monounsaturated specificity)
OG1RF_ RS07200 (FakB2)
54%
OG1RF_ RS06660 (FakB1)
27%
OG1RF_ RS00080 (FakB4)
26%
S. pneumoniae FakB3 (polyunsaturated specificity)
OG1RF_RS07200 (FakB2)
20%

Percent positive
substitutions
60%
51%
51%
50%
58%
55%
53%
51%
61%
49%
48%
73%
50%
49%
46%
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acids palmitic acid (C16:0), and stearic acid (C18:0) caused increased generation time of
OG1RF relative to growth in media supplemented with the solvent control (ethanol) [18].
We decided to investigate whether deletion of the fakB genes alters growth in these
specific fatty acids, as this could give insights into the specificity for the four predicted
FakB proteins. Given the possible redundancy of the protein functions, we generated
single, double, and triple fakB deletion strains. However, when we attempted to make a
quadruple fakB deletion strain we were unable to do so unless tesS was also deleted (see
below).
When we grew the triple deletion strain ΔfakB1,2,4 in rich media (BHI) containing
solvent control, we found there was an approximate 8 min increase in generation time
relative to wild-type (Table 3.2; Supplemental Figure 3.3). Note that there are no fatty
acids detected in BHI at the levels of detection via GC-FAME [1]. When medium was
supplemented with linoleic acid (polyunsaturated; C18:2 cis9,12), ΔfakB1,2,4 had a 20-min
higher generation time compared to the wild-type strain (Table 3.3: ΔfakB1,2,4, 86 min;
wild-type, 66 min; P = 0.04). Similarly, supplementation of ΔfakB1,2,4 with palmitoleic
acid (C16:1 cis9) or oleic acid (C18:1 cis9) resulted in a generation time approximately 20 and
30 min slower, respectively, than that of the wild-type strain in the same fatty acid (Table
3.3). No difference was observed in generation time for growth in saturated fatty acids
C16:0 and C18:0 (data not shown).
Growth of ΔfakB1,4,5 in unsupplemented media or in media containing the fatty acid
solvent control was similar to the wild-type strain (Table 3.2, Supplemental Figure 3.3).
However, when supplied with stearic acid (C18:0), ΔfakB1,4,5 had a generation time nearly
double that of wild-type (Table 3.4: 185.9 min for ΔfakB1,4,5 compared to 82 min for wildtype; P = 0.03). Interestingly, we observed no difference in growth in palmitic acid (C 16:0)
or any unsaturated fatty acids examined (data not shown).
To pinpoint which specific combinations of fakB deletions were responsible for these
phenotypes, we grew related single and double gene deletion strains in the same media
and found that the combined deletion of fakB1 and fakB2 (ΔfakB1,2) had slower growth
in both solvent control and in media supplemented with unsaturated fatty acids, as
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Table 3.2. Generation times of E. faecalis strains grown in unsupplemented media
and in the fatty acid solvent control.
P-values for each deletion strain compared to wild-type OG1RF calculated using Welch’s
T-test. White cells indicate no difference and red indicates a significant increase in
generation time of the given strain compared to wild-type OG1RF. n = 3 replicates.
Mediaa Supplement
and Concentrationb

Strain

OG1RF
ΔtesS
ΔfakB1,2,5
No supplement
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS
OG1RF
ΔfakB1
ΔfakB2
ΔfakB4
ΔfakB5
ΔfakB1,2
ΔfakB1,5
c
Ethanol
ΔfakB2,4
ΔfakB4,5
ΔfakB1,2,4
ΔfakB1,2,5
ΔfakB1,4,5
ΔtesS
ΔfakB21,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS
aBrain heart infusion (BHI)
bEthanol:
cEthanol

Generation
Time (Minutes)
32.3 ± 0.5
31.8 ± 1.6
36.3 ± 1.2
36.2 ± 1.0
31.2 ± 0.4
37.6 ± 0.5
39.1 ± 0.8
40.7 ± 0.7
38.6 ± 1.2
39.9 ± 0.4
42.4 ± 0.0
37.3 ± 2.8
38.1 ± 0.8
31.2 ± 5.4
45.5 ± 0.8
46.2 ± 1.4
36.9 ± 2.4
38.5 ± 0.3
46.5 ± 0.7
39.5 ± 1.0

P-values
against OG1RF
NA
0.75
0.03
0.02
0.09
NA
0.10
0.01
0.40
P < 0.01
P < 0.01
0.88
0.49
0.23
P < 0.01
P < 0.01
0.72
0.12
P < 0.01
0.09

0.1%

is the solvent control for fatty acid supplements
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Table 3.3. Generation times of E. faecalis strains in unsaturated fatty acids.
P-values for each deletion strain compared to wild-type OG1RF calculated using Welch’s
T-test. White cells indicate no difference, blue indicates a significant decrease in
generation time, and red indicates a significant increase in generation time of the given
strain compared to wild-type OG1RF. n = 3 replicates, with the exception of OG1RF wildtype, which was n = 6 replicates.
Mediaa Supplement
and Concentrationb

Strain

OG1RF
ΔfakB1
ΔfakB2
ΔfakB4
ΔfakB1,2
C18:2 cis9,12
ΔfakB2,4
(linoleic acid)
ΔfakB1,2,4
ΔfakB1,2,5
ΔtesS
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS
OG1RF
ΔfakB1
ΔfakB2
C16:1 cis9 (palmitoleic
ΔfakB4
acid)
ΔfakB1,2
ΔfakB2,4
ΔfakB1,2,4
aBrain heart infusion (BHI)
bLinoleic

Generation
Time (Minutes)
66.0 ± 15.2
57.4 ± 5.4
49.7 ± 11.1
58.3 ± 13.3
86.4 ± 5.7
51.9 ± 5.4
86.0 ± 5.8
135.3 ± 9.6
81.4 ± 8.9
118.6 ± 2.4
75.7 ± 1.4
41.3 ± 0.5
42.9 ± 4.92
38.6 ± 2.2
40.2 ± 1.6
55.2 ± 3.9
42.6 ± 3.7
62.9 ± 4.6

P-values
against OG1RF
NA
0.27
0.06
0.35
0.05
0.09
0.04
P < 0.01
0.15
P < 0.01
0.22
NA
0.69
0.22
0.44
0.04
0.68
0.02

acid: 10 µg/mL; Palmitoleic acid: 10 µg/mL; Oleic acid: 20 µg/mL
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Table 3.3 Continued
Mediaa Supplement
and Concentrationb

Strain

OG1RF
ΔfakB1
ΔfakB2
ΔfakB4
ΔfakB1,2
C18:1 cis9
ΔfakB2,4
(oleic acid)
ΔfakB1,2,4
ΔfakB1,2,5
ΔtesS
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS
aBrain heart infusion (BHI)
bLinoleic

Generation
Time (Minutes)
37.9 ± 0.6
35.5 ± 1.5
35.3 ± 0.7
36.4 ± 1.7
58.2 ± 3.0
35.9 ± 0.9
67.1 ± 4.9
92.6 ± 4.9
37.5 ± 1.1
85.8 ± 2.7
37.9 ± 8.6

P-values
against OG1RF
NA
0.14
0.01
0.35
0.008
0.07
0.01
P < 0.01
0.71
P < 0.01
1.0

acid: 10 µg/mL; Palmitoleic acid: 10 µg/mL; Oleic acid: 20 µg/mL
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Table 3.4. Generation times of E. faecalis strains in saturated fatty acids.
P-values for each deletion strain compared to wild-type OG1RF calculated using Welch’s
T-test. White cells indicate no difference, blue indicates a significant decrease in
generation time, and red indicates a significant increase in generation time of the given
strain compared to wild-type OG1RF. n = 3 replicates, with the exception of OG1RF wildtype, which was n = 6 replicates.
Mediaa Supplement
and Concentrationb

C18:0
(Stearic acid)b1

C16:0
(Palmitic acid)b1
C14:0 (Myristic acid)
C16:0
(Palmitic acid)b2

aBrain

P-values
against OG1RF
NA
0.137
0.68
0.02
P < 0.01
0.34
0.02
0.03
0.04
0.11
P < 0.01
NAc

ΔfakB1,2,4,5/ΔtesS
ΔfakB1,2,5
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS

44.6 ± 1.3
120.2 ± 10.6
115.7 ± 16.1
40.8 ± 1.7

NAc
NAc
NAc
NAc

heart infusion (BHI)

b1Stearic

acid: 20 µg/mL; Palmitic acid: 5 µg/mL; Myristic acid: 5 µg/mL

b2Palmitic
cThe

OG1RF
ΔfakB1
ΔfakB4
ΔfakB5
ΔfakB1,5
ΔfakB4,5
ΔfakB1,2,5
ΔfakB1,4,5
ΔtesS
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS

Generation
Time (Minutes)
82.0 ± 12.5
107.3 ± 16.0
84.8 ± 5.1
107.0 ± 8.3
162.0 ± 10.8
94.4 ± 13.7
60.3 ± 6.8
185.9 ± 28.1
63.0 ± 7.2
62.3 ± 11.2
37.9 ± 1.4
43.8 ± 0.9

Strain

acid: 2.5 µg/mL

fatty acids at these concentrations caused wild-type E. faecalis to reach an early

growth stasis followed by the outgrowth of a suppressor, as previously reported [1]. This
resulted in inability to calculate a generation time; thus P-values were not calculated.
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observed in the ΔfakB1,2,4 strain (Tables 3.2 and 3.3, Supplemental Figure 3.3).
Additionally, ΔfakB1,5 had an increased generation time in stearic acid (C18:0), as
observed in the ΔfakB1,4,5 strain (Table 3.4). Taken together, these phenotypes indicate
a possible function for FakB1 as a generalist fatty acid binding protein, with potential roles
for FakB2 and FakB5 in specific uptake of either unsaturated or saturated fatty acids,
respectively.

Combined deletion of fakB1, fakB2, and fakB5 leads to growth defects
Given that ΔfakB1,2 and ΔfakB1,5 grew poorly in media supplemented with unsaturated
or saturated fatty acids, respectively (Tables 3.3 and 3.4), we examined a strain deleted
for fakB1, fakB2, and fakB5 (ΔfakB1,2,5). This strain had a significantly increased
generation time compared to the wild-type strain in the presence of the solvent control, a
phenotype observed in ΔfakB1,2,4 but not ΔfakB1,4,5 (Table 3.2). The phenotype did not
initially appear to be caused by a generalized growth defect, as growth in BHI was
equivalent to the wild-type strain (Table 3.2). Yet, we noted that for a given OD600 value,
the ΔfakB1,2,5 strain had approximately 10-fold fewer CFUs relative to wild-type when
grown in BHI media lacking any additional supplements (Figure 3.2A; P = 0.001). Given
these combined data, along with the observation that cells in overnight cultures tended to
clump towards the bottom of the tube (data not shown), we examined the cellular
morphology using transmission electron microscopy (TEM). As shown in Figures 3.2B
and 3.2C, wild-type OG1RF possesses an elongated diplococcus morphology when
grown in rich media. However, ΔfakB1,2,5 cells were very irregular in shape, size, with
clear hyperseptation relative to the wild-type control (Figures 3.2B and 3.2D). Indeed, only
a small percentage of the ΔfakB1,2,5 cells were diplococci (Figure 3.2B; P = 0.009). Note
that due to an error in image gathering, the scale bars may not be accurate in the TEM
images.
Growth of ΔfakB1,2,5 in media supplemented with unsaturated fatty acids also
resulted in increased generation time. Comparison of the growth of ΔfakB1,2,5 and
ΔfakB1,2,4 in media with linoleic acid revealed that ΔfakB1,2,5 had an approximately 50
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Figure 3.2. ΔfakB1,2,5 has reduced CFUs/mL at exponential phase compared to
wild-type E. faecalis.
(A) Wild-type E. faecalis and ΔfakB1,2,5 were grown in plain BHI until mid-logarithmic
phase (OD600 ~ 0.3), and colony forming units (CFUs) were enumerated. Shown are the
average CFUs/mL normalized to OD600 ± standard deviations for n = 3 replicates. (B)
Transmission electron microscopy was performed on wild-type E. faecalis and ΔfakB1,2,5
grown to mid-logarithmic phase. Shown are the average percentages of diplococci cells
± standard deviations for a total of n = 100 cells measured across n = 3 images.
Representative wild-type (C) and ΔfakB1,2,5 (D) electron microscopy images are shown.
Note that the scale bars may not be accurate. ** P = 0.01–0.001.
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min increase in generation time relative to ΔfakB1,2,4 (Table 3.3; P < 0.01). Further,
growth of ΔfakB1,2,5 and ΔfakB1,2,4 in oleic acid revealed that ΔfakB1,2,5 had an
approximately 25 min increase in generation time relative to ΔfakB1,2,4 (Table 3.3; P <
0.01).
When compared to wild-type, the generation time of ΔfakB1,2,5 in stearic acid did
not significantly increase (in fact, generation time decreased; Table 3.4). Additionally, we
were surprised to observe that when grown in stearic acid, the generation time of
ΔfakB1,2,5 was significantly lower than that of ΔfakB1,5 in stearic acid (Table 3.4; P =
0.02). This is corroborated by the data where we observed that the generation time of
ΔfakB1,2,5 was significantly lower than that of ΔfakB1,4,5 (Table 3.4; P = 0.02). As
deletion of fakB2 rescued the growth effects observed in ΔfakB1,5, it seems likely that an
overlap in protein specificities may cause substrate competition dynamics, which drive
the increased generation time phenotype stearic acid observed in ΔfakB1,5, as well as
its subsequent rescue in the quintuple deletion strain (see Discussion).

Combined deletion of fakB1, fakB2, and fakB5 leads to altered cellular
morphology and accumulation of free fatty acids in the membrane
Interestingly, similar morphological issues as seen in ΔfakB1,2,5 were observed on
supplementing wild-type cells with the saturated fatty acids stearic acid (C18:0) or palmitic
acid (C16:0) or myristic acid (C14:0) [18]. Further, data suggests that when supplemented
with fatty acids, those specific supplied fatty acids accumulate as free fatty acids within
the membrane of OG1RF [26, 29]. Given the morphological similarities of ΔfakB1,2,5 to
that of wild-type OG1RF grown in saturated fatty acids [18], we hypothesized that the
phenotypes observed were due to the accumulation of free fatty acids in the cells. We
thus performed TLC to separate free fatty acids from the major phospholipids. As lipid
extracts are not easily quantifiable, we normalized the free fatty acid signal to that of the
major lipid phosphatidylglycerol (PG) [26, 29, 30] and found that ΔfakB1,2,5 had
increased levels of free fatty acids relative to wild-type (Figure 3.3A; P < 0.001). As TLC
could not separate different free fatty acids from one another, to determine which specific
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Figure 3.3. Deletion of fakB genes leads to accumulation of free fatty acids.
(A) Thin layer chromatography (TLC) was performed on lipids extracted from indicated
strains grown in unsupplemented BHI (see Materials and Methods). Depicted are the
levels of free fatty acids normalized to phosphatidylglycerol (PG) detected by TLC. One
way ANOVA and Tukey’s multiple comparisons tests were used to determine the
differences between means for n = 3 replicates. *P = 0.05–0.01; **P = 0.01–0.001; ***P
≤ 0.001;

ns

P > 0.05 (B) Mass spectrometry lipid analysis as described in Materials and

Methods was used to determine relative levels of free fatty acids in ΔfakB1,2,5 compared
to wild-type OG1RF. Depicted are the log-transformed fold changes of free fatty acids in
ΔfakB1,2,5 compared to wild-type OG1RF for n = 5 replicates. Data represented is
normalized to OD600 at time of harvest. *P = 0.05–0.01; **P = 0.01–0.001; ***P ≤ 0.001.
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free fatty acids were increased in ΔfakB1,2,5, we performed an ultra-high performance
liquid chromatography high-resolution mass spectrometry (UHPLC-HRMS) analysis on
the lipids of wild-type E. faecalis and the ΔfakB1,2,5 strain (Figure 3.3B). We observed
that in ΔfakB1,2,5 C14:0 was increased relative to wild-type by ~2–fold, C16:0 was increased
by ~1.6–fold relative to wild-type, and that C20:0 and C20:1 were decreased by 2.5-fold and
1.7-fold, respectively (Figure 3.3B). We also observed an increase a mass corresponding
to the m/z ratio of C20:4, a lipid which OG1RF is not known to produce. However, a lipid
standard was not used to confirm the presence of C20:4.
To validate the UHPLC-HRMS data, we performed a gas chromatography fatty acid
methyl ester (GC-FAME) analysis of the lipids present within select deletion strains. Of
note, the fatty acids present in the cell globally, regardless of being attached to
phospholipid head groups, as detected by GC-FAME, were also altered in the ΔfakB1,2,5
deletion strain (Table 3.5). Most notably, we observed an ~7% increase in palmitic acid
(C16:0) in the ΔfakB1,2,5 strain (P = 0.002), combined with an ~14% decrease in cisvaccenic acid (C18:1

cis11;

P < 0.001) and a ~1% decrease in stearic acid (C18:0; P =

0.002;Table 3.5; Supplemental Table 3.3). These data matched the overall trends
observed via UHPLC-HRMS (Figure 3.3B). Interestingly, we also observed that
ΔfakB1,2,5 had a significant increase in the ratio of saturated fatty acids in its membrane:
while wild-type had a nearly 1:1 ratio of saturated to unsaturated fatty acids, ΔfakB1,2,5
had a 2:1 ratio of saturated to unsaturated fatty acids in its membrane (Table 3.5,
Supplemental Table 3.3). These data indicate that combined deletion of fakB1, fakB2,
and fakB5 alters lipid metabolism even in the absence of supplied fatty acids.

Deletion of tesS rescues negative growth effects of the fakB deletion strains and
reduces accumulation of free fatty acids
Given the above combined data, including the increase in free fatty acids in ΔfakB1,2,5
relative to wild-type, we hypothesized that the activity of TesS may be contributing to
these observations. TesS is a thioesterase that will cleave fatty acids from the acyl carrier
protein; normally, these fatty acids are bound and phosphorylated via the Fak system
117

Table 3.5. GC-FAME analysis of strains during log phase growth in BHI.
Shown are the averages ± standard deviations for n = 3 replicates. ND indicates that the
fatty acid indicated was not detected for the given strain.

Fatty acid
C12:0
C14:0
C16:1
C16:0
C17:1 cis10
C17:0 2OH
C18:1 cis11
C18:0
C19:0 cyclo11
Unknown
Othersa
Saturated/
Unsaturated ratio
aOthers

% of total membrane content for indicated strain (avg ± SD)
ΔfakB1,2,4,5/ΔtesS
Wild-type
ΔtesS
ΔfakB1,2,5
(quintuple)
0.9 ± 0.0
0.9 ± 0.1
0.9 ± 0.1
0.1 ± 0.2
4.3 ± 0.1
5.5 ± 0.2
5.4 ± 0.1
5.5 ± 0.0
5.7 ± 0.0
6.7 ± 0.24 4.8 ± 0.1
6.6 ± 0.1
41.4 ± 0.7
38.8 ± 0.1 48.4 ± 0.1 37.2 ± 0.7
1.0 ± 0.8
0.9 ± 0.8
3.1 ± 0.1
2.3 ± 0.2
4.4 ± 0.1
4.6 ± 0.3
5.8 ± 0.1
6.1 ± 0.2
37.0 ± 0.5
36.3 ± 0.3 22.7 ± 0.4 37.0 ± 0.5
4.8 ± 0.1
4.8 ± 0.2
3.6 ± 0.2
3.5 ± 0.0
0.6 ± 0.0
0.7 ± 0.1
1.6 ± 0.1
1.4 ± 0.2
ND
0.3 ± 0.6
1.9 ± 0.6
0.2 ± 0.4
ND
0.3 ± 0.4
0.9 ± 0.2
0.1 ± 0.1
1.3 ± 0.0

1.3 ± 0.0

2.1 ± 0.1

1.2 ± 0.0

are fatty acids which comprised <1% of the total membrane content.
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(Figure 3.1) [15]. Loss of multiple fakB genes in OG1RF could result in free fatty acid build
up due to continued activity of TesS. Thus, we deleted tesS in the ΔfakB1,2,5 strain. After
deleting tesS, we were able to delete all of the fakB genes, generating the
ΔfakB1,2,4,5/ΔtesS strain (referred to as the “quintuple deletion strain”).
Notably, some of the lipid changes observed in ΔfakB1,2,5, were reversed in the
quintuple deletion strain (Figure 3.3, Table 3.5). Indeed, with regards to palmitic acid
(C16:0), the quintuple deletion strain had a significant reduction relative to wild-type (P =
0.002), while palmitoleic acid (C16:1) was significantly increased in the quintuple deletion
strain relative to wild-type (P = 0.007; Table 3.5 and Supplemental Table 3.3). However,
stearic acid (C18:0) was reduced in the quintuple deletion strain relative to wild-type (P =
0.002; Table 3.5 and Supplemental Table 3.3), similar to what was observed for
ΔfakB1,2,5. These trends indicate that the Fak system is necessary for de novo fatty acid
biosynthesis and phospholipid production when TesS is active. However, on deletion of
tesS, the cells are able to return closer to a wild-type membrane makeup.
Having observed the restoration of free fatty acid levels in the quintuple deletion strain
in the absence of fatty acids, we next determined its growth phenotypes in media
supplemented with specific fatty acids. We observed that the quintuple deletion strain had
generation times in unsaturated fatty acids similar to wild-type (Table 3.3).
Wild-type E. faecalis, as well as other bacterial strains, can overcome inhibition by
cerulenin, an inhibitor of de novo fatty acid biosynthesis, if supplied with specific fatty
acid(s) in its growth media [7, 18]. This is likely because the Fak system can utilize the
supplied fatty acids to generate the acyl-phosphates required for lipid synthesis (Figure
3.1). To confirm that the quintuple deletion strain (ΔfakB1,2,4,5/ΔtesS) could no longer
utilize exogenous fatty acids to support lipid synthesis, we examined its growth when
treated with cerulenin, an inhibitor of de novo fatty acid biosynthesis (and hence
membrane synthesis). Like the wild-type strain, growth was inhibited by cerulenin (Figure
3.4A). However, whereas the addition of oleic acid could prevent cerulenin-induced
growth inhibition of wild-type OG1RF, it could not for the quintuple deletion strain (Figure
3.4A).
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Figure 3.4. Oleic acid does not rescue growth inhibition by cerulenin in the
ΔfakB1,2,4,5/tesS and ΔfakB1,2,5 deletion strains.
Wild-type E. faecalis OG1RF, (A) ΔfakB1,2,4,5/ΔtesS, and (B) ΔfakB1,2,5 were grown in
BHI containing 5 µg/mL cerulenin. The cultures were supplemented with 5 µg/mL oleic
acid or an equivalent volume of solvent (see Materials and Methods for full details).
Represented are average OD600 values ± standard deviations for n = 3 replicates.
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This indicated that the presence of the fakB and tesS genes are required for utilization of
exogenous fatty acids to generate phospholipid precursors.

Combined deletion of tesS and the fakB genes rescues growth in saturated fatty
acids
The saturated fatty acids myristic acid (C14:0) and palmitic acid (C16:0) negatively impact
cellular growth and result in severely distorted morphology of E. faecalis [18]. Indeed,
growth in either fatty acid when supplemented at 5 µg/ml occurs only upon outgrowth of
a genetic suppressor (mutant) cell [18]. As the quintuple deletion strain cannot incorporate
free fatty acids into phospholipids (Figure 3.4), we examined whether incorporation of free
fatty acids is responsible for these negative effects. We thus grew the quintuple deletion
strain in media containing either palmitic acid or myristic acid, and observed that in each
of these fatty acids, it grew with a generation time of ~44 min, while the other strains were
inhibited (Table 3.4, Figure 3.5). Deletion of tesS alone was not enough to allow the cells
to overcome growth inhibition by myristic acid or palmitic acid (Figure 3.5).
To determine whether the fakB genes or tesS were primarily responsible for the ability
of the quintuple deletion strain to grow unimpeded in myristic acid and palmitic acid, we
grew these strains in lower concentrations of palmitic acid. We noted that when grown in
2.5 µg/mL palmitic acid (half the concentration used for Figure 3.5), the ΔfakB1,2,5 and
ΔfakB1,2,5/ΔtesS strains were able to continue growing (Table 3.4 and Figure 3.6).
Generation times of ΔfakB1,2,5 and ΔfakB1,2,5/ΔtesS

were higher relative to the

quintuple deletion strain in 2.5 µg/mL palmitic acid (Table 3.4 and Figure 3.6). Under this
condition, the generation time of ΔfakB1,2,5 was 120 min, while the quintuple deletion
strain had a generation time of 44 min (P < 0.01). Further, the ΔfakB1,2,5/ΔtesS deletion
strain was approximately 75 min longer than that of the quintuple deletion strain (P = 0.02;
Table 3.4 and Figure 3.6). These results suggested that the toxicity of palmitic acid in
wild-type OG1RF is due to its incorporation into the phospholipid biosynthesis cycle of E.
faecalis; reduced incorporation due to deletion of the fakB genes resulted in ability to grow
in these fats.
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Figure 3.5. The quintuple deletion strain grows unimpeded in the presence of
toxic fatty acids.
Indicated strains were grown in media supplemented with (A) 5 µg/mL myristic acid or (B)
5 µg/mL palmitic acid. Shown are the average OD600 values over time ± standard
deviations for n = 3 replicates.
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Figure 3.6. Deletion of fakB1, fakB2, and fakB5 drive ability of the quintuple
deletion strain to grow in palmitic acid.
Indicated strains were grown in media supplemented with 2.5 µg/mL palmitic acid. Shown
are the average OD600 values over time ± standard deviations for n = 3 replicates.
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Discussion
While previous literature has indicated that the primary role for the Fak system is
scavenging fatty acids from the environment, we report that in E. faecalis, the Fak system
is necessary for phospholipid synthesis and proper cellular division. Given that the fak
genes were deleted from S. aureus and S. pneumoniae with ease [11, 12], indicating a
nonessential role in cell growth, we were surprised when we were unable to do so in E.
faecalis. Indeed, other researchers attempted to delete the fakA homolog in E. faecalis,
but could only truncate it. The resulting strain carrying truncated fakA had altered
morphology with multiple septation events [31]. These data indicate that the Fak system
plays an essential role in enterococcal physiology. Interestingly, E. faecalis has four
homologs of the FakBs in S. aureus and S. pneumoniae – this is possibly due to the need
to specifically bind fatty acids or to allow for better regulation under diverse environmental
conditions. The ability to bind and incorporate different fatty acids may also explain why
different fatty acids are toxic to different Gram-positive organisms. For instance, palmitic
acid is toxic to E. faecalis [18] but not to S. aureus [32] at the concentrations used. Another
example is that in Streptococcus pyogenes, lauric acid is toxic [33], while this fatty acid is
not toxic to E. faecalis at the concentrations used [18]. The fatty acid binding specificities
of the FakB proteins in these strains may explain the differential effects of fatty acid
supplementation.
Given

that

the

S.

pneumoniae

FakB

proteins

can

bind

to

saturated,

monounsaturated, and polyunsaturated fatty acids, it is interesting that enterococci
typically have four FakB homologs. Our findings indicated that the FakBs of E. faecalis
have specific fatty acid binding functions, as well as potential differences in protein
expression, stability, or activity. Here, deletion of fakB1 was necessary, combined with
deletion of either fakB2 (resulting in increased generation time in unsaturated fatty acids)
or fakB5 (resulting in increased generation times in saturated fatty acids) to elicit marked
phenotypes in media supplemented with free fatty acids (Tables 3.3 and 3.4). This is
interesting, as it indicates that efFakB1 may have a generalist fatty acid binding function
which is heretofore unreported in the literature. We also observed that when fakB4 was
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deleted in combination with other fakBs, there was no phenotype under the growth
conditions tested, yet we were unable to delete fakB4 in the ΔfakB1,2,5 background. This
indicates that while phenotypes were not observed on deletion of fakB4, efFakB4 has a
function. Notably, the models generated by Phyre2 [19] did not reveal any predicted
differences in protein folding or in the shape of the fatty acid binding pocket (Supplemental
Figure 3.1). Additionally, residues important for fatty acid binding [22] were conserved in
each of the efFakB protein sequences (Supplemental Figure 3.2). Given this, it is possible
that the expression, activity, or stability may be different for efFakB4 (likely lower given
our phenotypic evidence) or FakB1 (likely higher given our phenotypic evidence). Due to
our lack of data on the efFakB proteins, additional detailed biochemical analyses are
warranted to measure the binding specificities, activity, stability, and expression of FakB4
and FakB1.
While we noted that deletion of fakB1 alone had no measurable impacts, deletion of
fakB2 and fakB5 each had an effect when combined with deletion of fakB1. This
suggested that efFakB1 plays a role as a generalist fatty acid binding protein. These
effects were seemingly driven by the presence of free fatty acids, which, whether present
due to activity or expression of TesS, or due to supplementation in the media, likely have
pleiotropic effects on the cell. Free fatty acids have been demonstrated to impact
membrane permeability [34], membrane protein function [35, 36], and membrane fluidity
[27]. Furthermore, free fatty acids, in both E. faecalis and S. pneumoniae, repress de
novo fatty acid biosynthesis [8-10]. Given these findings, it is possible that some of the
effects observed in our triple deletion strain background upon supplementation are due
to a combination of repressed de novo fatty acid biosynthesis and reduced ability to
efficiently phosphorylate fatty acids.
While it might be expected that generation time differences would be observed in
media supplemented with fatty acids, the altered morphology and reduced CFUs of
ΔfakB1,2,5 compared to wild-type OG1RF in BHI lacking fatty acid supplements were
unexpected, as deletion of the fakB genes of S. aureus or S. pneumoniae did not alter
normal cellular physiology [11, 12]. Given the gross morphological differences observed
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for the ΔfakB1,2,5 strain, we suspected that these phenotypes were caused by increased
free fatty acids in the membrane, which is similar to what we observed when
supplementing wild-type cultures with fatty acids [18, 26, 29]. An accumulation of free
fatty acids, negative growth phenotypes, and altered morphology have not been
previously noted on deletion of the fak genes of S. aureus or S. pneumoniae [11, 12]. This
is in contrast to published literature, which indicated that truncation of the fakA gene of E.
faecalis led to morphological issues [31]. We therefore hypothesize that in S. aureus and
S. pneumoniae, the thioesterase TesS plays an auxiliary role, while in E. faecalis, this
protein may play a more prominent role in phospholipid synthesis. Expression and protein
activity data are needed to further test this hypothesis.
While we initially noted that fatty acids increased generation times significantly in
select mutants, we also noted that additional deletions decreased generation times. It
was not surprising, given our initial data for ΔfakB1,2 and ΔfakB1,5, to see major
increases in generation time upon exposure of ΔfakB1,2,5 to unsaturated exogenous fatty
acids. However, we were surprised to note that ΔfakB1,2,5 had a decreased generation
time in stearic acid relative to wild-type levels (Table 3.4). Further, we observed a rescue
of generation time in unsaturated fatty acids for the quintuple deletion strain (Table 3.3).
One potential reason for this observation is that supplementation of specific deletion
strains with fatty acids might overload the system when there is only one FakB remaining,
which has ability to bind the fatty acid supplement. In this instance, deletion of all of the
fakB genes which have binding specificity for that supplement would ameliorate the
negative growth phenotype observed in a lower-order or different combination deletion
strain. As we noted that the generation time of ΔfakB1,5 in stearic acid was rescued in
ΔfakB1,2,5, this leads us to the hypothesis that FakB2 may be able bind to the saturated
fatty acid stearic acid, even if weakly. Alternatively, it is possible that ΔfakB1,2,5 in this
case was unable to bind to stearic acid; thus stearic acid was not incorporated into
membrane phospholipids and because it was not incorporated, did not have a negative
impact on generation time.
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Given that ΔfakB1,2,5 had increased levels of free fatty acids (Figure 3.3), we initially
anticipated that deletion of tesS would rescue many of the phenotypes we previously
noted in ΔfakB1,2,5, especially accumulation of free fatty acids. However, we observed
that ΔfakB1,2,5/ΔtesS had many of the same peculiarities as ΔfakB1,2,5. Specifically,
this deletion strain had increased levels of free fatty acids relative to wild-type (Figure 3.3)
and similar generation times to ΔfakB1,2,5 when grown in media supplemented with fatty
acids (Tables 3.3 and 3.4). These data indicated that while deletion of tesS was necessary
to partially reduce free fatty acid levels, deletion of all of the fakB genes was necessary
to complete this reversion, indicating again that retaining a FakB with at least partial
binding specificity for a supplement can be detrimental. However, our analysis of free fatty
acids using thin layer chromatography relied upon normalizing levels of free fatty acids to
phosphatidylglycerol. If phosphatidylglycerol levels are different between wild-type and
deletion strains, this would impact our data analysis. Thus, mass spectrometry data will
be required to determine whether free fatty acid levels in ΔfakB1,2,5/ΔtesS are truly
increased relative to free fatty acid levels in wild-type E. faecalis.
While it seems energetically inefficient for cells to make a thioesterase which cleaves
endogenous fatty acids from the acyl carrier protein, one potential reason for this is that
it could help the cell to produce acyl-phosphates. In Gram-positive organisms, acylphosphates can be generated in two ways. As discussed above, the Fak system can
directly phosphorylate free fatty acids [12], or PlsX can convert acyl-ACP into acylphosphates (Figure 3.1) [3]. If PlsX functions poorly to convert acyl-ACP to acylphosphate, it would then be necessary for the cells to find other ways to generate acylphosphates. Thus, if PlsX activity is weak, if it is inadequately expressed, or if its stability
is poor, having another means to produce free fatty acids for phosphorylation by the Fak
system might be necessary to generate lysophosphatidic acid. Consequently, such a
situation would likely necessitate that TesS play a more prominent role in phospholipid
biosynthesis. Our data point therefore towards TesS having higher expression or activity
and PlsX having lower expression or activity in E. faecalis relative to S. aureus and S.
pneumoniae. This is further evidenced by the ability of the quintuple deletion strain
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(ΔfakB1,2,4,5/ΔtesS) to grow in the toxic fatty acids myristic acid and palmitic acid; it is
likely that the toxicity of these fatty acids in wild-type OG1RF is due to their incorporation
onto lysophosphatidic acid (Figure 3.1). In wild-type OG1RF, these fatty acids may never
enter the de novo fatty acid synthesis cycle following conversion from acyl-phosphates to
acyl-ACP; instead they may be incorporated as-is onto the SN-1 position of glycerol-3phosphate by PlsY. This could cause significant alterations to the lipid makeup of the cells
and could have an effect on membrane motion, as it was previously found that increased
tail length increases ability of the lipid bilayer to bend [37]. Furthermore, if exogenous fatty
acids are typically incorporated at the SN-1 position while endogenous fatty acids are
typically incorporated at the SN-2 position, this could lead to lipid asymmetry. Studies on
lipid asymmetry demonstrated that a bilayer consisting of phospholipids with asymmetric
tails has reduced ability to stretch [37, 38]. Alteration of the biophysical properties of the
lipid bilayer might thus partially explain the reason that specific fatty acids are toxic when
incorporated into membrane phospholipids.
However, while these data may point towards an inefficient PlsX, it is also possible
that E. faecalis has a highly efficient Fak system. As E. faecalis is commensal to the
mammalian intestine, it is exposed to numerous fatty acids present in bile. To utilize the
plentiful fatty acid resources around it, E. faecalis may have evolved to, with extreme
efficiency, incorporate exogenous fatty acids into its membrane using the Fak system. In
an environment where fatty acids are plentiful, TesS may not be extremely useful, except
perhaps to ensure that endogenous fatty acids are incorporated onto the correct position
of a phospholipid head group. However, E. faecalis can survive for long periods in
nutrient-limiting environments [39]. If the Fak system were extremely efficient, in
environments where exogenous fatty acids are not abundant, it may be beneficial for E.
faecalis to also have a high-functioning TesS. Our data point towards an imbalance,
relative to other studied organisms, in the fatty acid metabolism of E. faecalis, where the
Fak system, along with TesS, play a vital role in membrane homeostasis.
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Appendix
Supplemental Table 3.1. Bacterial strains and plasmids used in this study.
Strain
Enterococcus
faecalis OG1RF
Escherichia coli
EC1000
E. faecalis
CK111/pCJ10-101

Relevant genotype or description
Laboratory strain
RifR, FusR

G. Dunny, University of
Minnesota

Conjugative donor strain; harbors non-transferable
pCJ10 derivative plasmid
SpecR

Kristich et al. (2007)

Used for markerless exchange

pCIE

Used for overexpression in E. faecalis

pRDJ2
pRDJ3
pRDJ4
pRDJ5

Lab stock

Cloning strain for repA-dependent plasmids

Plasmid
pCJK47

pRDJ1

Source

pCJK47 derivative containing
OG1RF_RS06660 (fakB1)
pCJK47 derivative containing
OG1RF_RS07200 (fakB2)
pCJK47 derivative containing
OG1RF_RS00080 (fakB4)
pCJK47 derivative containing
OG1RF_RS05020 (fakB5)
pCJK47 derivative containing
OG1RF_RS01405 (tesS)

flanking regions of
flanking regions of
flanking regions of
flanking regions of
flanking regions of

Kristich et al. (2007)
K. Weaver,
Weaver et al., (2017)
This work
This work
This work
This work
This work

135

Supplemental Table 3.2. Oligonucleotides used in this study.
Name
EF1492
EF1493
EF1494
EF1495
EF1496
EF1497
EF1564
EF1512
EF1511
EF1565
EF1566
EF1567
EF1526
EF1527
EF1528
EF1529
EF1530
EF1531
EF1536
EF1537
EF1538

Sequence
GTGATACACATGGAAGCAATTCGTCGTGTTGCCCGGGTA
CCATGGCATGCTAAGCTTGATTTTCGTTC
GAAAGAATGGATAACCAAATCAGAAGGTAGTCTAGAACT
AGCGATTCTGAAATCACCATTTAAAAAACTC
GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGA
CTACCTTCTGATTTGGTTATCCATTCTTTC
CTTTTAAAGAAAGAGTGATAAATTTATGACAAACGCTATA
CAGACTAAGAAATAACGAGGTTGGGTCTCAC
GTGAGACCCAACCTCGTTATTTCTTAGTCTGTATAGCGTT
TGTCATAAATTTATCACTCTTTCTTTAAAAG
GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGCA
ACACGACGAATTGCTTCCATGTGTATCAC
CTGAGTCAGCGATGAATGCCACTTTATCCCCGGGTACCA
TGGCATGCTAAGCTTGATTTTCGTTC
GATTCCCACCCGTGCTGCTTTATCCATGTCTAGAACTAG
CGATTCTGAAATCACCATTTAAAAAACTC
GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGA
CATGGATAAAGCAGCACGGGTGGGAATC
CAAAAGAAAACACAGCAATACAACCTATTCCGGGACAAT
TGCCCCCTTCATGTTTTCTTTTATTTTAC
GTAAAATAAAAGAAAACATGAAGGGGGCAATTGTCCCGG
AATAGGTTGTATTGCTGTGTTTTCTTTTG
GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGGA
TAAAGTGGCATTCATCGCTGACTCAG
GAAAGTATCAAATAAGATTAGAAGGAAAAAGAGCCCGGG
TACCATGGCATGCTAAGCTTGATTTTCGTTC
CATCAACGTAACTAGTAATACGCCATAGCACTCTAGAACT
AGCGATTCTGAAATCACCATTTAAAAAACTC
GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGA
GTGCTATGGCGTATTACTAGTTACGTTGATG
CAAAAAAATTTGAGGGGATTTTTCATTTAATTAATCGTGC
GATCTTTTCTTTATTCATGTGTCATCTCATC
GATGAGATGACACATGAATAAAGAAAAGATCGCACGATT
AATTAAATGAAAAATCCCCTCAAATTTTTTTG
GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGCT
CTTTTTCCTTCTAATCTTATTTGATACTTTC
GAAAAACGACAACACTTTGCAGAACGTATGCCCGGGTAC
CATGGCATGCTAAGCTTGATTTTCGTTC
GAACCGTTGCCACCACCTGAATCTGTTTGTCTAGAACTA
GCGATTCTGAAATCACCATTTAAAAAACTC
GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGA
CAAACAGATTCAGGTGGTGGCAACGGTTC

Use
Generate overhangs
pCJK47 for fakB2
Generate overhangs
pCJK47 for fakB2
Generate overhangs
fakB2 piece 1 insert
Generate overhangs
fakB2 piece 1 insert
Generate overhangs
fakB2 piece 2 inserts
Generate overhangs
fakB2 piece 2 insert
Generate overhangs
pCJK47 for fakB4
Generate overhangs
pCJK47 for fakB4
Generate overhangs
fakB4 piece 1 insert
Generate overhangs
fakB4 piece 1 insert
Generate overhangs
fakB4 piece 2 insert
Generate overhangs
fakB4 piece 2 insert
Generate overhangs
pCJK47 for fakB5
Generate overhangs
pCJK47 for fakB5
Generate overhangs
fakB5 piece 1 insert
Generate overhangs
fakB5 piece 1 insert
Generate overhangs
fakB5 piece 2 insert
Generate overhangs
fakB5 piece 2 insert
Generate overhangs
pCJK47 for fakB1
Generate overhangs
pCJK47 for fakB1
Generate overhangs
fakB1 piece 1 insert

on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
on
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Supplemental Table 3.2 Continued
Name
EF1539
EF1540
EF1541
EF1877
EF1878
EF1873
EF1874
EF1875
EF1876

Sequence
GAGACAGAAGTAGTTTACTTTTGTCTCATCCATTTTGTAA
CCTCGTTTCACTAATTTTC
GAAAATTAGTGAAACGAGGTTACAAAATGGATGAGACAA
AAGTAAACTACTTCTGTCTC
GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGCA
TACGTTCTGCAAAGTGTTGTCGTTTTTC
CTTGAATTTGAGTTACGATGATTTGAATCCCCCGGGTAC
CATGGCATGCTAAGCTTGATTTTCGTTC
CTTTCAGAAGTAAATCAAGCCTACAATGTCTCTAGAACTA
GCGATTCTGAAATCACCATTTAAAAAACTC
GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGA
GACATTGTAGGCTTGATTTACTTCTGAAAG
GACTTTCGACTTCTTGGCCATATTCTACCCCACGAAATAA
TCTCCTTTTTCCAATG
CATTGGAAAAAGGAGATTATTTCGTGGGGTAGAATATGG
CCAAGAAGTCGAAAGTC
GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGG
GATTCAAATCATCGTAACTCAAATTCAAG

Use
Generate overhangs
fakB1 piece 1 insert
Generate overhangs
fakB1 piece 2 insert
Generate overhangs
fakB1 piece 2 insert
Generate overhangs
pCJK47 for tesS
Generate overhangs
pCJK47 for tesS
Generate overhangs
tesS piece 1 insert
Generate overhangs
tesS piece 1 insert
Generate overhangs
tesS piece 2 insert
Generate overhangs
tesS piece 2 insert

on
on
on
on
on
on
on
on
on
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Supplemental Table 3.3. P-values for GC-FAME analysis.
Welch’s T-test was used to compare the average % total membrane content of fatty acids
detected by GC-FAME analysis. The strains compared are as “strain 1 vs. strain 2”.
Colors indicate whether there was an increase or a decrease of the indicated fatty acid in
the strain 2 relative to strain 1. White indicates no difference, blue illustrates that strain 2
had a decrease in the indicated fatty acid, and red indicates that strain 2 had an increase
in the indicated fatty acid relative to strain 1. ND means the specified fat was not detected
in either of the indicated strains.
Fatty acid
C12:0
C14:0
C16:1
C16:0
C17:1 cis10
C17:0 2OH
C18:1 cis11
C18:0
C19:0 cyclo11
Unknown
Others: C15:1 cis7
Others: C17:1 iso cis12
Others: C18:1 cis9
Others: 11 methyl C18:1 cis11
Others: C20:1 cis13
Others: C20:2 cis11,14
Saturated:
Unsaturated
Ratio

Wild-type
vs.
Δtess
P = 1.000
P = 0.002
P = 0.019
P = 0.018
P = 0.981
0.232
P = 0.128
P = 0.755
P = 0.159
P = 0.423
ND
P = 0.423
P = 0.423
ND
ND
ND

Wild-type
vs.
ΔfakB1,2,5
P = 0.553
P < 0.001
P = 0.003
P = 0.002
P = 0.044
P < 0.001
P < 0.001
P = 0.002
P< 0.001
P = 0.031
P < 0.001
ND
P = 0.013
ND
ND
ND

Wild-type
vs.
Quintuple
P = 0.013
P < 0.001
P = 0.007
P = 0.002
P = 0.105
0.003
P = 0.894
P = 0.002
P = 0.026
P = 0.423
P = 0.423
ND
ND
P = 0.423
P = 0.423
P = 0.423

Quintuple
vs.
Δtess
P = 0.007
P = 0.909
P = 0.566
P = 0.059
P = 0.099
0.002
P = 0.121
P = 0.005
P = 0.026
P = 0.791
P = 0.423
P = 0.423
P = 0.423
P = 0.423
P = 0.423
P = 0.423

Quintuple
vs.
ΔfakB1,2,5
P = 0.004
P = 0.087
P < 0.001
P < 0.001
P = 0.014
P = 0.195
P < 0.001
P = 0.518
P = 0.299
0.020
P = 0.011
ND
P = 0.013
P = 0.423
P = 0.423
P = 0.423

P = 0.225

P < 0.01

P = 0.019

P = 0.014

P < 0.01
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Supplemental Figure 3.1. Predicted structural models of FakB homologs
generated by Phyre2.
Phyre2 models were generated for the FakB homologs of E. faecalis and FakB1 of S.
aureus. The models are depicted alongside the published crystal structure of S. aureus
FakB2 (Broussard 2016).
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Supplemental Figure 3.2. Residues important for binding fatty acids are
conserved in the E. faecalis FakB homologs.
Clustal Omega was used to align the protein sequences of saFakB1, saFakB2, spFakB1,
spFakB2, spFakB3, efFakB1, efFakB2, efFakB3, and efFakB4. Residues necessary for
Fak activity (Broussard 2016) are highlighted. Red: residues are conserved with saFakB2;
Blue: residues are similar to saFakB2. Note that spFakB3 had two substitutions for
strongly similar amino acid residues at Thr-61 His-266 of saFakB2.
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ABJ55200.1_spFakB3
WP_002357950.1_efFakB5
WP_002359214.1_efFakB4
ABD20605.1_saFakB1
ABJ55113.1_spFakB1
WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

---MTWKIIADSGCDYRQLPTPAINTTFVSVPLTIQV-ADQVFVDDASLD--IDQMMETM
MNKEKIALLVDSGTDVPEALVKQYGMYVL--PLQIIY-PEKTYTDKVDIT--PEEVYQRL
---MNYQLVTDSCCDLPYTYLKENQVPFI--SMNIQI-DGKEYRDDLGETFDYQNFLTAI
---MKIAVMTDSTSYLSQDLIDKYNIQIA--PLSVTFDDGKNFTESNEIA--IEEFYNKM
---MKLAVFTDSSAYLSAETLQREDLFVL--DIPVNI-DGEEYVEGINLS--AEEFYQKM
---MKIAIVTDSTAYLPERIKDHPNLFVI--PIPVIL-DGKIYNEGIDIE--ADEYYALL
--MTKQIIVTDSTSDLSKEYLEANNIHVI--PLSLTI-EGASYVDQVDIT--SEEFINHI
--MTKIKIVTDSSVTIEPELVKQLDITIV--PLSVMI-DNVVYSDADLKE--EGKFLQLM
--MTNVKIVTDSSCTMEKSLRDELNIHMM--PLSIMV-DGVVYPDDDHLP--GEKFMDMM
. :..**
.
: :
: :
:
:

54
55
54
53
52
52
53
53
53

ABJ55200.1_spFakB3
WP_002357950.1_efFakB5
WP_002359214.1_efFakB4
ABD20605.1_saFakB1
ABJ55113.1_spFakB1
WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

YATAEASKSACPSPDDYLRAFE-----GAKNIFLVTITGTLSGSHNSAQLAKNIYLEDHP
E--KEIPSTSLPDGATIQAIFDKIKEAGYEKVLAVTISSGLSGTYNVVRLLGEQ----TE
KN-GSMPTTSQVNVGRYNEFFRPFVEQGL-PVIYLAFSSGLSGSYQSALQSVEMLKEEYD
ASSQTIPTTSQPAIGEWITKYEMLRDQGYTDIIVICLSSGISGSYQSSYQAGEM----VE
AQASELPKTSQPSIAKLDEILTSLKEQGYTHALGLFLSSGISGFYQSIQYMVDD----YE
NNSKEFPTTSQPALGEVLELYKSIAEQGYDTIISIHLSSGISGFVHTLHGLTDE----IP
ENDED-VKTSQPAIGEFISAYEELGKDGS-EIISIHLSSGLSGTYNTAYQASQM----VD
QESKNLPKTSQPPVGVFAEIFEDLCKDGG-QILAIHMSHALSGTVEAARQGASL----ST
ANAKALPKTSQPPIGEFVELYDRLGEDGS-EVISIHMTKGLSGTVEAARQASNL----SS
.::
*
: : :: :** .
.

109
109
112
109
108
108
107
108
108

ABJ55200.1_spFakB3
WP_002357950.1_efFakB5
WP_002359214.1_efFakB4
ABD20605.1_saFakB1
ABJ55113.1_spFakB1
WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

DTKIHVIDSLSAGGEVDLLVEKLNDLIDQGLSFEEVVEAITAYQEKTKLLFVLAKVDNLV
GLDVFVLDTKNIGIGAGIQAIRAAELIETGLGWQELQQKLTEEVANAKVFFNVATLEYLQ
NVEIHIIDTKAASLGQGMLVREAIRLQTDGHSLGEVVAYLEEQKMKLHSWVTVDDLKHLE
GVNVHAFDSKLAAMIEGCYVLRAIEMVEEGYEPQQIIDDLTNMREHTGAYLIVDDLKNLQ
GLTIAFPDTLITSAPLGIMVESVFNWRDQGDDFASIQDKLAIQISRTSAFIMVDDLDHLV
GVALYPYDSKITSMPMGHMVEAALDLTEEKASLEEIFAKLDLIRDNTYAYLIVEDLNNLV
-ANVTVIDSKSISFGLGYQIQHLVELVKEGVSTSEIVKKLNHLRENIKLFVVIGQLNQLI
-ADVIVVDSSFTDQALKFQVVEAAKLAQEGKDMEAILSHVEEVKNHTELYIGVSTLENLV
-SKVTVIDSDFTDQGLSFQVIQAAKLAQAGAGVPEILAEIERVKQNTKLYIGISTLDNLV
:
*:
:
:
.
. : :. *

169
169
172
169
168
168
166
167
167

ABJ55200.1_spFakB3
WP_002357950.1_efFakB5
WP_002359214.1_efFakB4
ABD20605.1_saFakB1
ABJ55113.1_spFakB1
WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

KNGRLSKLIGTVVGLLNIRMVGKASETGTLELLQKARGSKKSVQAAYDELVKAG---YAG
KGGRIGLVTSILGNALKLNPIISCNEEGIYYTVAKSRGRKKSLDKTFELVTNFIGEA-PR
RGGRISKTAAALGGLMNIKPIIRVDAAGKLASVGKTRGRNKSLQKIAQETIQGIVEP-MK
KSGRITGAQAWVGTLLKMKPVLKFEDG-KIIPEEKVRTKKRAIQTLEKKVLDIVKDF-EE
KGGRLSNGAAILGNLLSIKPILYFNDQGVIEVYEKVRTEKKATKRLIEIIKETTAS--GQ
RGGRLTNGAALIAGLLKIKPILTFEDG-KIVLFEKIRSTKKAFARAEKIIGERNAGIEAP
KGGRISKTKGLIGNLMKIKPIGTLDDG-RLELVHNARTQNSSIQYLKKEIAEFIGDH-EI
KGGRIGRVTGLLSSLLNIRVVMQMKDH-ELQPMVKGRGTKTFKKWLDELITSLSER--AV
KGGRISRTTGLLSNIFNMKVVMDFENT-ELIPVAKGRGVKTFNKWFDELKSELSKIP-NV
:.**:
. :
:.:. :
.
: * :
.
.
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WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

GRIVMAQRNNEKCCQQLSERIRETFPQ-ADIKILPTSGLCSFYAEEGGLLMGYEID---FRLAVAHGAAEEEAKAMMERLKAAFPQAEEIYFGTISPALVVHTGPGLLGVGIQLLND-QTLLIAYAGTKDDAEKVKELIEKEIEV-NEILIYPLGPTITSHTGIGCIAVFSFGEKRKVTLFVINGDHFEDGQALYKKLQDDCPSAYQVAYSEFGPVVAAHLGSGGLGLGYVGRKIRL
YRVIVIHGNAPEKAEELRQHLLDFGLG-SDVSLATFGSVIGTHLGAGSIALGYIPVI--VKLYVIHANNRIVAEKEQAKLQKLYPN-AEIEIGHFGPVIGTHLGEKAIGLAISAQ---KSIGVAHANVIEYVDKLKKVFNEAFHV-NNYDINVTTPVISAHTGQGAIGLVVLKK---AEIGISYSGSDDWAKEMKESLQAY-VE-KPISVLETGSIIQTHTGENAWAILIRYHS--RQIGISHADGLELANGFKEGLQAIFKD-MDIPVLHTNPVIATHTGKNAFAIMYYTD---: :
.
:
:
:

281
286
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287
282
282
279
279
280

ABJ55200.1_spFakB3
WP_002357950.1_efFakB5
WP_002359214.1_efFakB4
ABD20605.1_saFakB1
ABJ55113.1_spFakB1
WP_002382324.1_efFakB1
ABD22554.1_saFakB2
ABJ55472.1_spFakB2
WP_002357444.1_efFakB2

T
-
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141

Supplemental Figure 3.3 ΔfakB1,4,5 and ΔfakB1,2,4 do not have different growth
kinetics from wild-type OG1RF in BHI media supplemented with ethanol (0.1%).
Shown are the average optical density readings ± standard deviations for n = 3 replicates.
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CHAPTER 4: THE FATTY ACID KINASE SYSTEM OF ENTEROCOCCUS
FAECALIS CONTRIBUTES TO DAPTOMYCIN TOLERANCE
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Experiments were completed by Rachel Johnston, with the exception of MIC
determination for ΔfakB1,2,5 in ampicillin and fosfomycin, which was performed by
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Abstract
Fatty acids are an important nutrient for bacterial cells, as they can be used as carbon
sources or for building the lipid membrane. As a commensal colonizer of the
gastrointestinal tract, and as a pathogen of clinical import, Enterococcus faecalis is
exposed to free fatty acids in its environment, yet cannot break them down to generate
energy. However, previous evidence suggested that free fatty acids are incorporated into
the membrane phospholipids of E. faecalis, indicating the presence of a pathway for fatty
acid uptake. Here we performed a network analysis of DegV domains, which have been
shown to bind fatty acids, and identified that E. faecalis has four distinctly-clustering DegV
domain-containing proteins. Two of these proteins cluster with the FakB proteins of S.
aureus and S. pneumoniae, which were previously found to bind different fatty acids,
allowing for their phosphorylation by the enzyme FakA. The remaining FakB homologs of
E. faecalis clustered separately from each other and from the FakB proteins of S. aureus
and S. pneumoniae. Our network analysis showed that organisms which are isolated from
different environmental sources cluster differently. This indicated that having different
numbers and/or functions of fatty acid-binding proteins may be necessary depending on
niche. As previous findings have shown that supplementation of E. faecalis with free fatty
acids increases tolerance to the drug daptomycin, we investigated how the fakB
homologs of E. faecalis impact daptomycin tolerance, and found that combined deletion
of fakB genes results in increased basal daptomycin tolerance. Furthermore, we found
that on supplementation of these strains with protective free fatty acids, daptomycin
tolerance was still induced. Taken together, these findings indicate that the FakB
homologs of E. faecalis decrease the ability of this organism to tolerate exposure to
daptomycin.
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Introduction
Enterococcus faecalis is a Gram-positive facultative anaerobe which is ordinarily a
commensal colonizer of the gastrointestinal tracts of humans and other mammals [1].
However, this bacterium is also able to colonize other tissues within its host, causing
infections which include bacterial endocarditis, infections of the urinary tract, and sepsis
[1]. In recent years, infections by enterococcal strains resistant to other treatments have
been combatted with the antibiotic daptomycin, which has been hypothesized in the
literature to act by disrupting the cell membrane [2-5]. Several instances of daptomycin
resistance have been reported in the clinic [6-8], and subsequent research has
demonstrated that mutations within genes involved in cell membrane homeostasis and
phospholipid metabolism are linked to daptomycin resistance in E. faecalis [9-17].
Further, exposure to the host fluids bile and serum, both of which are rich in fatty acids,
changes the membrane composition of E. faecalis and confers tolerance via unknown
mechanisms to membrane stressors, including daptomycin [18, 19]. Given that exposure
to fatty acids drastically changes the response of E. faecalis to daptomycin, we wished to
determine whether incorporation of fatty acids into membrane phospholipids is required
for inducing daptomycin tolerance.
Incorporation of exogenous fatty acids into the membrane of Gram-positive
organisms such as Staphylococcus aureus and Streptococcus pneumoniae is mediated
by a fatty acid kinase system. In this system, FakB, a protein consisting of a sole fatty
acid-binding DegV domain, binds to free fatty acids which are subsequently
phosphorylated by FakA [20]. The resulting acyl-phosphates can be used as donors for
acylation of glycerol-3-phosphate, or can be converted into acyl-ACP, which can be used
to acylate lysophosphatidic acid or enter into the fatty acid biosynthesis cycle. In E.
faecalis, there are 4 homologs to the characterized FakB proteins of S. aureus and S.
pneumoniae ([20, 21], Chapter 3). Here, we performed a network analysis to determine
potential fatty acid binding specificities of the FakB homologs of E. faecalis. We found
that OG1RF_RS07200 (efFakB2) clustered with the FakB2 proteins of S. aureus and S.
pneumoniae, while OG1RF_RS06660 (efFakB1) clustered with the FakB1 proteins of S.
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aureus and S. pneumoniae. OG1RF_RSS00080 (efFakB4) and OG1RF_RS05020
(efFakB5) were demonstrated to cluster away from annotated FakB proteins. To
determine whether the FakB homologs of E. faecalis play a role in fatty acid-mediated
daptomycin tolerance, we tested the ability of several fakB deletion strains to tolerate
daptomycin. Interestingly, on deletion of multiple fakB homologs of E. faecalis, we found
that there was an increase in basal daptomycin tolerance. Furthermore, we observed that
supplementation with fatty acids, which, in wild-type E. faecalis, protect from daptomycin
killing, was still protective in strains deleted for fakB genes, indicating that incorporation
of free fatty acids into phospholipids is not necessary for fatty acid-induced daptomycin
tolerance.

Materials and Methods
Identification of E. faecalis FakB homologs and network analysis of DegV
domain-containing proteins
EFI-EST (Enzyme Function Initiative’s Enzyme Similarity Tool, which draws networks of
proteins and clusters them based on amino acid sequence similarity [22]) was used to
generate a representative node sequence similarity network (rep node SSN) for proteins
within the DegV family (Pfam PF02645). As this family is large (containing 34,797 proteins
at date of accession, (8/7/2021), we grouped sequences that shared ≥50% identity over
80% of the sequence into cluster IDs (UniRef50). Each of these cluster IDs is a node
within the rep node SNN. Additionally, as we wished to gain insight into fatty acid binding
specificities rather than additional functions, we trimmed the input sequences to the
domain boundaries prior to generating the rep node SSN. Note that the annotated FakB
proteins of S aureus and S. pneumoniae only contain one domain which makes up the
majority (>95%) of the proteins, yet there are other instances where DegV is one domain
within a multidomain protein. Fragments (sequences which do not contain a start and/or
a stop codon) were not used in the analysis. An initial (permissive) BLAST E-value of 10-5
was used to calculate the similarity between cluster IDs. On calculating the similarities,
the edges between cluster IDs in the rep node SSN were calculated using an alignment
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score of 55 (more stringent than initial E-value; corresponding to ~35% identity between
nodes). The EFI-EST Color SSN tool was used to assign cluster numbers.

Network plot visualization
Networks were visualized and interpreted using Cytoscape v3.7.1 [23] and Gephi V0.9.2
[24]. Nodes were arranged with the OpenOrd layout algorithm. As the FakB proteins of
S. aureus and S. pneumoniae, along with the E. faecalis FakB homologs were present in
Cluster 1, we opted to analyze only this cluster. Cluster 1 originally contained 1,332
nodes, and 5,176 organisms were represented. However, as we wished to obtain
accurate information on copy number, organisms which appeared within the network
nodes were eliminated from further analysis if they represented >1 strain of that organism,
or if they could not be identified as a single strain (for instance, if “marine sediment
metagenome” or Coprococcus sp. were listed as an organism, they would be eliminated).
Thus, the resulting network contained 3,423 organisms, 1,010 nodes, and 7,515 edges.
To visualize subclusters within cluster 1, network connectivity, calculated by EFI-EST,
was used to color the network plot.
Using NCBI Taxonomy Browser and the Joint Genome Institution’s resources, each
organism within the network was examined and manually curated for the type of organism
(Gram stain, virus, or archaea), along with environmental origin, consisting of the
following categories: animal gut, animal airways, animal oral cavity/throat, other animal
sources, water sources, terrestrial sources, food sources, plant/algae sources, manmade
object sources, multiple sources, atmospheric (air) sources, and other sources. Using
GephiV0.9.2, these categories were used to color the network plot.

Bacterial growth conditions
Bacterial strains and plasmids used in this study are listed in Supplemental Table 4.1.
Enterococcus faecalis was grown statically in brain heart infusion medium (BHI; BD Difco)
at 37°C. Overnight cultures were diluted to an optical density at 600 nm (OD 600) of 0.01
prior to performing assays. Where indicated, cultures were supplemented with fatty acids
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at the following concentrations: oleic acid (C18:1 cis9) at 20 µg/mL; linoleic acid (C18:2 cis9,12)
at 10 µg/mL. Antibiotics were added as indicated in the text at the following
concentrations: daptomycin: 30 or 40 µg/mL; ampicillin: 0, 1, 2, 4, 6, or 8 µg/mL; and
Fosfomycin: 64, 128, 256, 512, 1024, and 2048 µg/mL.

Cell survival assays
Where indicated, cells were grown short-term in supplied fatty acids, where the fatty acid
was added to cultures at early exponential phase (OD600 = 0.225 to 0.250) and the
cultures were grown an additional 30 minutes. Cells were then harvested by centrifugation
(2379xg for 10 minutes), washed twice with 1X phosphate buffered saline (1X PBS), and
resuspended in an equivalent volume of “challenge medium” consisting of BHI containing
1.5 mM CaCl2 and 30 or 40 µg/mL daptomycin, as indicated in the text. Serial dilutions
were plated onto BHI agar at 0, 15, 30, and 60 min after resuspension in the challenge
medium.

Minimal inhibitory concentration determination
To determine minimal inhibitory concentration, the indicated strain was grown overnight
in BHI, and in the morning, was diluted to an OD600 of 0.01 in BHI containing daptomycin
and 1.5 mM CaCl2, ampicillin, or Fosfomycin. The cells were grown overnight at 37°C,
and after 24 hours were examined for growth.

Results
Network analysis of DegV domains reveals clustering of annotated FakB proteins
On generating a sequence similarity network (SSN) of the DegV domains (Pfam =
PF02645) and annotating the locations of the FakB homologs of E. faecalis, along with
those of S. aureus and S. pneumoniae (Figure 4.1), we found that OG1RF_RS06660
clustered with saFakB1 and spFakB1, which are specific for binding of saturated fatty
acids [20, 21]. Further, we observed that OG1RF_RS07200 clustered with the saFakB2
and spFakB2, indicating its similarity with proteins specific for binding monounsaturated
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Figure 4.1. E. faecalis FakB homologs cluster distinctly.
SSN of DegV protein domains (protein family = PF02645) generated by the EFI-EST as
accessed on 8/7/2021. Each node is representative of a group of proteins sharing ≥50%
identity over 80% of the sequence (see Materials and Methods) to each other; although
in many cases, they are from different organisms. Edges were drawn between nodes
using an alignment score of 55, resulting in edges being drawn only between nodes where
the DegV domains represented therein had ≥35% identity. Node darkness demonstrates
connectivity between nodes as calculated by EFI-EST. The darker the color, the higher
the network connectivity. The specific nodes containing the DegV sequences of the FakB
proteins of S. aureus and S. pneumoniae are highlighted in red and blue, respectively,
while the nodes containing the FakB homologs of E. faecalis OG1RF are highlighted in
purple.
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fatty acids. We thus named OG1RF_RS06660 and OG1RF_RS07200 FakB1 and FakB2,
respectively. We noted that none of the E. faecalis FakB homologs clustered with
spFakB3. However, OG1RF_RS00080 was located in a highly connected portion of the
network, yet did not cluster with annotated FakB proteins, thus we named it efFakB4.
Similarly, OG1RF_RS05020 clustered alone in a separate branch of the network, thus we
named it efFakB5.
The network data indicate that OG1RF_RS06660 may be specific for binding of
saturated fatty acids, while OG1RF_RS07200 may be responsible for binding of
monounsaturated fatty acids. The specificity of efFakB2 for unsaturated fatty acids is
supported by data demonstrating that combined deletion of fakB2 and fakB1 resulted in
increased generation time in unsaturated fatty acids (Chapter 3; Table 3.3). While deletion
fakB1 or fakB2 alone did not give this result (Chapter 3; data not shown), indicating that
efFakB2 is the primary FakB necessary for binding unsaturated fatty acids. Peculiarly,
deletion of fakB1 alone did not result in growth defects in saturated fatty acids, yet
combined deletion of fakB1 with fakB5 (note that deletion of fakB5 had no observed effect)
resulted in increased generation time in these fatty acids (Chapter 3; Table 3.4). These
combined data indicate that efFakB5 may play a role in utilization of saturated fatty acids,
while efFakB1 may play a more promiscuous role (Chapter 3). This is in contrast with
previous literature reporting FakB1 homologs as primarily binding saturated fatty acids
[20, 21].

Organisms with DegV domains are predominantly Gram-positive and cluster
according to isolation source
Cluster 1 of the DegV network predominantly comprised Gram-positive bacteria (Figure
4.2A). However, some were Gram-negative bacteria, and there was one archaeote,
Methanomassilicoccales archaeon RumEn M1, which was found in the rumen of a cow
[25] (thus it was classified as a gut organism). The archaeote had only one appearance
in cluster 1 of the network, indicating that it only had one DegV domain within the cluster.
In addition, we observed a virus in our network plot, which was originally found inserted
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Figure 4.2. Organisms which encode DegV domain proteins are predominantly
Gram-positive, are predominantly found in the gut, and partially cluster in the
DegV network according to their isolation source.
(A) Number of organisms in the DegV network classified as Gram-positive, Gramnegative, Gram-variable or Gram-indifferent, archaea, virus, or organisms which could
not be classified. (B) Number of organisms classified according to isolation source. In
both A and B, shown are the raw numbers of organisms belonging to each classification.
(C) Clustering of Gram-positive and Gram-negative organisms in the DegV network. (D)
Clustering of organisms isolated from different sources in the DegV network.
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in the genome of Streptococcus suis, an emerging zoonotic pathogen [26]. The specific
strain the virus was isolated from, S. suis P1/7, did not appear in our network analyses,
although 6 other strains of S. suis did, each with 4 or 5 appearances in different nodes,
indicating that they each had 4 or 5 different DegV domains.
To determine if specific fatty acid-binding domains are correlated with environment,
we examined the isolation sources of the organisms within our analysis by manual
annotation. Over one-third of the organisms within the network were from the gut (Figure
4.2B), although other animal sources, including the respiratory system (airways), and oral
cavity and oropharynx (oral cavity/throat) were also noted (Figure 4.2B). Other isolation
sources observed were various water sources (including ocean, aquariums, pools, lakes
and ponds, wastewater, ground water, and hot springs) or various terrestrial sources
(including soil, compost, and aquifers), as well as food sources, plants and algae, and
manmade objects (such as spacecraft, airplanes, and bioreactors). Other sources were
from fungi and dinoflagellates (n = 4 organisms).
Of note, several of the classifications had some overlap with others: for instance,
aquifers, while made of permeable rock, are often filled with water, although some of the
aquifers annotated as isolation sources in this network were used for oil storage.
Additionally, while bioreactors are manmade objects, many of the bioreactors annotated
as isolation sources within this study were used for the breakdown of wastewater sludge,
although others were used for production of biofuels and breakdown of plant matter.
With these limitations in mind, we plotted both the organism classification (Figure
4.2C) and the isolation source (Figure 4.2D) onto the network plot. We observed that
many of the nodes held only Gram-positive organisms (Figure 4.2C). However, towards
the center of the network, we noted a grouping of nodes which contained more Gramnegative organisms or with multiple or no Gram-classification (Figure 4.2C). This area of
the graph became even more distinct when we plotted isolation sources onto the network
graph (Figure 4.2D). Here we observed that there was a large grouping of organisms
predominantly isolated from water and terrestrial sources which corresponded with the
grouping of Gram-negative and multiple/unclassified organisms (Figure 4.2C).
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Different isolation sources are associated with different numbers of DegV nodes
As we observed that many of the subclusters in the network plot had organisms from
mixed isolation sources, and because it was previously noted that different organisms
have different numbers of FakBs [27], we wished to determine if there was a pattern with
regards to the isolation source of an organism and the number of DegV domains it
contains. Thus, we calculated the number of nodes each organism appeared in, and for
each isolation source, calculated the percentage of organisms from that isolation source
found in different numbers of nodes (Table 4.1). Interesting trends we observed were that
organisms isolated from the gut were overall evenly split between appearing in one node
and four nodes, indicating that the number of different DegV domains ranged between
one and four. Interestingly, there was a heavy shift towards favoring three DegV domains
in several other isolation sources, including animal airways, the oral cavity/throat,
terrestrial sources, the atmosphere, and plants. However, in water sources, species with
only one DegV domain dominated. Organisms isolated from food shifted towards having
increased numbers of DegV domains, as ~19% of these organisms had five nodes, more
than double the percentage of organisms from other isolation sources. Organisms
isolated from fungal sources and dinoflagellate sources (Other sources) all appeared in
four nodes, indicating the presence of 4 DegV domains.
Of note, S. aureus strains typically only had between one and two DegV domains
within separate nodes (95% were found in two nodes, while the remaining 5% were found
in one node; Supplemental Figure 4.1). This is in contrast to S. pneumoniae isolates,
which appeared in three nodes (87% of isolates) or four nodes (13%), indicating the
presence of 3-4 DegV domains within species (Supplemental Figure 4.1). However, E.
faecalis had predominantly 4 DegV domains, as isolates appeared in four nodes (96% of
isolates) or three nodes (4% of isolates; Supplemental Figure 4.1). These pathogens each
have a different commensal colonization niche of mammals. S. aureus colonizes the skin
and nasal cavity; S. pneumoniae colonizes the upper airway; and E. faecalis, named for
its primary isolation source [28], colonizes the gut. While there were only 18 skin isolates
analyzed within the DegV network, ~44% of these were found to appear in only two
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Table 4.1. Number of nodes in which organisms from specific isolation sources
appear.
Shown in percentages is the number of nodes that organisms from different isolation
sources appeared in.
Organism
isolation
source
Gut
Airways
Oral
cavity/Throat
Other animal
sources
Water
Terrestrial
Atmosphere
Food
Plants/algae
Manmade
Multiple
Other
Unclassified

1194
74

% in
one
node
22.3
5.4

% in
two
nodes
23.9
13.5

% in
three
nodes
24.3
50.0

% in
four
nodes
20.9
31.1

% in
five
nodes
5.8
0.0

% in
six+
nodes
2.8
0.0

173

16.8

14.5

38.2

25.4

3.5

1.7

259

10.4

22.8

33.6

29.0

2.7

1.5

488
478
12
211
204
154
24
4
148

32.4
20.7
16.7
4.7
8.8
21.4
4.2
0.0
12.8

19.9
13.2
8.3
14.7
18.6
22.1
16.7
0.0
23.0

24.0
43.1
50.0
33.2
44.1
24.7
16.7
100
19.6

9.8
12.6
16.7
24.2
22.1
18.2
58.3
0.0
35.8

8.8
8.4
8.3
19.4
4.9
7.1
4.2
0.0
6.1

5.1
2.1
0.0
3.8
1.5
6.5
0.0
0.0
2.7

Number of
organisms
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nodes, indicating that necessity for increased numbers fatty acid binding domains is
reduced relative to organisms which colonize the gut and respiratory pathways. These
data are indicative of potential differences in nutrient scavenging or regulation needs for
organisms which reside in different environments.

Deletion of fakB genes increases basal daptomycin tolerance
As a commensal member of the gut microbiota, E. faecalis is likely exposed to high
concentrations of and numerous fatty acids in its environment. Specifically, bile contains
palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1 cis9), and linoleic acid (C18:2 cis9,12)
[19]. Of note, exposure to these fatty acids alters overall physiology, including cell
morphology and growth patterns of E. faecalis [29]. Further, specific fatty acids can confer
the ability to survive in bactericidal concentrations of the antibiotic daptomycin [18, 19,
29-31]. Specifically, long-term exposure of E. faecalis to specific fatty acids, namely the
unsaturated fatty acids found in bile and serum, oleic acid (C18:1 cis9) and linoleic acid
(C18:2 cis9,12), conferred protection to membrane damaging agents, including the detergent
sodium dodecyl sulfate (SDS) and the membrane depolarizing antibiotic daptomycin [19,
29]. We thus investigated whether the fakB homologs play a role in inducing tolerance to
these agents in the presence of known protective fatty acids in E. faecalis. Specifically,
we wished to address whether these beneficial fatty acids need to be incorporated onto
phospholipid head groups via the Fak system to induce daptomycin tolerance. We first
examined the fakB deletion strains for their basal sensitivity to the antibiotic without
exogenous fatty acid supplementation. We found that the basal tolerance of ΔfakB1,2,4
and ΔfakB1,4,5 was increased relative to wild-type (Figure 4.3), indicating that together,
the FakB proteins of E. faecalis contribute to the efficacy of daptomycin.
We previously observed that combined deletion of fakB1, fakB2, and fakB5 (e.g.,
fakB4 only) led to several phenotypic differences from wild-type, including hyperseptation
of cells in unsupplemented medium and increased generation time in medium
supplemented with unsaturated fatty acids (Chapter 3; Figure 3.3, Tables 3.3 and 3.4).
Further, supplementation of ΔfakB1,2,5 with fatty acids did not overcome inhibition of de
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Figure 4.3. Deletion of fakB genes results in increased basal tolerance against
daptomycin.
Wild-type E. faecalis OG1RF and (A) ΔfakB1,2,4, (B) ΔfakB1,4,5, and (C) ΔtesS,
ΔfakB1,2,5, ΔfakB1,2,5/ΔtesS, and ΔfakB1,2,4,5/ΔtesS were grown in BHI until midlogarithmic phase, were harvested, washed, and challenged with daptomycin at 30
µg/mL. Depicted are the average log ratios of survivors over time ± standard deviations.
n = 3 replicates for all experiments.
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novo fatty acid biosynthesis by the drug cerulenin, (Chapter 3; Figure 3.4; [29]),
suggesting that ΔfakB1,2,5 could no longer incorporate protective fatty acids into its
phospholipids. As cellular morphology is driven by cell wall placement, and ΔfakB1,2,5
had gross differences in its morphology (Chapter 3; Figure 3.2), and because lipid II, a
peptidoglycan precursor, has been indicated as a target of daptomycin [32], we wished
to determine whether this strain had increased daptomycin tolerance. We thus challenged
ΔfakB1,2,5 (as above) with daptomycin, and observed a large increase in survivors
relative to wild-type (Figure 4.3C).
Altered phospholipid composition and levels of free fatty acids in the cell were
previously linked to ability to withstand daptomycin treatment [19, 31]. As we previously
observed, ΔfakB1,2,5 had increased levels of free fatty acids (note, normalized to
phosphatidylglycerol) in the membrane (Chapter 3; Figure 3.3). Therefore, our
observations suggest that the daptomycin tolerance observed in ΔfakB1,2,4, ΔfakB1,4,5,
and ΔfakB1,2,5 may be driven by an accumulation of free fatty acids in the membrane.
Notably, free fatty acid levels were restored to wild-type levels in the quintuple deletion
strain ΔfakB1,2,4,5/ΔtesS, which was deleted for the fakB genes along with a
thioesterase thought to cleave fatty acids from acyl-ACP ([33]; Chapter 3; Figure 3.3).
Given that the quintuple deletion strain had wild-type levels of free fatty acids normalized
to phosphatidylglycerol, we examined whether the basal tolerance of the quintuple
deletion strain was reverted to wild-type basal tolerance. We found, however that the
quintuple deletion strain also had increased basal daptomycin tolerance relative to wildtype (Figure 4.3). This phenotype was not driven by deletion of tesS, as deletion of tesS
did not increase basal tolerance. These data suggest that free fatty acids may not be the
drivers for increasing basal daptomycin tolerance.

Exposure of fakB deletion strains to fatty acids still induces protection to
daptomycin
While the fakB deletion strains displayed increased basal tolerance to daptomycin relative
to wild-type E. faecalis, this observation did not disentangle whether incorporation of
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exogenous fatty acids is required for induction of tolerance to daptomycin. Our previous
data demonstrated that combined deletion of fakB1, fakB2, and fakB5 resulted in a strain
which was unable to utilize exogenous fatty acids to rescue growth inhibition by the de
novo fatty acid biosynthesis inhibitor cerulenin (Chapter 3; Figure 3.4). These results
indicated that incorporation of exogenous fatty acids into membrane phospholipids was
greatly reduced. Thus, we exposed our deletion strains to protective fatty acids and
assayed for daptomycin tolerance. Given that the deletion strains grew slowly relative to
the wild-type strain in media supplemented with specific fatty acids, we used short-term
exposure of fatty acids. Specifically, we exposed cultures to oleic acid or linoleic acid at
log phase, grew an additional half hour, then challenged with daptomycin. We found that
short-term exposure to oleic acid still induced protection against daptomycin in
ΔfakB1,2,4, ΔfakB1,4,5 and ΔfakB1,2,4,5/ΔtesS (Figure 4.4). However, for each of these
strains, the fold protection was reduced by ~1 log relative to protection observed for the
wild-type strain at every time point (Table 4.2). These trends were repeated on exposure
of the strains to linoleic acid (Figure 4.5 and Table 4.2). However, linoleic acid was 3 logs
more protective in wild-type compared to ΔfakB1,4,5 (Table 4.2). Notably, exposure of
ΔfakB1,2,5 to these fatty acids did not induce protection; indeed, the solvent control in
these experiments yielded no difference from exposure to the fatty acids oleic acid (Figure
4.4, Table 4.2) and linoleic acid (Figure 4.5, Table 4.2).
To test the protective role of fatty acids in ΔfakB1,2,5, we used daptomycin at a higher
(40 µg/mL) concentration (as has been used for resistant isolates in the past; [18]) to
accommodate the high basal tolerance of this strain. We noted that exposure of
ΔfakB1,2,5 to a higher concentration of daptomycin caused a decrease in survivors
relative to the starting population (Figure 4.6). Additionally, oleic acid was protective
against daptomycin at all time points in these cases (Figure 4.6A), yet when ΔfakB1,2,5
was treated with linoleic acid, a short-term exposure resulted in a significant difference
between the solvent control and linoleic acid-treated cells at early time points but not at
late time points (Figure 4.6B; P < 0.05 after 15 and 30 minutes of daptomycin exposure
and P > 0.05 at the remaining time points).
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Figure 4.4. Addition of oleic acid protects against daptomycin in fakB deletion
backgrounds.
Wild-type E. faecalis OG1RF and (A) ΔfakB1,2,4, (B), ΔfakB1,4,5 (C) ΔfakB1,2,5, and (D)
ΔfakB1,2,4,5/ΔtesS were grown to exponential phase, then the solvent control or 20
µg/mL oleic acid were added. The cells were then grown an additional 30 minutes prior
to harvesting. After harvest, cells were washed and challenged with daptomycin at 30
µg/mL. Depicted are the log ratios of survivors over time. n = 3 replicates for all
experiments.
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Table 4.2. Log fold protection against daptomycin induced by addition of fatty
acids.
Represented are the average log fold protection values ± standard deviations induced by
addition of oleic acid or linoleic acid relative to the solvent control.
Oleic acid
Strain

Linoleic acid

Time
(min)

Log fold
protection

P-value
against
Wild-type

Log fold
protection

P-value
against
Wild-type

0
15
30
60
0
15
30
60
0
15
30
60
0
15
30
60
0
15
30
60

0±0
3.4 ± 0.6
3.7 ± 0.7
3.9 ± 0.7
0±0
2.1 ± 0.2
2.3 ± 0.1
2.5 ± 0.3
0±0
2.0 ± 0.1
2.1 ± 0.1
2.3 ± 0.1
0±0
-0.1 ± 0.1
0.0 ± 0.1
0.0 ± 0.1
0±0
2.3 ± 0.2
3.0 ± 0.1
2.9 ± 0.1

NA
NA
NA
NA
P=1
P < 0.01
P < 0.01
P < 0.01
P=1
P < 0.01
P < 0.01
P < 0.01
P=1
P < 0.01
P < 0.01
P < 0.01
P=1
P < 0.01
P < 0.01
P < 0.01

0±0
3.5 ± 0.6
3.8 ± 0.8
4.1 ± 1.0
0±0
2.6 ± 0.1
3.0 ± 0.3
3.1 ± 0.2
0±0
0.8 ± 0.2
0.9 ± 0.1
0.8 ± 0.1
0±0
0.0 ± 0.1
0.1 ± 0.1
0.1 ± 0.1
0±0
2.7 ± 0.1
2.9 ± 0.2
2.9 ± 0.1

NA
NA
NA
NA
P=1
P < 0.01
P = 0.03
P = 0.02
P=1
P < 0.01
P < 0.01
P < 0.01
P=1
P < 0.01
P < 0.01
P < 0.01
P=1
P < 0.01
P = 0.01
P < 0.01

30 µg/mL daptomycin
Wild-typea

ΔfakB1,2,4

ΔfakB1,4,5

ΔfakB1,2,5

ΔfakB1,2,4,5/ΔtesS

an=12

for wild-type replicates; n = 3 for other deletion strains.
was not compared, as daptomycin concentrations tested were different.

bWild-type
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Table 4.2 Continued
Oleic acid
Strain

Linoleic acid

Time
(min)

Log fold
protection

P-value
against
Wild-type

Log fold
protection

P-value
against
Wild-type

0
15
30
60
120
240

0.0 ± 0.0
0.6 ± 0.1
0.5 ± 0.1
0.7 ± 0.2
0.6 ± 0.3
0.8 ± 0.1

NA
NA
NA
NA
NA
NA

0.0 ± 0.0
1.3 ± 0.2
1.1 ± 0.2
0.5 ± 0.2
0.2 ± 0.3
0.1 ± 0.3

NA
NA
NA
NA
NA
NA

40 µg/mL daptomycinb

ΔfakB1,2,5

an=12

for wild-type replicates; n = 3 for other deletion strains.
was not compared, as daptomycin concentrations tested were different.

bWild-type
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Figure 4.5. Addition of linoleic acid protects against daptomycin in fakB deletion
backgrounds.
Wild-type E. faecalis OG1RF and (A) ΔfakB1,2,4, (B), ΔfakB1,4,5 (C) ΔfakB1,2,5, and (D)
ΔfakB1,2,4,5/ΔtesS were grown to exponential phase, then the solvent control or 10
µg/mL linoleic acid were added. The cells were then grown an additional 30 minutes prior
to harvesting. After harvest, cells were washed and challenged with daptomycin at 30
µg/mL. Depicted are the log ratios of survivors over time. n = 3 replicates for all
experiments.
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Figure 4.6. Oleic acid and linoleic acid protect ΔfakB1,2,5 against daptomycin, but
only at concentrations above that seen for other strains.
The solvent control and (A) 20 µg/mL oleic acid or (B) 10 µg/mL linoleic acid were added
to exponential phase cultures of wild-type E. faecalis OG1RF and ΔfakB1,2,5. The cells
were then grown an additional 30 minutes prior to harvesting. After harvest, cells were
washed and challenged with daptomycin at 30 µg/mL (wild-type) or 40 µg/mL
(ΔfakB1,2,5) daptomycin. Depicted are the log ratios of survivors over time. n = 3
replicates for all experiments.
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Daptomycin and other cell wall-targeting antibiotics do not have a higher MIC
against ΔfakB1,2,5 relative to wild-type E. faecalis
As we observed that ΔfakB1,2,5 had increased basal tolerance relative to wild-type E.
faecalis, we tested the minimal inhibitory concentration (MIC) of daptomycin against
ΔfakB1,2,5. The ΔfakB1,2,5 strain had the same daptomycin MIC as wild-type (Table
4.3). Of note, recent evidence suggests that daptomycin is a wall-targeting antibiotic [32],
and we previously noted that removal of the cell wall of E. faecalis resulted in increased
daptomycin tolerance ([34]; Chapter 2). Furthermore, ΔfakB1,2,5 had hyperseptation
relative to wild-type E. faecalis (Chapter 3; Figure 3.2). Thus, we tested the efficacy of the
cell wall-targeting antibiotics ampicillin and fosfomycin against ΔfakB1,2,5 (Table 4.3),
and observed no difference. These data suggest that there is a difference between the
killing kinetics observed when performing a cell survival assay (which is a short-term
exposure at 7-10X the MIC of the antibiotic) and performing an MIC assay (a long-term
exposure at ~1X the MIC of the antibiotic). These data indicate that while ΔfakB1,2,5 is
not resistant to daptomycin, as it does not have increased ability to grow in it or in other
peptidoglycan-targeting drugs. However, it is able to better survive short-term exposure
to high concentrations of daptomycin relative to wild-type.

Discussion
In this study, we indentified that two out of four of the FakB homologs of E. faecalis
clustered spatially with the characterized FakB proteins of S. aureus and S. pneumoniae,
indicating that they may share similar functions. Notably, none of the E. faecalis FakB
homologs clustered with FakB3 of S. pneumoniae, which is specific for binding of
polyunsaturated fatty acids [21]. However, we observed distinct clustering of the
remaining two FakB homologs of E. faecalis in other regions of the network. efFakB4
(OG1RF_RS00080) clustered in a densely connected portion of the network, which was
predominantly populated with organisms isolated from the gut (Figure 4.1). This
potentially indicates that this specific FakB homolog may play an important role in
scavenging fatty acids abundant in the gut. It is possible that while deletion of the gene
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Table 4.3. Minimal inhibitory concentrations of daptomycin, ampicillin, and
fosfomycin for wild-type OG1RF and ΔfakB1,2,5.
Antibiotic
Daptomycin

Ampicillin

Fosfomycin

Bacterial strain

MIC range (µg/mL)

Wild-type

3-4

ΔfakB1,2,5

1-3

Wild-type

2-6

ΔfakB1,2,5

2-4

Wild-type

512-1024

ΔfakB1,2,5

256-512
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encoding this homolog did not cause specific phenotypes to arise on supplementation
with long-chain fatty acids (Chapter 3; Tables 3.3 and 3.4), that it may be central for
utilization of other resources, including short-chain fatty acids, which are produced by
members of the gut microbiota [35]. The other FakB homolog (efFakB5),
OG1RF_RS05020, clustered distinctly with a predominantly Gram-positive region of the
network containing other organisms with a variety of isolation sources.
While there were numerous Gram-negative organisms annotated within cluster 1,
with no distinct spatial organization within the network, we noted that some of these were
in a “gray” area in terms of classification. For instance, the genus Acidaminococcus, while
noted as being Gram-negative via staining, is more closely related to Gram-positive
organisms [36]. Similarly, the genus Dehalobacter, which came up in the network analysis
and was also annotated as being Gram-negative, is a member of the clostridia class,
which is made up of predominantly Gram-positive organisms. Paenibacillus species
annotated as being Gram-negative also appeared. This genus is known to stain in a
Gram-variable manner [37] – thus it is of little surprise that several isolates were
annotated as Gram-negative. Other Gram-negative organisms within the cluster analyzed
included members of the well-known genera Deinococcus, Thermus, Pseudomonas, and
Fusobacterium. An underwhelming number of the species annotated in cluster 1 were of
Gram-negative origin, however this does not rule out that other clusters not examined
contained higher ratios of Gram-negative to Gram-positive organisms.
Interestingly, we also observed an archaeote isolated from the gut of a cow [25].
Given that there was only one such example of an archaeote, this leads to speculation
on whether there could have been a horizontal gene transfer event between another gut
bacterium and Methanomassiliicoccales archaeon RumEn M1. However, the evidence
for this from our analysis is poor, given that while the other organisms within this node
were of gut origin, none were from the rumen of a cow. Similarly, one could speculate
that the virus (Streptococcus phage phiZJ20091101-1) annotated within this study
acquired the DegV domain from its Streptococcus host, yet that specific isolate was not
found within our network.
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One captivating observation that we made was that organisms partially clustered
according to isolation source. Specifically, several distinct subclusters appeared to
contain more isolates which were found in animal sources, while a large subcluster at the
center of the network appeared to have more isolates from water sources. Of note, many
of the nodes which had multiple or unclassified Gram-staining also appeared within water
environments. Over 33% of the Gram-negative organisms annotated as a part of this
study were from water sources, while over 28% of the unclassified organisms were also
from water sources, potentially accounting for this observation. Many of the unclassified
organisms were from metagenome analyses, where a genome of a strain was assembled,
but not further classified experimentally.
We observed a large subcluster of organisms, which included efFakB4. Note that
there was no specific phenotype different from wild-type associated with long-chain fatty
acid supplementation upon deletion of fakB4 (Chapter 3; Tables 3.3 and 3.4). However,
the efFakB4 homologs within the network contained many isolates of animal gut origin
(Figure 4.2). These observations lead to the question of whether there is a specific fattyacid binding motif which is important for survival under different conditions. Further, our
data highlight that some environments, such as the animal gut, may select for more copies
of FakB homologs, potentially with different binding specificities. These observations call
into question why specific strains may have more copies of genes encoding FakB
proteins. We and others noted that S. aureus often has two copies of FakB, S.
pneumoniae often has three, and E. faecalis primarily has four (Supplemental Figure 4.1)
[27]. Given that S. aureus resides on the skin or in the nares, it is likely that it has little
need to scavenge for fatty acids, as the fatty acids present are often antimicrobial in
nature [38-41]. However, it may be beneficial for this organism to be able to bind and
subsequently detoxify the fatty acids with which it comes into contact. Additionally,
incorporation of specific fatty acids can be detrimental to the bacterium: uptake of linoleic
acid (C18:2 cis9,12) by S. aureus boosted the host immune response against it [42]. In the
case of S. pneumoniae, which resides in the upper respiratory tract, exposure to fatty
acids likely occurs on coming into contact with sputum, of which most of the dry weight
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consists of fatty acids [43], including palmitic acid (C16:0), stearic acid (C18:0) and oleic acid
(C18:1

cis9)

[44]. Notably, although S. pneumoniae has a FakB (spFakB3) specific for

binding polyunsaturated fatty acids, this class of fatty acids was not detected in sputum
samples [44]. However, sputum samples from patients with different conditions
(tuberculosis and other diseases) had different compositions, indicating that S.
pneumoniae could retain FakB3 for surviving under specific conditions [44]. One of these
conditions could be to respond to fatty acids released as a part of inflammation, such as
arachidonic acid (C20:4).
As a resident of the mammalian gut, E. faecalis is likely exposed to an abundance of
fatty acids. The fatty acids present in bile have varying effects on E. faecalis physiology,
with alterations in morphology induced by saturated fatty acids [29] and increases in
ability to tolerate daptomycin and membrane stressors induced by specific unsaturated
fatty acids [18, 19, 29-31]. Prior to this work, we hypothesized that induction of protection
against daptomycin by exogenous fatty acids was due to its incorporation onto
phospholipid head groups. However we instead found that deletion of the fakB genes,
which are required for incorporation of fatty acids onto phospholipids (Chapter 3; Figure
3.4) resulted in increased basal daptomycin tolerance. As we had previously observed
that free fatty acids were increased in ΔfakB1,2,5 (Chapter 3; Figure 3.3), we next
hypothesized that free fatty acids in this strain were responsible for inducing daptomycin
tolerance (Figure 3.3). However, in our quintuple deletion strain, which had wild-type
levels of free fatty acids normalized to phosphatidylglycerol (Chapter 3; Figure 3.3), the
basal tolerance was not restored to wild-type levels. However, the quantification of free
fatty acids performed by thin layer chromatography (Chapter 3; Figure 3.3) is not the most
accurate way to quantify fatty acids, and our analysis of free fatty acids did not take into
account that phospholipid levels may differ between strains. Therefore, to better
understand whether the quintuple deletion strain has free fatty acid levels similar to that
of wild-type, mass spectrometry analyses will need to be performed.
Another hypothesis for why deletion of the fakB genes would drive daptomycin
tolerance up could be that deletion of the fakB genes alters cell wall placement due to
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altered lipid metabolism. This is supported through the data demonstrating hyperseptation
of ΔfakB1,2,5 (Chapter 3; Figure 3.2). Peptidoglycan synthesis is closely tied to the
membrane. Indeed, the peptidoglycan precursors lipid I and lipid II, and the enzymes
which act upon them, MraY, MurG, MurM, MurN, and MurJ are membrane-bound. Thus,
it is possible that alterations of membrane organization through altered lipid biosynthesis
might drive mislocalization of the enzymes and lipid-bound precursors of peptidoglycan.
Mislocalization of lipid II, a potential target of daptomycin; [32, 34]) might then drive
increased basal daptomycin tolerance.
While basal daptomycin tolerance was increased in our deletion strains, fatty acid
supplements still provided some protection against daptomycin in the fakB deletion
strains (Figures 4.3–4.5), although not to the same extent as wild-type. These findings
indicate that exogenous fatty acids cause other physiological changes which induce
daptomycin tolerance. One known physiological effect of exogenous fatty acids on cells
is altered cellular morphology [29]. Specifically, supplementation with palmitic acid (C16:0),
myristic acid (C14:0), and stearic acid (C18:0) resulted in aberrant placement of septa, while
supplementation with palmitoleic acid (C16:1 cis9) resulted in a decrease in cell length [29].
Additionally, supplementation of cells with exogenous fatty acids was demonstrated to
increase the levels of free fatty acids within E. faecalis cells [31, 45]. In the ΔfakB1,2,5
deletion strain, we noted both an increase in free fatty acids and multiple septations
present in individual “cells” (Chapter 3; Figures 3.2 and 3.3). In this deletion strain, we
observed that addition of exogenous fatty acids did not induce protection beyond its basal
level of daptomycin tolerance until we increased the daptomycin concentration (Figures
4.4–4.6). This suggested that the physiological differences between these cells and wildtype E. faecalis may partially correspond with the changes induced by supplementation
with protective fatty acids. These data indicate that supplementation with free fatty acids
may induce daptomycin tolerance by altering the placement of cell division machinery,
including peptidoglycan synthesis proteins.
Overall, our data suggests that the specificities of DegV domains may be predictable
based on network clustering, as efFakB2 clustered with saFakB2 and spFakB2 and
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deletion of fakB2 in E. faecalis yielded an increased generation time in media
supplemented with unsaturated fatty acids (Chapter 3; Table 3.3). However,
discrepancies in observed phenotypes and fatty acid binding specificities may occur. Our
previous data indicated that efFakB1 may be a generalist fatty acid binding protein, as
deletion of the gene encoding this protein was necessary to elicit phenotypes in media
supplemented with both saturated and unsaturated fatty acids (Chapter 3; Tables 3.3 and
3.3). The efFakB1 DegV domain, however, clustered with the FakBs of S. aureus and S.
pneumoniae specific for binding saturated fatty acids [20, 21]. This discrepancy could
potentially be explained if fakB1 of E. faecalis is more highly expressed than the other
fakB genes. However, biochemical data indicating fatty acid binding specificities, along
with data elucidating transcription, translation, and efficiency of efFakB1 relative to the
other efFakBs, are needed to explain these data.
Overall, our data suggest that specific fatty acid binding domains are important for
organisms to survive and thrive in differing environments. Further, our data indicate that
disturbing the phospholipid biosynthesis pathway has broad impacts on the cell, as cell
wall placement, growth in the presence of fatty acids, and cell viability (Chapter 3; Figures
3.2, Tables 3.3 and 3.4) are impacted on deletion of the fakB genes. However, the specific
impacts of deleting these genes and supplementation with exogenous fatty acids on
daptomycin tolerance remains to be discovered.
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Appendix
Supplemental Table 4.1. Bacterial strains and plasmids used in this study.
Strain
Enterococcus
faecalis OG1RF
ΔfakB1,2,4
ΔfakB1,4,5
ΔfakB1,2,5
ΔfakB1,2,5/ΔtesS
ΔfakB1,2,4,5/ΔtesS

Relevant genotype or description
Laboratory strain
RifR, FusR
E. faecalis OG1RF deleted for fakB1, fakB2, and
fakB4
E. faecalis OG1RF deleted for fakB1, fakB4, and
fakB5
E. faecalis OG1RF deleted for fakB1, fakB2, and
fakB5
E. faecalis OG1RF deleted for fakB1, fakB2, fakB5,
and tesS
E. faecalis OG1RF deleted for fakB1, fakB2, fakB4,
fakB5, and tesS

Source
Lab stock
Chapter 3
Chapter 3
Chapter 3
Chapter 3
Chapter 3
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Supplemental Figure 4.1. DegV domain numbers of Staphylococcus aureus,
Streptococcus pneumoniae, and Enterococcus faecalis.
Represented are the number of isolates of Staphylococcus aureus (red), Streptococcus
pneumoniae (blue), and Enterococcus faecalis (purple) which had two, three, or four
DegV domains.
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Introduction
Daptomycin tolerance can be induced by supplementing Enterococcus faecalis cultures
with specific exogenous fatty acids [1-5]. However, the mechanism underlying this
phenomenon has not been fully elucidated. Previous work has ruled out links between
fatty acid-induced daptomycin tolerance and membrane fluidity (via anisotropy) [1].
Furthermore, supplementation of E. faecalis cultures with protective fatty acids induced
protection even in the absence of a functional LiaFSR system, which has been implicated
in daptomycin resistance, indicating that fatty acid-induced protection was not dependent
on LiaFSR [2]. Mass spectrometry data, combined with gas chromatography analyses,
indicated that supplementation with fatty acids results in decreased phosphatidylglycerol
and increased cardiolipin species [5, 6]. These data, combined with findings indicating
phospholipid changes occurred in daptomycin resistant mutants [7, 8], led to the
hypothesis that specific changes in lipid composition are responsible for the induction of
daptomycin tolerance by free fatty acids. Specifically, cardiolipin synthase genes were
mutated in daptomycin resistant isolates [9-11]. Interestingly however, while deletion of
the specific genes required for synthesizing cardiolipin eliminated cardiolipin production,
it did not eliminate the protection afforded by exposure to the protective fatty acids oleic
acid (C18:1 cis9) or linoleic acid (C18:2 cis9,12) [5]. This indicates that changes in cardiolipin
production induced by fatty acid exposure did not result in daptomycin protection [5]. The
mechanism of daptomycin thus remained unclear.
Notably, daptomycin treatment results in a pattern of biphasic killing [2-4, 12-16],
which is indicative of the presence of a subpopulation of persister cells. Persister cells,
while genetically identical to the non-persister portion of the population [17], are killed
slowly by the drug [18, 19] and can outgrow on removal of the drug from the growth
medium [20-22]. Daptomycin persister cells can be awakened by the addition of glucose
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to the media [16]. On awakening, these persisters were more efficiently killed by
daptomycin [16]. Thus, we wanted to determine whether daptomycin tolerance could be
induced by perturbation of active cell processes. Recent literature proposed that
daptomycin directly interacts with a peptidoglycan (PG) precursor, lipid II [23]. Notably,
fatty acids alter the morphology of E. faecalis, and cellular morphology is directly linked
to placement of the cell wall. Thus, we tested how cell wall and incorporation of
exogenous fatty acids into membrane lipids play a role in daptomycin efficacy.

Cell wall and daptomycin efficacy
In the literature, new evidence supports that daptomycin’s primary mechanism of action
is to bind to the lipid-bound peptidoglycan precursor, lipid II, impacting cell wall synthesis
[23]. Our findings in Chapter 2 corroborate these data by demonstrating that daptomycin
tolerance-inducing conditions lead to changes in peptidoglycan precursor levels ([24];
Figures 2.1, 2.3, and 2.4). Additionally, we found that removal of the cell wall led to
daptomycin tolerance. Furthermore, when we combined other cell wall-targeting
antibiotics with daptomycin, they acted in an additive or synergistic fashion ([24]; Table
2.1). These findings, along with the discovery that daptomycin strongly inhibited the
incorporation of alanine into peptidoglycan and the formation of peptidoglycan precursors
[25] and that daptomycin binds to lipid II [23], indicate that lipid II is a target of daptomycin.
However, it remains unclear whether the daptomycin tolerance-inducing conditions
elucidated in Chapter 2 (entry into stationary phase, blocked protein synthesis, and
disruption of de novo fatty acid biosynthesis) alter the composition of the cell wall and
whether cell wall composition plays a role in daptomycin tolerance. To probe this, it would
be of major interest to isolate the cell wall of wild-type E. faecalis under daptomycin
tolerance-inducing conditions as well as the cell wall of deletion strains tolerant to
daptomycin (Chapter 4) to see if there is a clear pattern of changes inducing daptomycin
tolerance. Preliminary evidence gathered through cell wall extraction and running the
extract on a native polyacrylamide gel indicates that major shifts in cell wall composition
occur under daptomycin tolerance inducing conditions (data not shown). However, the
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specific chemical changes would need to elucidated through compositional analysis,
which is achievable through GC/MS [26]. If the changes are not chemical, as would be
detected in the above assay, but rather a specific pattern of wall misplacement, it would
be of interest to characterize localization of peptidoglycan synthesis proteins under
daptomycin-tolerance inducing conditions. Given that daptomycin was demonstrated to
interact with lipid II [23], localization of the enzyme responsible for synthesizing lipid II,
MurG, is of particular interest.

Impact of cellular processes on membrane organization
While in Chapter 2 we demonstrated that peptidoglycan, fatty acid biosynthesis, and
protein synthesis are important for daptomycin efficacy, the full impacts of these
processes on membrane organization remain unclear. However, evidence in the literature
suggests that membrane organization is critical for daptomycin function, as daptomycin
localizes to and subsequently causes deterioration of regions of increased fluidity (RIFs)
of the membrane, causing delocalization of several proteins [27, 28] and altered cell
morphology [28]. Notably, lipid II, the putative target of daptomycin [23], has an
undecaprenyl chain which is inserted into the membrane. This molecule has been
observed to localize to regions of the membrane with sharp curvature [29]. Thus, it is
crucial to elucidate how the processes indicated in daptomycin function, including
peptidoglycan synthesis, protein synthesis, and de novo fatty acid biosynthesis impact
membrane organization.
Treatment of cells with chloramphenicol, which blocks protein synthesis, alters
membrane microdomain structure [30, 31], thus potentially explaining why treatment with
this drug impacts daptomycin efficacy ([24]; Chapter 2; Figure 2.3). Further, treatment of
B. subtilis cells with the drug cerulenin, which blocks de novo fatty acid biosynthesis,
causes

a

down-regulation

of

flotillin

[32]

(E.

faecalis

homolog

Accession:

WP_002357808), a lipid raft-associated protein which is important for formation of
membrane microdomains [33]. Flotillins of B. subtilis are critical for localization of
peptidoglycan synthesis [34], potentially explaining older data which demonstrated that
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treatment with cerulenin led to misplaced peptidoglycan synthesis [35]. These data
suggest that multiple cellular processes impact membrane microdomains. However, it
remains unclear whether alteration of protein synthesis, fatty acid biosynthesis, and
peptidoglycan synthesis impact daptomycin efficacy by perturbing membrane
microdomains.

Lipid II and membrane organization
As noted above, daptomycin interacts with lipid II [23], which in turn influences protein
localization [36-38] and may facilitate bacterial cell division. Remarkably, while lipid II is
a precursor to peptidoglycan, lipid II biosynthesis enzymes are conserved amongst and
produced by bacterial species that lack cell wall, indicating that lipid II is important for
processes other than peptidoglycan production [36]. For Bacillus subtilis, lipid II controls
the membrane association of MreB, a cytoskeletal element which forms membraneassociated filaments that regulate cell wall synthesis and cell division [38]. Depletion of
the enzyme responsible for generating lipid II, MurG, caused MreB to disassemble [38].
Lipid II is also responsible for the localization of MurJ, which flips lipid II from the inner
membrane leaflet to the outer membrane leaflet [37]. Further, depletion of MurG (and thus
lipid II) caused altered anionic lipid accumulation at the cell poles [39]. Moreover,
sequestration of lipid II by nisin results in aberrant division site placement, with multiple
sites of division and the formation of minicells [40]. These data suggest that localization
of lipid II is critical for the recruitment of membrane-associated proteins, cell membrane
organization, and localization of the divisome. Previous data from Saito et al.
demonstrated that supplementation of E. faecalis cultures with free fatty acids impacted
morphology [4], indicating mislocalization of cell division machinery. It is thus our
hypothesis that exogenous free fatty acids impact localization of lipid II, resulting in
daptomycin tolerance. However, further lipid II localization studies are needed to
determine if there is a correlation between fatty acid supplementation, lipid II
delocalization, and daptomycin tolerance.
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Impact of fatty acid supplementation on cellular physiology
Fatty acids within the growth environment can have major impacts in bacterial physiology.
In the Gram-negative organism Escherichia coli, polyunsaturated fatty acids increase
membrane permeability [41]. Similarly, the polyunsaturated fatty acid linoleic acid (C18:2
cis9,12),

which induces daptomycin protection in E. faecalis, increased the membrane

permeability of Pseudomonas aeruginosa [42]. In vitro evidence suggested that free fatty
acids can also affect the activity of transmembrane proteins. Notably, in Streptococcus
sobrinus and S. mutans, polyunsaturated fatty acids inhibited the activity of
glucosyltransferase, an enzyme involved in glucan production [43, 44]. Furthermore, free
fatty acids inhibit fatty acid biosynthesis in several organisms, including E. faecalis [4548]. Given that free fatty acids can be utilized in phospholipid biosynthesis, it is to be
expected that in E. faecalis, the protective fatty acids oleic acid (C18:1 cis9) and linoleic acid
(C18:1

cis9,12),

were found to induce global phospholipid composition changes [5, 6].

Specifically, supplementation of wild-type E. faecalis with these fatty acids resulted in
increases in free fatty acids in the membrane as well as increases in cardiolipin [5, 6]. Yet
further investigation revealed that deletion of the genes responsible for producing
cardiolipin synthases did not eliminate the protection induced by fatty acid supplements,
revealing that their incorporation into cardiolipin did not explain why these supplements
are protective [5].
One major finding of the studies outlined in this dissertation is that free fatty acids
induce protection against daptomycin independently of their incorporation into membrane
phospholipids (Chapter 4; Figures 4.4 and 4.4, quintuple deletion strain). Given this, it
seems that free fatty acids, rather than specific phospholipid changes induced by fatty
acid supplementation, induce protection against daptomycin. Combined with the above
data demonstrating that membrane organization is impacted by and influences several
cellular processes, including orchestration of the divisome, it is unsurprising that
supplementation of cells with free fatty acids results in altered cellular morphology [4] and
membrane fluidity [1]. However, these studies were unable to directly correlate cellular
morphology or membrane fluidity with daptomycin protection. Yet, given that incorporation
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of free fatty acids is not necessary to induce daptomycin tolerance (Chapter 4), it is likely
that free fatty acid supplements induce another physiological response leading to
tolerance. Thus, a particularly enticing question which remains is whether supplementing
cells with protective fatty acids stabilizes the membrane in such a way that daptomycin
cannot interfere with membrane organization. Worth noting is the fact that while we
previously observed that membrane fluidity was not correlated with daptomycin protection
[1], this measurement represents a bulk measurement, and does not investigate how
microdomains are impacted. Thus, it would be of interest to further investigate how
addition of fatty acids to the growth media impacts membrane microdomains.

Impact of the Fak system on cellular physiology
While we observed that free fatty acids induce tolerance even when they are not
incorporated into membrane phospholipids (Figures 4.4-4.6), we also observed that
combined deletion of three or more fakB genes increases daptomycin tolerance (Figure
4.3). Given our findings that combined deletion of fakB1, fakB2, and fakB5 (ΔfakB1,2,5)
resulted in several physiological changes, including altered cell size and morphology and
accumulation of free fatty acids (Chapter 3), this was foreseeable. From these data, we
hypothesize that the accumulation of free fatty acids in this strain impacts membrane
organization and the biophysical properties of the membrane, thus leading to daptomycin
mislocalization and consequently, decreased efficacy.
As previous research carried out in S. aureus and S. pneumoniae indicated that the
Fak system was mainly useful for uptake of exogenous fatty acids [49, 50], the difficulty
of deleting all four fakB homologs and our observation that the ΔfakB1,2,5 deletion strain
had altered phenotypes even in the absence of fatty acid supplements was initially
puzzling. However, we found that deletion of the gene encoding a homolog of a
thioesterase, tesS, demonstrated in S. pneumoniae to cleave the acyl group from acylACP [51], enabled deletion of all four fakB homologs of E. faecalis. Examining our
quintuple deletion strain (ΔfakB1,2,4,5/ΔtesS) revealed that phenotypes associated with
supplementation of toxic free fatty acids were relieved (Table 3.4, Figures 3.5 and 3.6),
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indicating that incorporation of free fatty acids facilitates their impact on cellular
physiology. These data were interesting, as they highlighted a potential difference
between the function of enterococcal PlsX and streptococcal or staphylococcal PlsX.
In the literature, PlsX has been clearly demonstrated to interconvert (in both
directions) acyl-phosphate and acyl-ACP [45, 52]. However, if this conversion was equally
efficient in both directions in E. faecalis, one might expect that the toxifying effects of
supplementation with myristic acid (C14:0) or palmitic acid (C16:0) could be reduced if they
were assimilated into the de novo fatty acid biosynthesis pathway through the action of
PlsX converting the corresponding acyl-phosphate into acyl-ACP. Given that these fatty
acids are toxic to E. faecalis, causing growth stasis (and eventual selection of suppressor
strains which can grow in these fats) [4], it seems likely that these fatty acids, in wild-type
E. faecalis, are converted to acyl-phosphates through the activity of the Fak system, and
are then directly incorporated onto the SN-1 position of glycerol-3-phosphate (G3P),
forming lysophosphatidic acid. The secondary addition of an endogenously produced fatty
acid onto lysophosphatidic acid (forming phosphatidic acid) might then produce an
asymmetric phospholipid. Asymmetric phospholipids (meaning an imbalance of different
acyls on the SN-1 vs. the SN-2 position of the phospholipid head group) impact
membrane biophysical properties, namely through decreasing the stretching capability of
the membrane [53, 54].
These suppositions lead to the novel question of whether there is a specific difference
between enterococcal PlsX and the PlsX homologs of other bacterial genera. PlsX has
been studied most thoroughly in B. subtilis, where several amino acid residues have been
identified as important for its function (Table 5.1). Of these residues, most are conserved
in Enterococcus (Figure 5.1; conservation indicated by red letters, substitution with a
similar amino acid indicated in blue letters). While substitution with a similar amino acid
occurred in some cases, these substitutions were only observed in the sequences of S.
aureus or S. pneumoniae, except in the cases of: Ile242, substituted in E. faecalis for
methionine; Leu254, substituted in E. faecalis for valine; and Leu258, substituted in E.
faecalis for methionine. The Ile242 residue in bsPlsX was found to be critical for
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Table 5.1. PlsX residues of interest and their phenotypes on mutation.
Organism/reference
Bacillus/Jiang 2019

Residues (mutation) -- result
Thr253 (mutated to Ala)

Bacillus/Jiang 2019

Thr255 (mutated to Ala)

Bacillus/Jiang 2019

Lys257 (mutated to Ala)

Bacillus/Jiang 2019

Leu258 (mutated to Ser and Ala) –
caused delocalization
Leu254 (mutated to Glu) – no
effect; (mutated to Asp and Ala) –
caused delocalization
Leu254 (mutated to Glu) – no
protein in pellet/membrane
Val262 (mutated to Glu) – no
protein in pellet
Leu258+Ala259 (mutated to Glu) –
no protein in pellet
Ile242+Phe243 (insertion of Ala-Glu
between) – monomers/multimers
form, compromised membrane
localization, and abolished
catalysis; (insertion of Glu-Glu-Leu
between) – monomers/dimers form,
mixed localization pattern, and
catalysis still occurred
Leu235 (mutated to Glu) –
monomers/multimers instead of
dimers, compromised membrane
localization and catalysis abolished
Proposed but not tested as catalytic
triad: Ser279-Tyr278-Lys295
Proposed but not tested as catalytic
triad: Ser107-Tyr136-Lys140

Bacillus/Jiang 2019

Bacillus/Sastre 2020
Bacillus/Sastre 2020
Bacillus/Sastre 2020
Bacillus/Sastre 2020

Bacillus/Sastre 2020

Enterococcus/Kim
2010
Enterococcus/Kim
2010

Important for
Localizing to RIFs;
membrane binding
Localizing to RIFs;
membrane binding
Localizing to RIFs;
membrane binding
Localizing to RIFs;
membrane binding
Localizing to RIFs;
membrane binding
Localizing to
membrane
Localizing to
membrane
Localizing to
membrane
Dimerization/membrane
localization/catalysis

Dimerization/membrane
localization/catalysis

Catalytic triad; NADP
binding
Catalytic triad; NADP
binding
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Table 5.1 Continued
Organism/reference
Bacillus/Jiang 2020
Bacillus/Jiang 2020
Bacillus/Jiang 2020
Bacillus/Jiang 2020

Bacillus/Jiang 2020

Bacillus/Jiang 2020

Bacillus/Jiang 2020

Residue, mutation(s), and result
Arg73 (mutated to Ala) – increased
Km for acyl-ACP
Arg120 (mutated to Ala) –
increased Km for acyl-ACP
Arg120+Arg73 (mutated both to
Ala) -- activity undetectable
Asn229 (mutate to Ala) – Kcat
decreased and increased Km for
phosphate and acyl-ACP; (mutate
to Glu) -- recovery of catalytic
activity
Lys184 (mutate to Ala) – Kcat
decreased and increased Km for
phosphate; (mutate to Gln) – no
recovery; (mutate to Arg) – activity
recovered
Glu181 (mutate to Ala) – increased
Km for phosphate
Proposed but not tested:
Val178

Important for
Catalytic activity; acylACP binding
Catalytic activity; acylACP binding
Catalytic activity
Catalytic activity;
substrate binding

Phosphate binding;
stabilizing transition
state

Phosphate binding;
stabilizing transition
state
Stabilizing transition
state
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PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

MKKIAVDAMGGDYAPQAIVEGVNQALSDFSDIEVQLYGDEAKIKQYL-TATERVSIIHTD
-MKIAVDAMGGDNAPQAIVEGVMLAKQDFPDIEFQLYGKEAEIKKYI-TDEKNITIIHTD
-MKIAVDAMGGDNAPQAIVEGVMLAKQDFPDIEFQLYGKEAEIKKYI-TDEKNITIIHTD
MVKLAIDMMGGDNAPDIVLEAVQKAVEDFKDLEIILFGDEKKY----NLNHERIEFRHCS
-MRIAVDAMGGDHAPKAVIDGVIKGIEAFDDLHITLVGDKTTIESHLTTTSDRITVLHAD
-MRIAVDAMGGDHAPKAVIDGVIKGIEAFDDLHITLVGDKTTIESHLTTTSDRITVLHAD
::*:* **** **. :::.* . . * *:.. * *.:
..: . * .

59
58
58
56
59
59

PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

EKIDSDDEPTRAIRNKKNASMVLAAKAVKDGEADAVLSAGNTGALLAAGFFIVGRIKNID
EKIASDDEPVKAIRRKKTASMVLAAQAVKNGEADAIFSAGNTGALLAAGLFIVGRIKNVE
EKIASDDEPVKAIRRKKTASMVLAAQAVKNGEADAIFSAGNTGALLAAGLFIVGRIKNVE
EKIEMEDEPVRAIKRKKDSSMVKMAEAVKSGEADGCVSAGNTGALMSAGLFIVGRIKGVA
EVIEPTDEPVRAVRRKKNSSMVLMAQEVAENRADACISAGNTGALMTAGLFIVGRIKGID
EVIEPTDEPVRAVRRKKNSSMVLMAQEVAENRADACISAGNTGALMTAGLFIVGRIKGID
* *
***.:*::.** :*** *: * ...**. .********::**:*******.:

119
118
118
116
119
119

PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

RPGLMSTLPTVD--GKGFDMLDLGANAENTAQHLHQYAVLGSFYAKNVRGIAQPRVGLLN
RPGLMSTLPVMGEPDKGFDMLDLGANADNKPEHLVQYAVLGSFYAEKVRNVQNPRVGLLN
RPGLMSTLPVMGEPDKGFDMLDLGANADNKPEHLVQYAVLGSFYAEKVRNVQNPRVGLLN
RPALVVTLPTID--GKGFVFLDVGANADAKPEHLLQYAQLGDIYAQKIRGIDNPKISLLN
RPALAPTLPTVS--GDGFLLLDVGANVDAKPEHLVQYAIMGSVYSQQVRGVTSPRVGLLN
RPALAPTLPTVS--GDGFLLLDVGANVDAKPEHLVQYAIMGSVYSQQVRGVTSPRVGLLN
**.* ***.:. ..** :**:***.: . :** *** :*..*::::*.: .*::.***

177
178
178
174
177
177

PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

NGTESSKGDPLRKETYELLAADESLNFIGNVEARDLMNGVADVVVADGFTGNAVLKSIEG
NGTEETKGSELTKKAFELLAADETINFVGNVEARELLNGVADVVVTDGFTGNAVLKSIEG
NGTEETKGSELTKKAFELLAADETINFVGNVEARELLNGVADVVVTDGFTGNAVLKSIEG
IGTEPAKGNSLTKKSYELLNHDHSLNFVGNIEAKTLMDGDTDVVVTDGYTGNMVLKNLEG
VGTEDKKGNELTKQTFQILKETANINFIGNVEARDLLDDVADVVVTDGFTGNVTLKTLEG
VGTEDKKGNELTKQTFQILKETANINFIGNVEARDLLDDVADVVVTDGFTGNVTLKTLEG
*** **. * *:::::*
.:**:**:**: *::. :****:**:*** .**.:**

237
238
238
234
237
237

PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

TAMGIMGLLKTAITGGGLRAKLGALLLKDSLRGLKKQLNYSDVGGAVLFGVKAPVVKTHG
TAMNMMSLLKTAILSEGVKGKMGALLLKNALHGMKDEMDYSKHGGAVLFGLKAPVIKTHG
TAMNMMSLLKTAILSEGVKGKMGALLLKNALRGMKDEMDYSKHGGAVLFGLKAPVIKTHG
TAKSIGKMLKDTIMS-STKNKLAGAILKKDLAEFAKKMDYSEYGGSVLLGLEGTVVKAHG
SALSIFKMMRDVMTS-TLTSKLAAAVLKPKLKEMKMKMEYSNYGGASLFGLKAPVIKAHG
SALSIFKMMRDVMTS-TLTSKLAAAVLKPKLKEMKMKMEYSNYGGASLFGLKAPVIKAHG
:* .: ::: .: .
*:.. :** * : :::**. **: *:*::. *:*:**

297
298
298
293
296
296

PlsX_Streptococcus_pneumoniae_D39
PlsX_Enterococcus_faecalis_V583
PlsX_Enterococcus_faecalis_OG1RF
PlsX_Staphylococcus_aureus_USA300_FPR3757
PlsX_Bacillus_subtilis_168
PlsX_Bacillus_subtilis_PY79

SSDAKAVYSTIRQIRTMLETDVVAQTAREFSGE---ATGPDAVRYTIRQIHTMLETQVVPQLVEYYEGKAE-ATGPDAVRYTIRQIHTMLETQVVPQLVEYYEGKAE-SSNAKAFYSAIRQAKIAGEQNIVQTMKETVGESNE-SSDSNAVFHAIRQAREMVSQNVAALIQEEVKEEKTDE
SSDSNAVFHAIRQAREMVSQNVAALIQEEVKEEKTDE
::. .*. :*** :
. ::.
.
.

330
333
333
328
333
333

Figure 5.1. Multiple sequence alignment of PlsX of several organisms.
Red letters mark conserved important residues. Blue letters mark that important residues
were substituted with a similar amino acid.
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dimerization of PlsX [55]. This residue in E. faecalis therefore is unlikely to be the driver
for a difference in function, as a crystal structure for E. faecalis V583 PlsX demonstrated
that the protein formed dimers [56]. Interestingly, the other residue substitutions occurred
in an α-helix, observed in B. subtilis to be responsible for localization of PlsX [57]. These
differences are reflected in an overlay of Phyre2 models of the PlsX proteins, (Figure 5.2;
red box shows a modelled loop corresponding to residues important for localization PlsX
to the membrane).
In Bacillus subtilis, PlsX associates with RIFs in the membrane [27, 57]. The targeting
of bsPlsX was observed to be driven by a 9-residue amphipathic α-helix (residues 253261) [57]. Alteration of the interaction of this α-helix to decrease its interaction with the
membrane (mutation of nonpolar residues to polar residues) or to increase its interaction
with the membrane (mutation of polar residues to nonpolar residues) caused
delocalization of PlsX from RIFs in the membrane [57]. This suggests that there is a
narrow range of hydrophobicity required for localization of PlsX to RIFs. Given this tight
specificity of PlsX for localization to specific regions of the membrane, it is probable that
membrane alterations delocalize PlsX. Thus, it is tempting to speculate that increased
levels of free fatty acids in the membrane lead to delocalization of PlsX. This would lead
to an inability to convert acyl-phosphates (generated by the Fak system) to acyl-ACP.
Thus, exogenous fatty acids would only be used for incorporation onto the SN-1 position
of G3P, while endogenous fatty acids would be necessary for acylating the SN-2 position
of G3P. This rewiring of phospholipid metabolism would then hypothetically induce
phospholipid changes and lead to mislocalization of important cellular machinery within
the membrane, thus potentially inducing daptomycin tolerance. Further testing through
studies elucidating whether PlsX is delocalized on addition of free fatty acids or in the
ΔfakB1,2,5 deletion strain, which we noted had accumulation of free fatty acids (Chapter
3; Figure 3.3) will be critical for elucidating whether delocalization is occurring.
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Figure 5.2. Phyre2 models of PlsX of several organisms.
Models of the PlsX proteins of: B. subtilis str. 168 (red), B. subtilis PY79 (orange), S.
pneumoniae D39 (Blue), S. aureus USA300_FPR3757 (Yellow), E. faecalis OG1RF (hot
pink), and E. faecalis V583 (magenta) were modelled using Phyre2 and overlaid using
Chimera. The red box indicates the loop important for localization of PlsX to the
membrane.
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Importance of fatty acid binding across species
Fatty acids are important constituents of many environments. As previously noted,
several species of fatty acids are present in bile as well as serum [3]. Additionally, fatty
acids are present on the skin [58] in sputum [59, 60], in water sources [61, 62], and in the
soil [63]. Given that fatty acids are present in these environments, it is logical to
hypothesize that the organisms present within these environments have adapted to utilize
the fatty acids around them. In Chapter 4, we performed a network analysis to determine
how the FakB proteins of E. faecalis are related to the DegV (fatty acid binding) domains
found in other organisms. Our findings indicated that the four FakB proteins of E. faecalis
each have a different functionality, as they clustered to different areas of the network
(Figure 4.1). Given that E. faecalis is commensal to the mammalian intestine, where it
may be exposed to bile, which contains numerous fatty acids [3], we were not surprised
that this was the case. Additionally, the network data matched our previous data (Table
3.1) which indicated that efFakB1 was most closely related to saFakB1 and spFakB1,
while efFakB2 was most closely related to saFakB2 and spFakB2 (Figure 4.1). However,
we noted that the two other FakB homologs of E. faecalis clustered with other regions of
the network (Figure 4.1). Specifically, efFakB1 clustered in a region of the network which
was dominated by Gram-positive organisms, yet there did not appear to be any pattern
with regards to the isolation source in the clustering of the DegV domain associated with
this protein (Figures 4.1 and 4.2). Interestingly however, FakB4 clustered in a region of
the network which was dominated by animal isolates – especially isolates originating from
the gut (Figures 4.1 and 4.2). This is indicative that the DegV domains within this region
are important to binding free fatty acids within the gut. In our studies, we noted that
deletion of fakB4 did not correspond to any specific phenotypes, except in the quintuple
deletion strain (Chapter 3). It is possible that the reason for this is because we did not
examine the correct conditions to observe a phenotype. While bile, which contains
numerous long-chain fatty acids (Saito 2014), is present in the gut, dietary fatty acid
sources are present as well. In particular, medium-chain fatty acids, including caproic acid
(C6:0), caprylic acid (C8:0), capric acid (C10:0), and lauric acid (C12:0), are constituents of
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plant and dairy food products [64]. It remains possible that efFakB4 is specific for dietary
fatty acids such as these, for microbially produced short-chain fatty acids which are
abundant in the gut [65, 66], or for omega-3 dietary fatty acids.
Another trend we noted was that there was a higher abundance of Gram-positive
organisms within the cluster of the network analyzed (Figure 4.2). There are two possible
reasons for this observation. It is possible that in other clusters of the network, Gramnegative organisms dominated as they were more distantly related to the DegV domains
of Gram-positive organisms. A second possibility could be that the organisms which lack
a system for β-oxidation of fatty acids may be more likely to have DegV domains for
binding fatty acids. In these organisms, while fatty acids cannot be used as carbon
sources, they might be used for building the bacterial membrane. However, the
distribution of organisms containing systems for β-oxidation across Gram-positive and
Gram-negative genera has not been examined. Overall, our data however point towards
specific trends linking isolation source with DegV relatedness.

Final thoughts
E. faecalis is a bacterium commensal to the mammalian gut, yet is able to colonize other
tissues. In these environments, it is exposed to free fatty acids, which it can ordinarily
incorporate into its membrane phospholipids. The work presented in this dissertation
started by asking how cellular physiology impacts tolerance to daptomycin. On our way
to answering this question, we discovered that the Fak system is important for normal
cellular physiology in E. faecalis. Further, we determined that inactivation of this pathway
not only increases basal daptomycin tolerance, but that free fatty acids, even when not
incorporated into phospholipids, are still able to protect against the clinically important
drug, daptomycin. This work further illuminates our understanding of the interplay
between cell wall synthesis and the bacterial membrane, and has expanded our
knowledge of how E. faecalis uses its resources to survive in its host.

197

References
1.

Brewer W, Harrison J, Saito HE, Fozo EM. Induction of daptomycin tolerance in

Enterococcus faecalis by fatty acid combinations. Appl Environ Microbiol. 2020;86(20).
Epub 2020/08/18. doi: 10.1128/aem.01178-20. PubMed PMID: 32801181; PubMed
Central PMCID: PMCPMC7531955.
2.

Harp JR, Saito HE, Bourdon AK, Reyes J, Arias CA, Campagna SR, et al. Exogenous

fatty acids protect Enterococcus faecalis from daptomycin-induced membrane stress
independently of the response regulator LiaR. Appl Environ Microbiol. 2016;82(14):441020. Epub 2016/05/22. doi: 10.1128/aem.00933-16. PubMed PMID: 27208105; PubMed
Central PMCID: PMCPMC4959211.
3.

Saito HE, Harp JR, Fozo EM. Incorporation of exogenous fatty acids protects

Enterococcus faecalis from membrane-damaging agents. Appl Environ Microbiol.
2014;80(20):6527-38. Epub 2014/08/17. doi: 10.1128/aem.02044-14. PubMed PMID:
25128342; PubMed Central PMCID: PMCPMC4178632.
4.

Saito HE, Harp JR, Fozo EM. Enterococcus faecalis responds to individual

exogenous fatty acids independently of their degree of saturation or chain length. Appl
Environ Microbiol. 2018;84(1). Epub 2017/10/29. doi: 10.1128/aem.01633-17. PubMed
PMID: 29079613; PubMed Central PMCID: PMCPMC5734047.
5.

Woodall BM, Harp JR, Brewer WT, Tague ED, Campagna SR, Fozo EM.

Enterococcus faecalis

readily adapts membrane

phospholipid

composition

to

environmental and genetic perturbation. Front Microbiol. 2021;12:616045. Epub
2021/06/08. doi: 10.3389/fmicb.2021.616045. PubMed PMID: 34093456; PubMed
Central PMCID: PMCPMC8177052.
6.

Tague ED, Woodall BM, Harp JR, Farmer AT, Fozo EM, Campagna SR. Expanding

lipidomics coverage: effective ultra performance liquid chromatography-high resolution
mass

spectrometer

methods

for

detection

and

quantitation

of

cardiolipin,

phosphatidylglycerol, and lysyl-phosphatidylglycerol. Metabolomics. 2019;15(4):53. Epub
2019/03/29. doi: 10.1007/s11306-019-1512-7. PubMed PMID: 30919213; PubMed
Central PMCID: PMCPMC6947919.
198

7.

Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, et al.

Characterization of the mechanisms of daptomycin resistance among gram-positive
bacterial pathogens by multidimensional lipidomics. mSphere. 2017;2(6):e00492-17. doi:
doi:10.1128/mSphere.00492-17.
8.

Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E, Dowhan W, et al.

Daptomycin resistance in enterococci is associated with distinct alterations of cell
membrane phospholipid content. PLoS One. 2012;7(8):e43958. Epub 2012/09/07. doi:
10.1371/journal.pone.0043958. PubMed PMID: 22952824; PubMed Central PMCID:
PMCPMC3428275.
9.

Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, et al. Genetic basis

for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365(10):892-900.
Epub 2011/09/09. doi: 10.1056/NEJMoa1011138. PubMed PMID: 21899450; PubMed
Central PMCID: PMCPMC3205971.
10. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for
daptomycin resistance in enterococci. Antimicrob Agents Chemother. 2011;55(7):334556. Epub 2011/04/20. doi: 10.1128/aac.00207-11. PubMed PMID: 21502617; PubMed
Central PMCID: PMCPMC3122436.
11. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, et al. Whole genome
characterization of the mechanisms of daptomycin resistance in clinical and laboratory
derived isolates of Staphylococcus aureus. PLoS One. 2012;7(1):e28316. Epub
2012/01/13. doi: 10.1371/journal.pone.0028316. PubMed PMID: 22238576; PubMed
Central PMCID: PMCPMC3253072.
12. Boaretti M, Canepari P, Lleò MM, Satta G. The activity of daptomycin on
Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action
on lipoteichoic acid synthesis. J Antimicrob Chemother. 1993;31(2):227-35. Epub
1993/02/01. doi: 10.1093/jac/31.2.227. PubMed PMID: 8385093.
13. Lechner S, Lewis K, Bertram R. Staphylococcus aureus persisters tolerant to
bactericidal antibiotics. J Mol Microbiol Biotechnol. 2012;22(4):235-44. Epub 2012/09/19.

199

doi: 10.1159/000342449. PubMed PMID: 22986269; PubMed Central PMCID:
PMCPMC3518770.
14. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against
stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents
Chemother. 2007;51(12):4255-60. Epub 2007/10/10. doi: 10.1128/aac.00824-07.
PubMed PMID: 17923487; PubMed Central PMCID: PMCPMC2167999.
15. Pee CJE, Pader V, Ledger EVK, Edwards AM. A FASII Inhibitor prevents
staphylococcal evasion of daptomycin by inhibiting phospholipid decoy production.
Antimicrobial

Agents

and

Chemotherapy.

2019;63(4):e02105-18.

doi:

10.1128/AAC.02105-18.
16. Prax M, Mechler L, Weidenmaier C, Bertram R. Glucose augments killing efficiency
of

daptomycin

challenged

Staphylococcus

aureus

persisters.

PLoS

One.

2016;11(3):e0150907. Epub 2016/03/10. doi: 10.1371/journal.pone.0150907. PubMed
PMID: 26960193; PubMed Central PMCID: PMCPMC4784881.
17. Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, et al.
Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol.
2019;17(7):441-8. Epub 2019/04/14. doi: 10.1038/s41579-019-0196-3. PubMed PMID:
30980069; PubMed Central PMCID: PMCPMC7136161.
18. Bigger J. Treatment of staphylococcal infections with penicillin by intermittent
sterilisation. Lancet. 1944;244(6320):497-500. doi: 10.1016/S0140-6736(00)74210-3.
19. Hobby GL, Meyer K, Chaffee E. Observations on the mechanism of action of
penicillin. Exp Biol Med. 1942;50(2):281-5. doi: 10.3181/00379727-50-13773.
20. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a
phenotypic

switch.

Science.

2004;305(5690):1622-5.

Epub

2004/08/17.

doi:

10.1126/science.1099390. PubMed PMID: 15308767.
21. Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug
resistance.

Cell

Host

Microbe.

2013;13(6):632-42.

Epub

2013/06/19.

doi:

10.1016/j.chom.2013.05.009. PubMed PMID: 23768488; PubMed Central PMCID:
PMCPMC3695397.
200

22. Jõers A, Kaldalu N, Tenson T. The frequency of persisters in Escherichia coli reflects
the kinetics of awakening from dormancy. J Bacteriol. 2010;192(13):3379-84. Epub
2010/05/04. doi: 10.1128/jb.00056-10. PubMed PMID: 20435730; PubMed Central
PMCID: PMCPMC2897658.
23. Grein F, Müller A, Scherer KM, Liu X, Ludwig KC, Klöckner A, et al. Ca(2+)Daptomycin targets cell wall biosynthesis by forming a tripartite complex with
undecaprenyl-coupled

intermediates

and

membrane

lipids.

Nat

Commun.

2020;11(1):1455. Epub 2020/03/21. doi: 10.1038/s41467-020-15257-1. PubMed PMID:
32193379; PubMed Central PMCID: PMCPMC7081307.
24. Johnston RD, Woodall BM, Harrison J, Campagna SR, Fozo EM. Removal of
peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in
Enterococcus faecalis. PLoS One. 2021;16(7):e0254796. Epub 2021/07/24. doi:
10.1371/journal.pone.0254796. PubMed PMID: 34297729; PubMed Central PMCID:
PMCPMC8301656.
25. Allen NE, Hobbs JN, Alborn WE, Jr. Inhibition of peptidoglycan biosynthesis in Grampositive bacteria by LY146032. Antimicrob Agents Chemother. 1987;31(7):1093-9. Epub
1987/07/01. doi: 10.1128/aac.31.7.1093. PubMed PMID: 2821889; PubMed Central
PMCID: PMCPMC174877.
26. Korir ML, Dale JL, Dunny GM. Role of epaQ, a previously uncharacterized
Enterococcus faecalis gene, in biofilm development and antimicrobial resistance. J
Bacteriol. 2019;201(18). Epub 2019/03/27. doi: 10.1128/jb.00078-19. PubMed PMID:
30910809; PubMed Central PMCID: PMCPMC6707930.
27. Müller A, Wenzel M, Strahl H, Grein F, Saaki TNV, Kohl B, et al. Daptomycin inhibits
cell envelope synthesis by interfering with fluid membrane microdomains. Proc Natl Acad
Sci U S A. 2016;113(45):E7077-e86. Epub 2016/10/30. doi: 10.1073/pnas.1611173113.
PubMed PMID: 27791134; PubMed Central PMCID: PMCPMC5111643.
28. Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of
membrane architecture causes mislocalization of essential cell division proteins. J

201

Bacteriol. 2012;194(17):4494-504. Epub 2012/06/05. doi: 10.1128/jb.00011-12. PubMed
PMID: 22661688; PubMed Central PMCID: PMCPMC3415520.
29. Calvez P, Jouhet J, Vié V, Durmort C, Zapun A. Lipid phases and cell geometry
during the cell cycle of Streptococcus pneumoniae. Frontiers in Microbiology.
2019;10(351). doi: 10.3389/fmicb.2019.00351.
30. Fishov I, Woldringh CL. Visualization of membrane domains in Escherichia coli. Mol
Microbiol.

1999;32(6):1166-72.

Epub

1999/06/26.

doi:

10.1046/j.1365-

2958.1999.01425.x. PubMed PMID: 10383758.
31. Vanounou S, Pines D, Pines E, Parola AH, Fishov I. Coexistence of domains with
distinct order and polarity in fluid bacterial membranes. Photochem Photobiol.
2002;76(1):1-11.

Epub

2002/07/20.

doi:

10.1562/0031-

8655(2002)076<0001:codwdo>2.0.co;2. PubMed PMID: 12126299.
32. Nickels JD, Poudel S, Chatterjee S, Farmer A, Cordner D, Campagna SR, et al.
Impact of fatty-acid labeling of Bacillus subtilis membranes on the cellular lipidome and
proteome.

Front

Microbiol.

2020;11:914.

Epub

2020/06/06.

doi:

10.3389/fmicb.2020.00914. PubMed PMID: 32499768; PubMed Central PMCID:
PMCPMC7243436.
33. Bach JN, Bramkamp M. Flotillins functionally organize the bacterial membrane. Mol
Microbiol. 2013;88(6):1205-17. Epub 2013/05/09. doi: 10.1111/mmi.12252. PubMed
PMID: 23651456.
34. Zielińska A, Savietto A, de Sousa Borges A, Martinez D, Berbon M, Roelofsen JR, et
al. Flotillin-mediated membrane fluidity controls peptidoglycan synthesis and MreB
movement. Elife. 2020;9. Epub 2020/07/15. doi: 10.7554/eLife.57179. PubMed PMID:
32662773; PubMed Central PMCID: PMCPMC7360373.
35. Higgins ML, Carson DD, Daneo-Moore L. Morphological effect of cerulenin treatment
on Streptococcus faecalis as studied by ultrastructure reconstruction. J Bacteriol.
1980;143(2):989-94. Epub 1980/08/01. doi: 10.1128/jb.143.2.989-994.1980. PubMed
PMID: 6782085; PubMed Central PMCID: PMCPMC294404.

202

36. Henrichfreise B, Schiefer A, Schneider T, Nzukou E, Poellinger C, Hoffmann T-J, et
al. Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria
Chlamydia and Wolbachia: why is lipid II needed? Molecular Microbiology.
2009;73(5):913-23. doi: https://doi.org/10.1111/j.1365-2958.2009.06815.x.
37. Liu X, Meiresonne NY, Bouhss A, den Blaauwen T. FtsW activity and lipid II synthesis
are required for recruitment of MurJ to midcell during cell division in Escherichia coli. Mol
Microbiol. 2018;109(6):855-84. Epub 2018/08/17. doi: 10.1111/mmi.14104. PubMed
PMID: 30112777.
38. Schirner K, Eun YJ, Dion M, Luo Y, Helmann JD, Garner EC, et al. Lipid-linked cell
wall precursors regulate membrane association of bacterial actin MreB. Nat Chem Biol.
2015;11(1):38-45. Epub 2014/11/18. doi: 10.1038/nchembio.1689. PubMed PMID:
25402772; PubMed Central PMCID: PMCPMC4270829.
39. Muchová K, Wilkinson AJ, Barák I. Changes of lipid domains in Bacillus subtilis cells
with disrupted cell wall peptidoglycan. FEMS Microbiol Lett. 2011;325(1):92-8. Epub
2011/11/19. doi: 10.1111/j.1574-6968.2011.02417.x. PubMed PMID: 22092867; PubMed
Central PMCID: PMCPMC3433793.
40. Hyde AJ, Parisot J, McNichol A, Bonev BB. Nisin-induced changes in Bacillus
morphology suggest a paradigm of antibiotic action. Proceedings of the National
Academy of Sciences. 2006;103(52):19896-901. doi: 10.1073/pnas.0608373104.
41. Herndon JL, Peters RE, Hofer RN, Simmons TB, Symes SJ, Giles DK. Exogenous
polyunsaturated fatty acids (PUFAs) promote changes in growth, phospholipid
composition, membrane permeability and virulence phenotypes in Escherichia coli. BMC
Microbiology. 2020;20(1):305. doi: 10.1186/s12866-020-01988-0.
42. Baker LY, Hobby CR, Siv AW, Bible WC, Glennon MS, Anderson DM, et al.
Pseudomonas aeruginosa responds to exogenous polyunsaturated fatty acids (PUFAs)
by modifying phospholipid composition, membrane permeability, and phenotypes
associated with virulence. BMC Microbiology. 2018;18(1):117. doi: 10.1186/s12866-0181259-8.

203

43. Kurihara H, Goto Y, Aida M, Hosokawa M, Takahashi K. Antibacterial activity against
cariogenic bacteria and inhibition of insoluble glucan production by free fatty acids
obtained from dried Gloiopeltis furcata. Fisheries science. 1999;65(1):129-32. doi:
10.2331/fishsci.65.129.
44. Won S-R, Hong M-J, Kim Y-M, Li CY, Kim J-W, Rhee H-I. Oleic acid: An efficient
inhibitor

of

glucosyltransferase.

FEBS

Letters.

2007;581(25):4999-5002.

doi:

https://doi.org/10.1016/j.febslet.2007.09.045.
45. Lu Y-J, Rock CO. Transcriptional regulation of fatty acid biosynthesis in
Streptococcus

pneumoniae.

Molecular

Microbiology.

2006;59(2):551-66.

doi:

https://doi.org/10.1111/j.1365-2958.2005.04951.x.
46. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. Metabolic basis for
the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.
Proc Natl Acad Sci U S A. 2011;108(37):15378-83. Epub 2011/08/31. doi:
10.1073/pnas.1109208108. PubMed PMID: 21876172; PubMed Central PMCID:
PMCPMC3174620.
47. Yao J, Rock CO. Exogenous fatty acid metabolism in bacteria. Biochimie.
2017;141:30-9. Epub 2017/07/03. doi: 10.1016/j.biochi.2017.06.015. PubMed PMID:
28668270; PubMed Central PMCID: PMCPMC5665373.
48. Zhu L, Zou Q, Cao X, Cronan JE. Enterococcus faecalis encodes an atypical auxiliary
acyl carrier protein required for efficient regulation of fatty acid synthesis by exogenous
fatty acids. mBio. 2019;10(3). Epub 2019/05/09. doi: 10.1128/mBio.00577-19. PubMed
PMID: 31064829; PubMed Central PMCID: PMCPMC6509188.
49. Gullett JM, Cuypers MG, Frank MW, White SW, Rock CO. A fatty acid-binding protein
of Streptococcus pneumoniae facilitates the acquisition of host polyunsaturated fatty
acids.

Journal

of

Biological

Chemistry.

2019;294(44):16416-28.

doi:

https://doi.org/10.1074/jbc.RA119.010659.
50. Parsons JB, Broussard TC, Bose JL, Rosch JW, Jackson P, Subramanian C, et al.
Identification of a two-component fatty acid kinase responsible for host fatty acid

204

incorporation by Staphylococcus aureus. Proceedings of the National Academy of
Sciences. 2014;111(29):10532-7. doi: 10.1073/pnas.1408797111.
51. Panesso D, Reyes J, Gaston EP, Deal M, Londoño A, Nigo M, et al. Deletion of liaR
reverses daptomycin resistance in Enterococcus faecium independent of the genetic
background. Antimicrob Agents Chemother. 2015;59(12):7327-34. Epub 2015/09/16. doi:
10.1128/aac.01073-15.

PubMed

PMID:

26369959;

PubMed

Central

PMCID:

PMCPMC4649183.
52. Jiang Y, Qin M, Guo Z. Substrate recognition and catalytic mechanism of the
phosphate

acyltransferase

PlsX

from

Bacillus

subtilis.

ChemBioChem.

2020;21(14):2019-28. doi: https://doi.org/10.1002/cbic.202000015.
53. Ali S, Smaby JM, Momsen MM, Brockman HL, Brown RE. Acyl chain-length
asymmetry alters the interfacial elastic interactions of phosphatidylcholines. Biophysical
Journal. 1998;74(1):338-48. doi: https://doi.org/10.1016/S0006-3495(98)77791-4.
54. Illya G, Lipowsky R, Shillcock JC. Effect of chain length and asymmetry on material
properties

of

bilayer

membranes.

The

Journal

of

Chemical

Physics.

2005;122(24):244901. doi: 10.1063/1.1917794.
55. Sastre DE, Pulschen AA, Basso LGM, Benites Pariente JS, Marques Netto CGC,
Machinandiarena F, et al. The phosphatidic acid pathway enzyme PlsX plays both
catalytic and channeling roles in bacterial phospholipid synthesis. Journal of Biological
Chemistry. 2020;295(7):2148-59. doi: https://doi.org/10.1074/jbc.RA119.011147.
56. Kim Y, Li H, Binkowski TA, Holzle D, Joachimiak A. Crystal structure of fatty
acid/phospholipid synthesis protein PlsX from Enterococcus faecalis. J Struct Funct
Genomics. 2009;10(2):157-63. Epub 2008/12/06. doi: 10.1007/s10969-008-9052-9.
PubMed PMID: 19058030; PubMed Central PMCID: PMCPMC2771631.
57. Jiang Y, Dai X, Qin M, Guo Z. Identification of an amphipathic peptide sensor of the
Bacillus subtilis fluid membrane microdomains. Communications Biology. 2019;2(1):316.
doi: 10.1038/s42003-019-0562-8.

205

58. Feingold KR. Thematic review series: skin lipids. The role of epidermal lipids in
cutaneous permeability barrier homeostasis. J Lipid Res. 2007;48(12):2531-46. Epub
2007/09/18. doi: 10.1194/jlr.R700013-JLR200. PubMed PMID: 17872588.
59. Cha D, Cheng D, Liu M, Zeng Z, Hu X, Guan W. Analysis of fatty acids in sputum
from patients with pulmonary tuberculosis using gas chromatography-mass spectrometry
preceded by solid-phase microextraction and post-derivatization on the fiber. J
Chromatogr

A.

2009;1216(9):1450-7.

Epub

2009/01/28.

doi:

10.1016/j.chroma.2008.12.039. PubMed PMID: 19171347.
60. Sahu S, Lynn WS. Lipid composition of sputum from patients with asthma and
patients with cystic fibrosis. Inflammation. 1978;3(1):27-36. Epub 1978/03/01. doi:
10.1007/bf00917319. PubMed PMID: 581080.
61. Akinnifesi T. A. AFO, Ogunfowokan A. O., Ololade I. A., Oladoja N. A. Free fatty acid
levels in some surface waters and municipal water supply of south-western Nigeria.
International Journal of Advanced Research. 2017;5.
62. Hu J, Zhang H, Peng Pa. Fatty acid composition of surface sediments in the
subtropical Pearl River estuary and adjacent shelf, Southern China. Estuarine, Coastal
and Shelf Science. 2006;66(1):346-56. doi: https://doi.org/10.1016/j.ecss.2005.09.009.
63. Sánchez-Martín J, Canales FJ, Tweed JKS, Lee MRF, Rubiales D, Gómez-Cadenas
A, et al. Fatty acid profile changes during gradual soil water depletion in oats suggests a
role for jasmonates in coping with drought. Front Plant Sci. 2018;9:1077. Epub
2018/08/23. doi: 10.3389/fpls.2018.01077. PubMed PMID: 30131815; PubMed Central
PMCID: PMCPMC6090161.
64. Roopashree PG, Shetty SS, Suchetha Kumari N. Effect of medium chain fatty acid in
human health and disease. Journal of Functional Foods. 2021;87:104724. doi:
https://doi.org/10.1016/j.jff.2021.104724.
65. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The
role of short-chain fatty acids in the interplay between diet, gut microbiota, and host
energy metabolism. J Lipid Res. 2013;54(9):2325-40. Epub 2013/07/04. doi:

206

10.1194/jlr.R036012.

PubMed

PMID:

23821742;

PubMed

Central

PMCID:

PMCPMC3735932.
66. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota
and their impact on human metabolism. Gut Microbes. 2016;7(3):189-200. Epub
2016/03/11. doi: 10.1080/19490976.2015.1134082. PubMed PMID: 26963409; PubMed
Central PMCID: PMCPMC4939913.

207

VITA
Rachel Johnston was born in the warm month of June in Pensacola, Florida. Over the
course of her life, she has made a slow crawl northeastwards: from Pensacola FL (birth)
to Troy AL (undergrad school), to Knoxville TN (grad school). With each new move there
were new thermal horizons to explore for Rachel. In undergrad, she learned to double up
on clothing in the winter. In Knoxville she learned how to triple up on her clothing in the
winter. Now on to the next thermal challenge: Rachel will be pursuing a postdoc in
Bethesda MD. Will she be able to successfully wear four layers of clothing in the
wintertime? Only time will tell.

208

